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Muskulu distrofiak, muskulu eskeletikoaren degenerazio progresiboa eragiten duten 
jatorri genetikoko gaixotasun multzo bat dira. Hauen artean, gerrietako muskulu 
distrofiek (LGMD, ingelesezko Limb-Girdle Muscular Dystrophy izenetik) osatzen duten 
azpitaldean kokatzen dira gerri pelbikoko eta eskapularreko muskuluen eta muskulu 
proximalen ahultasuna eragiten duten gaixotasunak. Herentzia ereduen arabera, bi 
talde nagusitan banatzen dira: LGMD1 izenez ezagutzen dira herentzia gainartzailea 
dutenak, eta LGMD2 izenez herentzia azpirakorra dutenak.  
Azken hauen artean, 2A motako gerri distrofia (LGMD2A), CAPN3 genean kokatzen diren 
mutazioen ondorioa da. Gene honek, batik bat muskuluan espresatzen den kalpaina 3 
izeneko proteasa ez lisosomala kodetzen du. Gaixoei, orokorrean nerabezaroan 
agertzen zaizkie lehenengo sintomak. Hala ere, badira kasu goiztiarrak, 2 urterekin 
gaixotasunari hasiera eman diotenak, edota beste muturrean 50 urterekin hasitakoak 
ere. Gaixotasunaren hasieran, ohikoak dira eskailerak igo, korrika egin, pisua jaso edota 
aulkitik altxatzeko zailtasunak. Gaixotasunak aurrera egin ahala, muskuluen ahultasuna 
areagotuz joaten da eta gaixoek ibiltzeko zailtasunak izaten dituzte, gurpil-aulki baten 
beharra izatera iritsiz. Degenerazioak ez die muskulu guztiei berdin eragiten. Gorputz 
enborreko eta izterretako atzeko konpartimentuetako muskuluak dira endekapen 
handiena jasaten dutenak, beste muskuluen ahuldura txikiagoa edo hautemanezina 
izanik.  
Histologiari dagokionez, muskulu biopsietan distrofia agerikoa da. Gune nekrotikoak 
zein erregeneratiboak ageri dira, baita diametro aldakorreko zuntzak eta nukleo 
zentralizatuak ere. Gaixotasunaren hasieran, gaixoa ia asintomatikoa denean, ohikoa da 
muskuluetan zein odolean eosinofiloak agertzea; gaixotasuna aurrera doan heinean 
hauek desagertuz joaten dira. Hala, zuntz lobulatuak eta mitokondrioen kokapen 
anomaloa agertzen dira, azkenik fibrosiak eta ehun adiposoak muskulua ordezkatzen 
dutelarik.  
LGMD2A-ren oinarri genetikoa aztertzerako orduan, mutazio aniztasun handia 
deskribatu da gaixoen artean. Gaur egun, gaixotasunaren eragile diren 450 mutazio 
baino gehiago aurkitu dira CAPN3 genearen baitan. Mutazio hauek aldaera desberdinak 
eragiten dituzte kalpaina 3 proteinarengan: aminoazido baten ordezkapena, irakurketa 
arauaren aldaketa, exoi berrien sorrera, eta abar eraginez. Ondorioz, sortzen den 
proteinaren funtzioa eraldatua egon daiteke, edota aldaera hauek proteinaren 
degradazioa bultzatu dezakete.  
Fenotipoari dagokionez, azpimarratzekoa da gaixoen artean ikusten den aldakortasuna, 
baita familia bereko kideen artean ere. Aldakortasun hau histologikoki ere agerikoa da. 
Saiakerak egin diren arren, ezin izan da mutazio desberdinen eta gaixoen larritasunaren 
arteko korrelazio zuzenik finkatu. Hala ere, orokorrean, proteinaren desagertzea 
eragiten duten bi mutazio (null erako mutazioak) dituzten gaixoek fenotipo larriagoa 
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garatu ohi dute, gutxienez proteinaren galtzea ez dakarren mutazio bat (missense erako 
mutazioa) daramaten gaixoekin alderatuz. 
Gaixotasunaren jatorri genetikoa garbi ezagutzen den arren, oraindik ez da ongi ulertzen 
zein den kalpaina 3 proteinaren funtzioa muskulu eskeletikoan. Bereziki, ez da ezagutzen 
kalpaina 3-ren gabeziak zergatik muskulu espezifiko batzuei eragiten dien, ezta 
endekapen hau adin jakin batetik aurrera garatzearen arrazioa ere.  
Gaixoen muskulu biopsiak eta berauetatik lortutako mioblastoen hazkuntzak tresna 
baliagarri bilakatu dira LGMD2A-ren fisiopatologia eta kalpaina 3-ren funtzioa 
ikertzerako orduan. Hala ere, gaixotasun arraroa izateak eta gaur egun diagnostiko 
genetikoa odol lagin baten bidez egiteak asko murriztu ditu ikerketarako erabilgarri 
izango liratekeen biopsien kopurua. Muga hauek gainditu nahian, gaixotasunaren sagu 
ereduak sortu dira, bai saguari CAPN3 genea isilaraziz, baita proteinaren zentro 
aktiboaren aktibitatea eragozten dion mutazioa sortuz ere. Sagu hauen azterketek 
kalpaina 3-ren ezagutzarako informazio baliagarria eman duten arren, ez dute gaixoek 
pairatzen duten muskulu-endekapen progresiboa jasaten. Hau, saguek kalpaina 3-ren 
gabeziak sortutako kalteak konpentsatzeko beste mekanismo batzuk dituztelako izan 
daiteke. Aipaturiko zailtasun hauek direla eta, gaixoetatik eratorritako eredu zelular 
ezberdinak lortzea interesgarri gerta daiteke, berauek muskulua ez den beste ehun 
batean badute ere jatorria.  
Esan bezala, bai gaixoetatik lortutako mioblastoek, baita sagu ereduek eta bestelako in 
vitro sistemek ere, kalpaina 3-k burutu ditzakeen zenbait funtzio argitu dituzte. Ikerketa 
hauen arabera, 1) kalpaina 3-k NFkB seinalizazio bidezidorrean parte har lezake, eta 
gaixoetan kalpaina 3-ren gabeziak seinalizazioa eten lezake, bere funtzio 
antiapoptotikoa galaraziz. Bestalde, 2) kalpaina 3-k muskuluko proteina estruktural 
erraldoia den titina molekulekin bat egiten du gune desberdinetan, eta honi esker 
sarkomeroaren egituraren eraldaketan parte har lezake. Era berean, 3) kalpaina 3-k bai 
sarkomeroko gune jakin batzuetan, baita mintz zelularraren inguruan beste proteina 
batzuekin konplexuak osatuz, hautemate mekanikoan eta honen erantzunean parte har 
lezake. 4) In vitro burututako esperimentuek frogatu dute kalpaina 3-k zitoeskeletoko 
proteina desberdinak proteolizatu ditzakeela, eta honen ondorioz, zitoeskeletoaren 
birmoldaketan ere parte har lezakeela. 5) Kalpaina 3-ren gabeziak mitokondrioengan ere 
eragina izan lezake, gaixoen biopsietan ikusten den kokapen ezohikoak erakusten duen 
bezala. Organulu hauetan ATParen sintesia murriztua eta estres oxidatzailea areagotuak 
aurkitu dira, beste proteinetan aldaketak eraginez. 6) Azkenaldian, kalpaina 3-k 
kaltzioaren homeostasiaren mantenuan izan dezakeen parte-hartzea garrantzia hartuz 
joan da. Ikusi denez, muskuluaren uzkurketa eragiteko erretikulu sarkoplasmikotik 
zitoplasmara doazen kaltzio isuriak murriztuta daude kalpaina 3-ren knockout sagu 
ereduan. Gainera, uzkurketaren ondoren kaltzio hau berriro ere erretikulu 
sarkoplasmikora eramaten duten SERCA garraiatzaileak ere murriztuta daude LGMD2A 
gaixoen biopsietan. 7) Azkeneko hamarkadan kalpaina 3-k muskuluko ama zeluletan 
LABURPENA 
31 
  
(zelula sateliteetan) nahiz zelula tumoralen ziklo zelularraren kontrolean izan lezakeen 
funtzioa aztergai izan da, batez ere muskulu zelulen hazkuntzetan eta baita minbiziak 
erasandako zeluletan ere. 
Aurrekari hauek kontuan hartuta, LGMD2A-ren fisiopatologiaren ulermenean aurrera 
pauso bat eman ahal izateko, ikerlan honen helburua kalpaina 3-k muskuluko zelula 
sateliteetan nahiz miogenesiaren lehenengo faseetan izan dezakeen funtzioa aztertzea 
izan da. Helburu hau betetzeko bi estrategia desberdin erabili ditugu. Alde batetik, 
gaixoen eta pertsona osasuntsuen azaleko fibroblastoak birprogramatu eta muskulura 
desberdinduz, hauen in vitro ereduak sortu ditugu, bertan kalpaina 3-ren funtzioa 
aztertzeko. Bestalde, saguen zelula sateliteak isolatu eta berauetan gene adierazpena 
eta kalpaina 3-ren gabeziak sortutako fenotipoak aztertu ditugu, jarraian azaltzen diren 
emaitzak lortuz. 
Lehenengo atalean, Donostiako Ospitale Unibertsitarioan artatzen diren LGMD2A 
gaixoen taldearen ordezkari bezala, 5 gaixo hautatu ziren ikerketa honetan parte 
hartzeko, CAPN3 genean zeramatzaten mutazioetan eta beraien gaixotasunaren 
larritasun mailan oinarrituz. Hauen azaleko zelulak, adin eta sexuz parekatutako bi 
kontrol osasuntsuren azaleko fibroblastoekin batera, birprogramatuak izan ziren. 
Horretarako, OCT4, SOX2, KLF4 eta cMYC faktoreen adierazpena bultzatzen duten 
bektore retrobiralak erabili ziren. Ondoren, horrela lortutako zelula lerroen 
pluripotentzia egiaztatzeko, karakterizazio frogak egin ziren: a) fosfatasa alkalinoaren 
aktibitatea baieztatzea, b) birprogramatzeko erabilitako transgeneen adierazpena 
isiltzea eta pluripotentzia gene endogenoen adierazpenaren aktibazioa frogatzea, c) 
zelula lerro bakoitzaren genoman integratutako transgene bakoitzaren kopurua 
zehaztea, d) pluripotentzia markatzaileak antzematea, e) zelula hauek enbrioiko hiru 
lerro germinaletatik sortutako zelula motetara desberdintzea in vitro, f) pluripotentzia 
gene espezifiko batzuen promotoreetan aldaketa epigenetikoak eman direla frogatzea 
eta g) prozesu guzti honetan kariotipoa egonkor mantendu dela egiaztatzea.  
Honen ondoren, birprogramatutako zelula lerroak, zelula sateliteen markatzaile den 
PAX7 faktorearen aldi baterako adierazpena ahalmentzen duen sistemarekin 
transduzitu ziren. Zelula hauek zazpi egunez suspentsioan eta beste zazpi egunez 
itsatsita hazi ziren eta azken lau egunetan PAX7 transkripzio faktorearen adierazpena 
aktibatuz, zelula lerro pluripotenteetatik muskuluko zelula progenitoreak lortu ziren. 
Azkenik, progenitoreen diferentziazio terminala eraginez, miotubo hazkuntzak sortu 
ziren. 
Sortutako zelula lerroek miotuboak garatzeko ahalmen desberdina erakutsi zuten. 
Desberdintasun hauek ez ziren gaixo edo kontrol izatearen menpeko, hau da, CAPN3 
genean zituzten mutazioen ondorio. Emaitza hauek, eta karakterizazio prozesuan 
lortutakoek, sortutako zelula lerroen pluripotentzia maila ez dela lerro guztietan berdina 
LABURPENA 
32 
  
pentsarazi digute. Karakterizazio froga sakonagoak baliagarriak izan daitezke hipotesi 
hau egiaztatzeko.  
Diferentziatzeko ahalmen desberdina izan arren, lerro zelularrek diferentziatzean, 
CAPN3 genearen adierazpena aktibatu zuten, eta kalpaina 3 proteina ere aurkitu zen 
diferentziatutako kontrolen hazkuntzetan eta baita gaixo batzuenetan ere. Gainera, 
kontrolen diferentziazioan, CAPN3-k muskuluaren garapenean eta birsorpenean 
burutzen duen isoforma heldugabeetatik helduetarako trantsizioa ere ikus zitekeen 
progenitoreak diferentziatu ahala. Trantsizio hau behagarria izan zen ongi 
diferentziatzen ziren zelula lerroetan, baina ez okerrago diferentiatzen zen lerro batean.  
Bestalde, birprogramatutako zeluletatik sortutako muskuluko progenitoreen 
erregenerazio gaitasuna neurtzeko, progenitore hauek saguen muskuluetan 
transplantatu ziren, eta hilabetera, transplantatutako zelulen kopurua eta hauek 
sortutako zuntz berrien kopurua aztertu ziren. Bai gaixo batetik eta bai kontrol 
osasuntsu batetik lortutako progenitoreek muskulua birsortzeko ahalmena azaldu 
zuten. Hala ere, in vitro hazkuntzetan ikusitako zelula lerroen arteko desberdintasunak 
zirela eta, transplantearen ondoren berauen artean aurkitutako desberdintasunak ez 
ziren aintzakotzat hartu.  
Beraz, proiektu honi esker ondorioztatu dezakegu CAPN3 ez dela beharrezkoa zelulen 
birprogramaziorako, eta birprogramatutako zelulak erabil ditzakegula kalpaina 3-ren 
funtzioa ikertzeko miogenesian. Hala ere, zelula lerro desberdinen arteko konparaketak 
egin ahal izateko hobekuntzak egitea beharrezko litzateke, CAPN3 geneari atxiki ezin 
zaizkion lerroen arteko desberdintasunak gutxitu edo desagertarazteko. Arazo honi 
aurre egiteko modu bat zelula lerro isogenikoak sortzea izango litzeteke, gaixoen 
zeluletako mutazioak ezabatuz edota kontrol osasuntsuen zelula lerroetan CAPN3 
genearen adierazpena isilaraziz, horretarako gaur egun eskuragarri diren edizio 
genikoko teknikak erabiliz.  
Bigarren atalean, Capn3 genearen adierazpena eta bere funtzio hipotetikoa saguen 
zelula sateliteetan aztertzeari ekin genion. Zelula sateliteak, muskulua birsortzeaz 
arduratzen diren ama zelulak dira. Egoera basalean (muskuluko minik ez denean), zelula 
hauek kieszentzian aurkitzen dira. Muskuluak min bat jasotzen duenean ordea, aktibatu, 
ugaritu, eta zelulen gehiengoak diferentziazio miogenikoari ekiten dio, ehuna 
erregeneratuz. Aktibatutako zelulen gutxiengo bat ordea berriro ere kieszentziara 
bueltatzen da, aurrerago egon litezkeen minei erantzun ahal izateko. Prozesu guzti 
hauen erregulazio zorrotza beharrezkoa da muskuluak bere erregenerazio ahalmena 
denboran zehar mantendu dezan.  
Gure hipotesiari jarraituz, kalpaina 3-k zelula sateliteetan funtziorik izan dezakeen 
aztertzeko, lehenik eta behin, Capn3 genearen adierazpena aztertu genuen saguetatik 
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isolatutako zelula sateliteetan, bai kieszentzian, baita kardiotoxina bidez eragindako 
minaren ondorioz aktibatutakoetan ere. Gene adierazpen zein zitometria bidezko 
analisien emaitzen arabera ondorioztatu genuen zelulen aktibazio maila altuena mina 
egin eta 3 egunetara lortu genuela, eta ondoren, 5 eta 7 egunetara, aktibatutako zelulen 
kopurua progresiboki murriztuz zihoala. Kalpaina 3-ren adierazpenik altuena zelula 
aktibatuetan lortu zen, mina egin eta 3 egunetara, eta bere adierazpena murriztuz joan 
zen hurrengo egunetan.  
Emaitza honek kalpaina 3-k zelula sateliteetan izan lezakeen funtzioa haratago 
aztertzeko oinarri bat ezartzen du. Jarraian, beharrezkoa litzateke kalpaina 3 proteina 
mailan ere adierazten dela frogatzea zelula hauetan. Kontuan hartuta zelula sateliteen 
isolatze prozesuaren iraupena eta kalpaina 3-ren autolisi azkarra, ezinezkotzat jo genuen 
proteina hau Western blot bidez antzematea. Aukeran, sagu osasuntsuen eta C3KO 
(Capn3 knockout) saguen zelula sateliteak isolatu eta berauen artean desberdintasun 
funtzionalak aztertzeari ekin genion. Horretarako, colony assay izeneko froga gauzatu 
genuen, eta honi esker, zelula sateliteen ugaritze ahalmena, diferentziazio miogenikoa 
zein fusio ahalmena aztertu genituen zelula hazkuntzetan, G-tool programa 
informatikoa erabiliz.  
Ez zen desberdintasunik antzeman sagu osasuntsuetatik eta C3KO saguetatik isolatutako 
zelula sateliteen ugaritze ahalmenean, ezta beraien diferentziazio miogeniko nahiz fusio 
ahalmenean ere. Zelula sateliteak soleus eta tibialis anterior muskuluetatik isolatu ziren, 
sagu zein gizakietan muskulu hauek degenerazio handia eta txikia jasaten dituztelako, 
hurrenez hurren. Hauen artean ere ez zen desberdintasunik antzeman. 
Desberdintasunik ikusi ez izanaren arrazoia esperimentuetan erabilitako saguen adin 
txikia izan daiteke. Lehenago esan bezala, saguetan muskuluaren degenerazioa oso arina 
da gaixoenarekin alderatuz, eta gainera, gaixotasun progresiboa izanik, baliteke sagu 
gazteen zelula sateliteetan oraindik desberdintasunik ez egotea.  
Beraz, emaitza guztiak kontuan hartuta, Capn3 genea zelula sateliteetan adierazten dela 
frogatu dugu, berauen aktibazioarekin bat datorren adierazpen eredua jarraituz. Sagu 
helduagoekin esperimentu funtzional, proteomiko zein transkriptomikoak burutzeak, 
kalpaina 3-k zelula sateliteetan eta orokorrean muskuluen erregenerazioan izan 
lezakeen funtzioa argituko du, LGMD2A distrofiaren fisiopatologia hobeto ulertzeko 
ezagutza eskainiz.  
Laburbilduz, proieku honetan, LGMD2A duten gaixoen azaletik abiatuta eredu zelular 
miogenikoak sortu ditugu, kalpaina 3-ren funtzioa eta LGMD2A-ren fisiopatologia 
ikertzeko baliagarri diren zelula ereduak lortuz. Eredu hauek hobetu beharra dago 
beraien artean alderagarriak izan daitezen. Garrantzitsua da eredu hauek CAPN3 
genearen adierazpena aktibatu eta beronen heltze transkripzionala eragiten dutela ongi 
diferentziatzen diren zelula lerroetan, eta kalpaina 3 proteina mailan ere antzematen 
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dela kontrol osasuntsuen hazkuntzetan eta baita gaixo batzuenetan ere. CRISPR/Cas9 
bezalako aldaketa genetikoak eragiteko ahalmena duten teknikak erabiliz zelula lerro 
isogenikoak lortuz gero, azaldutako zailtasunak gainditzea espero da. Bestalde, 
saguetan, Capn3 genearen adierazpena zelula sateliteetan antzeman izanak, kalpaina 3-
ren funtzioa zelula hauetan eta muskuluaren erregenerazioan aztertzen jarraitzeko 
abiapuntua eman digu. Funtzio hau frogatuko balitz, LGMD2A gaixotasunaren 
fisiopatologiaren ulermenean aurrerapauso bat emango litzateke eta zelula sateliteak 
gaixotasunari aurre egiteko tratamenduen helburu bilakatuko lirateke. 
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Las distrofias musculares constituyen un grupo de enfermedades de origen genético que 
causan la degeneración progresiva del músculo esquelético. Entre estas enfermedades, 
las distrofias de cinturas o LGMD (de sus siglas en inglés Limb-Girdle Muscular 
Dystrophy) forman un subgrupo de enfermedades que causan la debilidad de los 
músculos de las cinturas pélvica y escapular y los músculos proximales. De acuerdo con 
su patrón de herencia, las distrofias de cinturas se clasifican en dos grupos: las de 
herencia dominante, que se denominan LGMD1, y las de herencia recesiva, conocidas 
como LGMD2.  
Dentro de este último subgrupo, la distrofia de cinturas de tipo 2A (LGMD2A) se 
desarrolla como consecuencia de mutaciones en el gen CAPN3. Este gen codifica la 
calpaína 3, una proteasa no lisosomal que se expresa mayoritariamente en el músculo 
esquelético. El inicio de los síntomas se da generalmente en la adolescencia, aunque se 
conocen casos extremos en los que se ha desarrollado tan pronto como a los 2 años de 
edad, o en el otro extremo, a los 50. Al principio de la enfermedad, los pacientes 
comienzan a tener dificultades para subir escaleras, correr, elevar peso o levantarse de 
la silla. A medida que la debilidad muscular aumenta, los pacientes presentan 
dificultades para caminar, acabando en silla de ruedas. La debilidad muscular no afecta 
de la misma forma a todos los músculos. Los músculos del tronco y del compartimento 
posterior de los muslos son los más afectados, mientras que los demás músculos 
presentan una debilidad menor o incluso ausente.  
En lo que respecta a la histología, las biopsias musculares presentan un aspecto 
distrófico con zonas necróticas y otras regenerativas, un diámetro de fibra variable y 
núcleos centralizados. Al inicio de la enfermedad es común la presencia de infiltraciones 
eosinofílicas, que también son detectables en sangre periférica, y que van 
desapareciendo a medida que progresa la enfermedad. También son frecuentes las 
fibras lobuladas y la presencia de mitocondrias desorganizadas. En fases más avanzadas, 
el tejido fibrótico y adiposo sustituyen progresivamente al tejido muscular.  
A la hora de estudiar la causa genética de la LGMD2A, se ha descrito una extensa 
variedad de mutaciones como causantes de la enfermedad. Hoy en día se conocen más 
de 450 mutaciones patogénicas en el gen CAPN3. Estas mutaciones afectan de distinta 
forma a la proteína que sintetizan, pudiendo dar lugar al cambio de un aminoácido, a un 
cambio del marco de lectura, a la creación de neo-exones, etc. modificando la 
funcionalidad de la proteína o favoreciendo su degradación.  
Es de destacar la gran variabilidad fenotípica existente entre los pacientes, incluso entre 
los afectados de una misma familia. Esta variabilidad también es visible a nivel 
histológico. Aunque varios estudios han intentado correlacionar las distintas mutaciones 
en el gen CAPN3 y la gravedad del fenotipo que presentan los pacientes, ha sido 
imposible establecer correlaciones directas. En general, los pacientes que presentan dos 
mutaciones null (que dan lugar a la pérdida de la proteína) tienden a desarrollar 
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fenotipos más graves, en comparación con los pacientes que presentan al menos una 
mutación missense (que sí que da lugar a una proteína diferente pero completa).  
Se desconoce cuál es la función principal de la calpaína 3 en el músculo esquelético, y 
por qué su ausencia o pérdida de función da lugar a la LGMD2A. También se desconoce 
el motivo por el que la deficiencia de calpaína 3 afecta a unos músculos más que a otros, 
y por qué la degeneración muscular está ausente en los recién nacidos, y se desarrolla a 
partir de la infancia tardía, en la adolescencia o incluso en edades más tardías.  
Las biopsias musculares de pacientes y los cultivos de miotubos derivados de ellos se 
han convertido en una herramienta muy valiosa para el estudio de la función de la 
calpaína 3 y la fisiopatología de la LGMD2A. Sin embargo, el hecho de que la LGMD2A 
sea una enfermedad rara y que en la actualidad su diagnóstico se pueda realizar de 
manera directa mediante estudios moleculares a partir de muestras de sangre, ha 
minimizado el número de biopsias disponibles para investigación. 
Para hacer frente a estas limitaciones y estudiar la fisiopatología de la enfermedad, se 
han generado varios modelos murinos de calpainopatía, tanto bloqueando la expresion 
de Capn3 en estos animales como introduciendo mutaciones que bloquean su actividad 
proteolítica. Estos modelos, a pesar de que han aportado información valiosa para el 
conocimiento de las funciones de la calpaína 3, no desarrollan la degeneración muscular 
causada por la enfermedad tal y como sucede en los pacientes, probablemente porque 
los ratones poseen otros mecanismos que compensan el efecto de la deficiencia de 
calpaína 3. Como alternativa, se podrían generar modelos celulares derivados de tejidos 
no musculares de pacientes que permitirían estudiar in vitro la enfermedad.  
Los estudios realizados con las biopsias de pacientes y los cultivos derivados de los 
mismos, así como los modelos murinos y los sistemas de expresión in vitro, han atribuido 
distintas funciones a la calpaína 3. De acuerdo a estos estudios, 1) la calpaína 3 podría 
participar en la vía de señalización NFkB, por lo que esta vía de señalización estaría 
desregulada en los pacientes, impidiendo que lleve a cabo su función antiapoptótica. 2) 
Por otro lado, se ha demostrado que la calpaína 3 interacciona en varias localizaciones 
con la titina, una proteína gigante del músculo con función estructural, y que a través de 
estas interacciones podría participar en el remodelado del sarcómero. 3) A su vez, la 
calpaína podría participar en la transducción de señales mediante su interacción con 
proteínas del sarcómero y de la membrana celular. 4) También se ha demostrado que la 
calpaína 3 es capaz de proteolizar numerosas proteínas del citoesqueleto in vitro, por lo 
que se espera que podría participar en el remodelado del citoesqueleto. 5) La calpaína 3 
podría jugar un papel en las mitocondrias, las cuales se encuentran desorganizadas en 
algunas fibras musculares de pacientes de LGMD2A, lo que se correlaciona con una 
capacidad reducida de síntesis de ATP y un aumento del estrés oxidativo que se refleja 
en las modificaciones protéicas. 6) La calpaína 3 también podría participar en el 
mantenimiento de la homeotasis del calcio. A este respecto, se ha visto que las 
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corrientes del calcio que se dan desde el retículo sarcoplásmico hacia el citoplasma para 
activar la contracción muscular, están disminuidas en el ratón knockout de calpaína 3. A 
su vez, también están reducidos los niveles de la proteína SERCA en biopsias de 
pacientes de LGMD2A, la cual se encarga de recaptar el calcio hacia el retículo 
sarcoplásmico para terminar la contracción. 7) Por último, en la última década se han 
publicado estudios que sugieren que la calpaína 3 podría ejercer alguna función en las 
células madre musculares, conocidas como células satélite, y en el control del ciclo 
celular en células tumorales.  
Basándonos en estos útimos estudios, nos hemos propuesto estudiar el papel que la 
calpaína 3 podría ejercer en las células satélite o en las fases tempranas de la miogénesis, 
para de esta manera contribuir al conocimiento de la fisiopatología de la LGMD2A. Para 
ello, se han diseñado dos estrategias. Por un lado, hemos establecido modelos 
miogénicos in vitro a partir de muestras de piel de pacientes de LGMD2A y de controles 
sanos. Por otro lado, hemos aislado células satélite de los músculos de ratones y hemos 
estudiado la expresión génica en ellas, así como el fenotipo al que podría dar lugar la 
falta de calpaína 3 en estas células, obteniendo los resultados que se detallan a 
continuación. 
En el primer capítulo, se seleccionaron 5 pacientes para participar en este estudio en 
representación de los pacientes de LGMD2A atendidos en el Hospital Universitario 
Donostia. La selección se realizó en base a la gravedad de su fenotipo y las mutaciones 
que albergaban en el gen CAPN3. Los fibroblastos de la piel de estos pacientes y de dos 
controles sanos pareados por edad y sexo, fueron reprogramados mediante vectores 
retrovirales que sobreexpresan los factores de transcripción OCT4, SOX2, KLF4 y cMYC. 
Como resultado, se establecieron líneas de células reprogramadas (iPSCs), cuya 
pluripotencia fue verificada mediante las siguientes pruebas de caracterización: a) 
comprobación de la actividad de la fosfatasa alcalina, b) silenciamiento de los transgenes 
utilizados para reprogramar las muestras e inducción de la expresión de genes 
endógenos de pluripotencialidad, c) determinación del número de inserciones de cada 
uno de los transgenes en el genoma de las líneas establecidas, d) detección de 
marcadores de pluripotencia, e) diferenciación in vitro hacia tipos celulares derivados 
de las tres líneas germinales embrionarias, f) detección de cambios epigenéticos en el 
patrón de metilación de los promotores de genes de pluripotencialidad, y g) 
comprobación del mantenimiento de la estabilidad del cariotipo.  
Tras ello, las células pluripotentes o iPSCs fueron transducidas con un sistema de 
sobreexpresión inducible de PAX7, y cultivadas en condiciones de inducción miogénica 
siguiendo un protocolo de siete días de cultivo en suspensión y agitación y otros siete 
días de cultivo en adherencia. Mediante la activación transitoria de la expresión de PAX7 
durante los cuatro últimos días del protocolo de inducción, se establecieron cultivos de 
progenitores miogénicos. La activación de la diferenciación terminal de estos 
progenitores dio lugar a cultivos de miotubos. 
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Las líneas pluripotentes generadas mostaron una capacidad variable de diferenciación 
miogénica. Estas diferencias no se dieron entre las líneas derivadas de pacientes y de 
controles, sino de forma general, y por tanto no fueron atribuidas a las mutaciones en 
el gen CAPN3. Estos resultados, junto con los indicios obtenidos de los resultados de la 
caracterización de las líneas pluripotentes, sugieren que las líneas reprogramadas 
adquirieron un estado de pluripotencia diferente. En este sentido, una caracterización 
más detallada de las líneas estabecidas podría corroborar dicha hipótesis.  
Sin embargo, las líneas establecidas fueron capaces de activar la expresión de CAPN3 al 
diferenciarse, y también se detectó calpaína 3 a nivel protéico en los cultivos derivados 
de controles sanos y en el de algunos pacientes. Además, a lo largo de la diferenciación 
miogénica de las líneas de controles sanos, fue posible observar la sustitución de 
tránscritos inmaduros de CAPN3 por las forma madura correspondiente, tal y como 
sucede durante el desarrollo miogénico y en modelos celulares de mioblastos. Es de 
destacar que esta sustitución se dio de forma notable en las líneas que mostraron un 
potencial de diferenciación contundente, mientras que no se dio en la línea que mostró 
una capacidad de diferenciación reducida.  
Por otro lado, con el objetivo de estudiar la capacidad regenerativa de los progenitores 
miogénicos derivados de las iPSCs, dichos progenitores fueron trasplantados en ratones 
mediante inyecciones intramusculares. Al mes, se analizó la cantidad de células 
trasplantadas que permanecían en los músculos y el número de fibras derivadas de 
dichos progenitores. Tanto los progenitores derivados de un paciente de LGMD2A como 
los derivados de un control sano mostraron capacidad regenerativa. Sin embargo, dadas 
las diferencias detectadas anteriormente en la capacidad de diferenciación de dichas 
líneas celulares, no se consideraron relevantes las comparaciones realizadas entre 
dichas líneas. 
Por tanto, concluímos que la CAPN3 no es esencial en el proceso de reprogramación 
celular, y que las células reprogramadas y los modelos derivados de ellas pueden ser 
utilizados para estudiar la función de la calpaína 3 en la miogénesis, dado que estos 
cultivos activan la expresión de CAPN3 y calpaína 3 durante su diferenciación miogénica. 
Sin embargo, es necesario optimizar el modelo para poder reducir o eliminar la 
variabilidad no atribuible a la CAPN3 y así poder realizar comparaciones entre las 
distintas líneas celulares generadas. Una opción consistiría en establecer líneas 
isogénicas, mediante la corrección de mutaciones en las líneas derivadas de pacientes o 
mediante el silenciamiento de CAPN3 en líneas de controles sanos, empleando técnicas 
de edición génica disponibles en la actualidad, como es el CRISPR/Cas9. 
En el siguiente apartado estudiamos la expresión de Capn3 y su hipotética función en 
las células satélite murinas. Las células satélite son las células madre musculares 
encargadas de la regeneración muscular. En condiciones basales (ausencia de daño 
muscular), estas células se encuentran en quiescencia. Cuando el músculo sufre un 
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daño, estas células se activan, proliferan, y la mayoría de ellas activan la diferenciación 
miogénica, regenerando el tejido muscular. A su vez, una pequeña parte de las células 
vuelve a quiescencia, para de esta manera poder hacer frente a daños musculares que 
pudieran ocurrir más adelante. Por ello, estos procesos requieren una estricta 
regulación para poder preservar la capacidad regenerativa del músculo.  
Para ahondar en nuestra hipótesis y determinar si la calpaína 3 podría ejercer alguna 
función en las células satélite, en primer lugar estudiamos la expresión génica de Capn3 
en las células satélite en quiescencia y tras su activación tras el daño inducido por la 
inyección intramuscular de cardiotoxina. Tanto los resultados de expresión de genes 
miogénicos como los resultados de la citometría nos permitieron concluir que el punto 
de mayor activación de células satélite se alcanzó a los 3 días tras la inyección de 
cardiotoxina, y que después, a los 5 y 7 días, dicha activación se fue reduciendo de forma 
progresiva. La mayor expresión de CAPN3 se detectó en las células satélite aisladas de 
las patas inyectadas con cardiotoxina a los 3 días post inyección, y su expresión se redujo 
de forma progresiva en días posteriores.  
Este resultado establece una base para seguir profundizando en el estudio de la función 
de la calpaína 3 en las células satélite. Sin embargo, para ello sería necesario corroborar 
la expresión de calpaína 3 a nivel protéico en estas células. Teniendo en cuenta la 
extensa duración del protocolo de aislamiento de células satélite y la rápida autolisis de 
la calpaína 3, se consideró inviable la detección de esta proteína mediante Western blot. 
En su lugar, se aislaron células satélite de ratones sanos y deficientes en capaína 3 
(C3KO) y se estudiaron las posibles diferencias funcionales entre ambas poblaciones 
mediante el ensayo colony assay. En concreto, este ensayo evaluó la capacidad de 
proliferación, diferenciación y fusión de las células satélite sanas y C3KO mediante el 
programa informático G-tool.  
No se encontraron diferencias funcionales entre las células satélite derivadas de ratones 
sanos y C3KO en cuanto a su capacidad proliferativa, potencial de diferenciación y fusión 
in vitro. Tampoco se encontraron diferencias entre las células satélite extraídas de 
músculos que tanto en ratones C3KO como en pacientes de LGMD2A se encuentran 
bastante afectados (soleo) y levemente afectados (tibialis anterior). La ausencia de 
diferencias fenotípicas puede deberse a la edad temprana de los ratones. Tal y como se 
ha mencionado anteriormente, la degeneración muscular es muy leve en ratones C3KO 
comparado con los pacientes de LGMD2A, y además, el hecho de que sea una 
enfermedad de caracter progresivo podría hacer que las células satélite de estos ratones 
no presentaran ningún fenotipo en edades tempranas.  
Por tanto, considerando estos resultados, se puede concluir que la Capn3 se expresa en 
células satélite, siguiendo un patrón dependiente de su activación. La realización de 
experimentos funcionales, proteómicos y transcriptómicos en células satélite aisladas 
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de ratones de edades más avanzadas esclarecerá el papel de la calpaína 3 en las células 
satélite, y en general, en el proceso de regeneración muscular, proporcionando 
conocimientos que permitan avanzar en el entendimiento de la fisiopatología de la 
LGMD2A. 
En conclusión, se han establecido modelos celulares miogénicos a partir de fibroblastos 
de la piel de pacientes con LGMD2A, que serán de utilidad para estudiar la función de la 
calpaína 3 y la fisiopatología de la LGMD2A. Es necesario optimizar estos modelos para 
que se puedan realizar comparaciones entre las distintas líneas celulares generadas. 
Estos modelos son capaces de activar la expresión de CAPN3 y su maduración 
transcripcional en las células que se diferencian de forma eficiente, detectándose 
calpaína 3 a nivel protéico en los cultivos derivados de controles sanos y de algunos de 
los pacientes. La obtención de líneas isogénicas mediante el empleo de técnicas de 
edición génica como el CRISPR/Cas9 prevendría gran parte de los problemas derivados 
de la variabilidad existente entre las distintas líneas celulares.  
Por otro lado, la detección de la expresión de Capn3 en células satélite de ratones 
establece una base para seguir estudiando la función que podría ejercer la calpaína 3 en 
estas células y en la regeneración muscular. Si se demostrara esta función, este 
descubrimiento supondría un avance en la comprensión de la fisiopatología de la 
LGMD2A y situaría a las células satélite como potencial diana para futuros tratamientos.  
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1. MUSCLE TISSUE  
Muscle tissue is involved in all kinds of body movements due to its ability to contract. 
This tissue can be classified into two categories based on the structure of its cells: 
striated muscle, which includes tissues showing transversal lines visible under a light 
microscope, and smooth muscle, where transversal striations are absent. According to 
its location and function, this tissue can be further classified into three categories 
(figure 1): 
a. Skeletal muscle: Comprised of striated and multinucleated cells. It is attached to 
bones, and voluntarily performs movements of axial and appendicular skeletons, 
as well as maintaining body posture.  
b. Cardiac muscle: Comprised of striated cells that bind to each other through 
intercalated discs, creating long fiber-like structures. This tissue is only found in 
the heart, where it induces spontaneous and continuous contraction. 
c. Smooth muscle: Does not show striations since muscle proteins do not achieve 
a high enough organizational level required to build these structures. This tissue 
is found coating several body parts, such as blood vessels, urinary bladder, 
kidneys, esophagus and small intestines. Induces spontaneous and sustained 
contraction. 
 
Figure 1. Optical microscopy images of different muscle types. a) Microphotography of a longitudinal 
section of skeletal muscle, where nuclei are purple-stained and fibers are a pink color. Striations can be 
observed as slightly darker pink vertical lines. (From: Eric Grave, Getty Images). b) Microphotography of a 
longitudinal section of cardiac muscle. Arrows indicate intercalated disks (From: Dr. Gladden Willis, Getty 
Images). c) Microphotography of smooth muscle from colon tissue. (From: Ross and Pawlina, 2013).  
1.1 SKELETAL MUSCLE 
Approximately 40% of body weight in humans corresponds to skeletal muscles 
(reviewed by Frontera and Ochala, 2015). More than 600 different skeletal muscles are 
found in the human body, each one with specific size, shape and contractile properties 
that allow them to perform specific roles (Dumont et al., 2015a). This tissue has a 
remarkable adaptive potential. For example, resistance training can induce muscle 
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hypertrophy, increasing muscle size and strength, as well as modifying the fiber type 
composition of muscles. Moreover, several diseases, such as cancer and dystrophies, 
can cause muscle atrophy and loss of function (Angelini et al., 2014; Kazior et al., 2016). 
1.1.1 STRUCTURE 
The skeletal muscle cell, or myofiber, is a multinucleated structure built by mononuclear 
muscle cells known as myoblasts that fuse with each other. In these myofibers, 
sarcomeres, which are the contractile units formed by several muscle proteins, account 
for most of the cytoplasmic space and the nuclei tend to locate right below the cell 
membrane, the sarcolemma. The sarcolemma is covered by a layer of glycoproteins and 
extracellular proteins, such as collagens and laminins, known as the basal lamina, which 
is the external coat of the myofiber. Lastly, each myofiber is surrounded by an outer 
sheath of conjunctive tissue known as endomysium. This tissue contains numerous 
blood vessels and nerves and extends beyond the muscles, creating tendons and similar 
structures that generally bind the muscles to the bones. Subsequently, muscle fibers 
converge forming fascicles that are surrounded by another layer of conjunctive tissue 
known as perimysium. Several fascicles are coated by a thick layer of conjunctive tissue 
called epimysium, leading to different skeletal muscles (figure 2). 
 
Figure 2. Structure of skeletal 
muscle. Myofibers are 
surrounded by endomysium 
and packed in groups, forming 
fascicles. Fascicles are 
surrounded by perimysium, 
and different fascicles are 
finally surrounded together by 
the epimysium. 
 
 
 
 
 
 
 
As previously mentioned, sarcomeres are the contractile units of the muscles. They 
consist of thick myosin type II filaments and thin actin filaments, which connect to 
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several other muscle proteins to build the contractile units. These myofilament bundles, 
named myofibrils, are surrounded by highly developed smooth endoplasmic reticulum, 
also known as sarcoplasmic reticulum, which encloses the myofibers and plays a key 
role in the muscle contraction process by controlling calcium influxes.  
Transversal striations formed by these myofilaments can be observed in longitudinal 
sections of skeletal muscle tissue. Electron microscopy images of these sections show 
dark A bands and light I bands. A bands are the regions where thick and thin filaments 
locate together, and they show a clearer middle region known as H band, where thin 
filaments are absent. The M line is located in the middle of the H band, and it 
corresponds to the region where thick filaments come together. I bands contain 
exclusively thin filaments and they are divided by a darker line known as the Z disk, 
where thin filaments of consecutive sarcomeres join together through α-actinin (figure 
3).  
 
Figure 3. Structure of sarcomeres. a) Electron microscopy image of striated muscle, where different bands 
of the sarcomere are visible. From: http://www.ks.uiuc.edu/~ericlee/Telethonin/. b) Simplified representation 
of the sarcomere, showing the protein composition of different bands. 
Skeletal muscle is a highly vascularized tissue. Medium-size arterioles and veins are 
visible between the muscle fascicles, while small capillaries are observed within the 
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fascicles, close to myofibers. Although less frequently than vasculature, nerves and 
neuromuscular junctions are also found in muscle biopsies, but specific 
immunohistochemical reactions are often required in order to visualize them properly.  
1.1.2 MUSCLE CONTRACTION 
Calcium flows between the sarcoplasmic reticulum and the sarcoplasm control muscle 
contraction. At a molecular level, this process occurs as follows: Actin filaments are 
associated with tropomyosin and troponin molecules (figure 4.c). In resting muscles, 
these molecules block the interactions between myosin and actin. When calcium is 
released from the sarcoplasmic reticulum to the sarcoplasm, calcium ions bind troponin, 
inducing conformational changes that enable the interaction between actin and myosin 
filaments. Contractions begin with myosin tightly binding actin, in the absence of 
adenosine triphosphate (ATP) (figure 4.c1). When a myosin head binds ATP, it separates 
from actin (figure 4.c2). Hereafter, the ATP molecule is hydrolyzed into adenosine 
diphosphate (ADP) and inorganic phosphate, and consequently the head of the myosin 
molecule moves along the actin filament (figure 4.c3). Finally, the phosphate group is 
released, and myosin and actin molecules bind strongly to each other (figure 4.c4). Next, 
the ADP molecule is released, and subsequently the head of the myosin molecule 
returns to its original position, inducing the movement of the actin molecule along the 
myosin filament (figure 4.c5). Actin and myosin filaments are packed, shortening the 
length of the I band and therefore, the length of the entire sarcomere, which results in 
muscle contraction (figure 4.a and figure 4.b). Despite the central role of myosin and 
actin filaments in the contraction process, titin potentially binds to calcium ions, 
increasing filament stiffness (Herzog, 2014).  
 
Figure 4. Muscle contraction. a) Structure of sarcomere, relaxed. b) Structure of sarcomere, contracted. 
c) Contraction mechanism, where myosin and actin filaments interact through an ATP-dependent 
mechanism that induces the movement of actin filaments along myosin filaments.  
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As previously mentioned, calcium ions activate the contraction process by interacting 
with troponin. Therefore, calcium release and uptake by the sarcoplasmic reticulum, 
which acts as an intracellular calcium storage, directly regulates this process. 
The sarcoplasmic reticulum embraces the myofibrils, creating structures that resemble 
a net. Each net surrounds an I band or an A band, forming a terminal cisternae exactly 
where the A and I bands join together (figure 5.a). These cisternae work as calcium 
storages and include a high number of channels that are able to release calcium ions to 
the cytosol when required. Numerous mitochondria and glycogen molecules are also 
observed close to the sarcoplasmic reticulum, which provide the energy required for the 
contraction process. In these regions, the sarcolemma creates invaginations known as 
T tubules, which are located between the terminal cisternae, transversely to the fiber, 
and are rich in voltage-sensitive proteins. The complex formed by the T tubule and the 
two adjacent terminal cisternae is known as the triad (figure 5.b). 
 
Figure 5. The sarcoplasmic reticulum. a) Structure of sarcoplasmic reticulum (in blue), surrounding 
myofibrils. The figure shows the location of triads with regard to the sarcomeres. b) Structure of the triad, 
representing calcium release following membrane depolarization. 
When a nerve impulse reaches a neuromuscular junction, acetylcholine is released, 
inducing a localized depolarization of the sarcolemma. As a result of this depolarization, 
voltage-sensitive sodium channels are activated, allowing Na+ to flow from the 
extracellular space to the sarcoplasm. Consequently, the depolarization is quickly 
extended over the muscle cell and when it reaches a T tubule, voltage-sensitive 
dihydropyridine receptor (DHPR) channels activate and couple with the ryanodine 
receptor (RyR) channels located in the membrane of the sarcoplasmic reticulum, 
inducing a large calcium release from the terminal cisternae to the sarcoplasm (figure 
5.b). As a result of the cytoplasmic calcium increase, Ca2+ ions bind to troponin and 
activate the previously detailed contraction process (figure 4.c). At the same time, ATP-
dependent Ca2+ pumps located in the sarcoplasmic reticulum (SERCA pumps) are 
activated and reuptake Ca2+ ions to the terminal cisternae, reducing the sarcoplasmic 
calcium concentration and therefore ending the muscle contraction. An example of the 
  INTRODUCTION 
50 
  
timing of the nerve impulse, calcium release and reuptake and muscle contraction is 
represented in figure 6.  
 
Figure 6. Timing of muscle contraction. Example of 
the timing (in milliseconds) of the nerve impulse (red 
line, in millivolts, mV), variation of sarcoplasmic 
calcium concentration (blue line, micromolar 
concentration, μM) and muscle contraction (black 
line, in newtons, N). The process takes milliseconds 
and the muscle contraction lasts longer than the 
variation in calcium levels that cause it. Similarly, 
cytoplasmic calcium increase lasts longer than the 
action potential that induces it. From: 
http://www.ucl.ac.uk/~sjjgsca/MuscleControl.html 
 
The force generated by the sarcomere contraction is transmitted to the sarcolemma and 
the extracellular matrix through the costameres, which are protein complexes that 
bridge the Z-disks of the sarcomeres with the membrane and the extracellular 
components of the skeletal muscle. Several proteins found in these complexes, as well 
as sarcomeric proteins, play an essential role in muscle contraction and functioning, 
since mutations in these protein-coding genes often lead to a wide spectrum of muscle 
pathologies (reviewed by Jaka et al., 2015).  
Muscle contractions require an important energy supply, because SERCA pumps and 
myosin heads consume ATP molecules during the contraction process. This energy arises 
from anaerobic as well as aerobic metabolic pathways, depending on the contraction 
type. Fast, short and high intensity contractions use anaerobic energy sources, whereas 
energy for low intensity and prolonged contractions is from aerobic pathways.  
Anaerobic pathways comprise two main catabolic reactions to generate ATP: the 
degradation of phosphocreatine (PCr), which is catalyzed by creatine kinase, and the 
breakdown of muscle glycogen to lactate. As for aerobic metabolism, oxidation of 
carbohydrates and lipids is the principal source of ATP. Among the carbohydrates, 
muscle glycogen and extracellular glucose are the main substrates, whereas free fatty 
acids stored in skeletal muscle and adipose tissue provide energy through lipid oxidation 
pathways. In specific situations, muscle protein degradation can potentially contribute 
to ATP production through aerobic metabolism, although the energy provided is very 
limited (reviewed by Westerblad et al., 2010).  
According to the main energy source used by muscle fibers, they have been classified 
into different fiber types, which can be studied based on their specific biochemical 
features.  
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1.1.3 FIBER TYPES 
Most skeletal muscles contain a combination of different fiber types, which are classified 
according to their metabolic activity, the speed of contraction and the myosin heavy 
chain isoforms they express. The categories are: 
a. Type I fibers or slow oxidative fibers. These small fibers are reddish and they 
contain large amounts of mitochondria and high levels of myoglobin and 
cytochrome complexes. These fibers twitch slowly since their myosin ATPase 
activity is the lowest of the three fiber types, and they do not generate 
considerable force, although they are highly resistant to exhaustion.  
In humans, dorsal muscles that contribute to the maintenance of body posture 
show a high type I fiber content, and these muscles perform slow and long-lasting 
contractions.  
b. Type IIa fibers or fast oxidative glycolytic fibers. These intermediate-size fibers 
also contain a large number of mitochondria and show high myoglobin content. 
However, contrary to type I fibers, type IIa fibers contain elevated amounts of 
glycogen and they are able to perform anaerobic glycolysis. These fibers contract 
rapidly, generating an intense peak strength, and they are also resistant to 
fatigue. In immunohistochemical analyses, both type IIa and IIb fibers specifically 
react with antibodies against fast myosin heavy chain.  
c. Type IIb fibers or fast glycolytic fibers. These large fibers appear whitish and 
have lesser amounts of mitochondria and myoglobin when compared to type I 
and type IIa fibers. They have a low oxidative enzymatic rate, but possess 
considerable anaerobic enzymatic activity, besides storing glycogen. Type IIb 
fibers contract rapidly and are able to perform intense contractions, although 
they become exhausted easily due to the production of lactic acid. 
Therefore, these fibers are suitable for quick and precise contractions, such as 
the ones that control the movement of the fingers and some eye muscles. They 
also express fast myosin heavy chain.  
In humans, type IIb fibers have been reclassified as type IIx/d fibers due to their 
similarity to type IIx/d fibers found in small mammals, which also have very fast 
type IIb fibers that are absent in humans. However, they are still named as type 
IIb fibers (Scott et al., 2001). 
d. Type IIc fibers or immature fibers. These fibers are rare in adult human muscles, 
but are commonly found in developing muscles and in some pathological 
conditions.  
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Moreover, along with the mentioned features (reviewed in table 1, upper part), several 
immunohistochemical reactions are performed regularly to determine the fiber type 
composition of skeletal muscle sections. These reactions are indicated in the lower 
portion of the following table (table 1):  
 Type I Type IIa Type IIb Type IIc 
Color Red White White  
Twitch speed Slow  Fast  Fast  
Fatigability Resistant Resistant Sensitive  
Metabolic activity Oxidative Oxidative 
and 
Glycolytic 
Glycolytic  
Fast MyHC  - +++ +++ ++/+++ 
Slow MyHC +++ - - -/+/++ 
SERCA pump type Type 2 Type 1 Type 1  
SERCA pump density Low High High  
ATPase pH 9.4 + +++ +++ +++ 
ATPase pH 4.6 +++ - ++ +++ 
ATPase pH 4.3 +++ - - ++/+++ 
NADH-TR +++ ++ + ++/+++ 
Cytochrome oxidase +++ ++ + + 
Succinic dehydrogenase +++ ++ + ++ 
Table 1. Fiber types. Summary of skeletal muscle fiber type-specific features (upper part) and 
immunohistochemical reactions regularly used to identify each fiber type (lower part). -/+/++/+++ 
represent the intensity of each staining. (Adapted from: Dubowitz and Sewry, 2007; Westerblad et al.,  
2010).  
The fiber-type composition of muscles varies among people, and even in different parts 
of a specific muscle. Factors such as innervation, hormones, exercise and disuse, drugs 
or age can influence fiber typing (Pette and Staron, 2000). For example, marathon 
runners generally have a higher percentage of type I fibers in the majority of their 
muscles, whereas intermediate distance runners and swimmers usually have a higher 
percentage of type IIa fibers. Further, sprinters and weight lifters tend to have more type 
IIb fibers, compared to the average population. Fiber typing has also been observed to 
be altered in several muscular dystrophies (Reviewed by Beedle, 2016). 
1.2 MUSCLE GENERATION 
1.2.1 REGULATION OF MYOGENESIS 
Mammalian skeletal muscle formation and regeneration have generally been studied 
using murine transgenic models. These studies have shown that both processes are 
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tightly regulated by specific transcription factors. Muscle stem cell specification is driven 
by paired box protein 3/paired box protein 7 (PAX3/PAX7) transcription factors in the 
trunk and T-box transcription factor 1/pituitary homeobox 2 (TBX1/PITX2) in the head 
muscles, whereas four transcription factors known as myogenic regulatory factors 
(MRFs), control the determination of muscle stem cells and the myogenic differentiation 
process: myogenic factor 5 (MYF5), myogenic factor 6 (MYF6 or MRF4), myoblast 
determination protein 1 (MYOD1) and myogenin (MYOG) (Reviewed by Comai and 
Tajbakhsh, 2014).  
Generally, PAX3 plays an important role in the embryonic development of trunk and 
limb muscles, whereas PAX7 is critical for perinatal muscle growth and for the 
maintenance of muscle stem cells in adult muscles, also known as satellite cells (Seale 
et al., 2000; Oustanina et al., 2004; Relaix et al., 2005; Kuang et al., 2006; Relaix et al., 
2006). Several transgenic mouse models have provided vital information about this 
process. For example, depletion of Pax3-expressing cells in postnatal muscles does not 
impair muscle regeneration in adult mice (Relaix et al., 2004). Further, depletion of Pax7 
in embryos has very mild effects, but it definitively blocks satellite cell formation in adult 
mice. Moreover, Pax7-null mice progressively lose satellite cells and demonstrate 
important deficiencies in muscle regeneration, leading to death quickly after birth (Seale 
et al., 2000; Oustanina et al., 2004; Kuang et al., 2006; Relaix et al., 2006; von Maltzahn 
et al., 2013).  
MRFs regulate the progression of muscle PAX3/PAX7+ stem cells across the myogenic 
differentiation program. Among the four MRFs, MYF5, MRF4 and MYOD1 determine 
skeletal muscle cell identity during embryogenesis. In this regard, it has been observed 
that a double Myf5:MyoD1 mutant mouse model neither generates myoblasts nor 
muscle fibers but has plenty of muscle stem cells (Rudnicki et al., 1993; Kassar-
Duchossoy et al., 2004). The last MRF, myogenin, is required for muscle differentiation 
(Hasty et al., 1993; Nabeshima et al., 1993), as well as MRF4 and MYOD1, which control 
the differentiation of myoblasts into skeletal muscle fibers (Reviewed by Moncaut et al., 
2013).  
1.2.2 SKELETAL MUSCLE DEVELOPMENT 
Skeletal muscle development and its regeneration following trauma involve common 
regulatory pathways and transcription factors, such as the previously mentioned MRFs. 
However, there are notable differences between both processes.  
Embryonic myogenesis has been primarily studied in mouse and avian models. However, 
it is necessary to highlight that considerable differences in the myogenic process may 
potentially exist among species and therefore, data is required to be carefully 
considered when applying this knowledge to human myogenesis.  
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Skeletal muscle development is a regulated, sequential process. Founder stem cells are 
specified and allocated to the lineage during prenatal development. These stem cells 
differentiate into myoblasts, which proliferate and further differentiate, fusing to each 
other and generating multinucleated muscle fibers (Biressi et al., 2007; Sambasivan and 
Tajbakhsh, 2007; Tajbakhsh, 2009).  
Skeletal muscle in the mouse is established from embryonic day 8.5/9 to 18.5 (birth at 
day 19), and it continues maturing during the first 3-4 weeks after birth. The long-term 
Pax7+ satellite cells are not found in the early stages of the embryo. They show up only 
after an anlage of differentiated cells is established during mid-embryogenesis. Next, 
primary embryonic fibers are formed in the anlage, and finally these fibers act as a 
scaffold allowing the formation of secondary fetal fibers, which subsequently fuse and 
enlarge to form adult muscles (figure 7). 
  
Figure 7. Muscle generation and regeneration in mice during embryonic, fetal, perinatal and adult 
stages. (Adapted from: Tajbakhsh, 2009).  
In humans, primary fiber formation occurs at approximately 7 weeks of gestation. At this 
point, post-mitotic myoblasts fuse to form centrally nucleated myotubes. At the 
initiation, these myotubes are clustered together, surrounded by a common basal 
lamina, but as differentiation proceeds, they become separated and surrounded 
individually by the basal lamina. Next, secondary myotubes arise on the surface of 
primary fibers. Similar to primary myotubes, they are initially surrounded by the same 
basal lamina, but get separated and individually coated as differentiation progresses 
forward. The number of fibers can keep increasing until four months after birth. 
Thereafter, muscle growth only occurs as a result of the addition of myoblasts to the 
end of the fibers.  
It has been shown that fetal fibers cannot be classified into regular type 1 and type 2 
fibers until 18 weeks of gestation, and thus, they are named as type 2C fibers or 
immature fibers. Between 20 and 28 weeks, type 1 fibers begin appearing, and only after 
28 weeks of gestation type 1 and type 2 fibers can be distinguished. At birth, there are 
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still 15-20% of type 2C fibers, but in one year these fibers are reduced to 3-5%, being 60-
65% type 1 fibers and 30-35% type 2 fibers (Dubowitz and Sewry, 2007). 
Muscle development in the mouse embryo occurs differently, depending on whether 
the cells are going to give rise to trunk muscles, limb muscles or head muscles. Trunk 
and limb muscles originate from somites, which are derived from the segmentation of 
the paraxial mesoderm on either sides of the neural tube, following an anterior-
posterior gradient (Sambasivan and Tajbakhsh, 2007) (figure 8). In contrast, head 
muscles are derived from the cranial mesoderm, which is non-segmented. 
The ventral side of the somites contains sclerotomal precursors that lead to the axial 
skeleton and ribs, whereas the dorsal side of the somites gives rise to the epithelial 
dermomyotome that over time leads to all skeletal muscles of the body, the tongue and 
some neck muscles, besides several other non-muscle cell types. Myogenesis is initiated 
in the somites when Myf5 is expressed in the epaxial domain first, and later in the 
hypaxial domain. Mrf4 is induced after Myf5, although later in the developmental 
process it is only expressed in differentiating cells. MyoD1 expression is also activated 
after Myf5. These cells rapidly constitute the first skeletal muscle (anlage) of the 
embryo.  
 
 
Figure 8. Schematic representation of the initial stages of myogenesis in the mouse embryo. (Adapted 
from: Buckingham and Rigby, 2014; Tajbakhsh,2009).  
Once this anlage is established, Pax3/Pax7+ stem cells migrate from the center of the 
dermomyotome to form the underlying myotome, which is comprised of MRF-
expressing cells that will continue proliferating to build the muscles of the trunk. Pax3+ 
cells that do not express any MRF and are located in the hypaxial lip of the 
dermomyotome undergo epithelial to mesenchymal transition (EMT) and migrate to the 
forming limb buds, where they start expressing Myf5 and MyoD1 (Kassar-Duchossoy et 
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al., 2005). Hepatocyte growth factor (HGF) and its receptor c-Met are critical to induce 
this EMT transition (Brand-Saberi et al., 1996).  
Regulation of head myogenesis differs from trunk and limb myogenesis. The previously 
mentioned MRFs participate in the development of these muscles, but contrary to trunk 
and limb muscle development, where PAX3 plays a central role, TBX1 and PITX2 
transcription factors guide head muscle myogenesis (Kelly et al., 2004; Sambasivan et 
al., 2009). 
1.3 MUSCLE REGENERATION 
1.3.1  SATELLITE CELLS 
In addition to their high plasticity, skeletal muscles possess an enormous regenerative 
potential. Muscle regeneration relies on muscle stem cells, also known as satellite cells 
(Reviewed by Dumont et al., 2015a). These are mononuclear cells located between the 
sarcolemma and the basal lamina of muscle fibers (Mauro, 1961) (figure 9). Only 2 to 
10% of cell nuclei found in skeletal muscles correspond to satellite cells. However, this 
proportion in greatly influenced by factors such as age (Gibson and Schultz, 1983), 
muscle type and specie. For example, a study performed in rats demonstrated that slow 
oxidative fibers contain more satellite cells when compared to fast glycolytic fibers, likely 
due to the high repair demand of postural muscles, which contain an important 
percentage of type I fibers (Schmalbruch and Hellhammer, 1977). In humans, aging 
induces a reduction of the cross-sectional area of type II fibers, as well as a progressive 
decrease of type II fiber-associated satellite cells, whereas the cross-sectional area and 
the number of satellite cells remains relatively constant in type I fibers (Verdijk et al., 
2014).  
 
Figure 9. Schematic representation of the location of a satellite cell, between the sarcolemma and the 
basal lamina.  
In addition to their anatomic location, satellite cells are also detected based on the 
expression of specific intracellular and membrane proteins. In adult muscles, PAX7 
transcription factor is the principal satellite cell marker, which is ubiquitously expressed 
in all satellite cells, both in a quiescent and active state, and in a wide range of species. 
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Pax7 expression is essential to generate and maintain the satellite cell pool (Seale et al., 
2000; von Maltzahn et al., 2013). Myf5 and MyoD1 are highly expressed in activated 
satellite cells, but not in quiescent satellite cells. As for surface proteins, no satellite cell-
specific markers have been reported. However, several combinations of markers have 
been used to detect and isolate satellite cells through fluorescence-activated cell sorting 
(FACS) (Reviewed by Tedesco et al., 2010). For example, M-cadherin, integrin α-7, 
Integrin β-1, hepatocyte growth factor receptor (c-MET), C-X-C chemokine receptor 
factor 4 (CXCR4), syndecan-3 and syndecan-4, hematopoietic progenitor cell antigen 
CD34 (CD34), vascular cell adhesion protein 1 (VCAM1) and neural cell adhesion 
molecule 1 (NCAM1) have been described as satellite cell markers in mice, and have 
been used in FACS-based satellite cell isolation in combination with the negative 
selection of hematopoietic and endothelial cells. The negative markers include receptor-
type tyrosine-protein phosphatase C (CD45), integrin α-M (CD11b), platelet endothelial 
cell adhesion molecule (CD31), or stem cell antigen-1 (SCA-1) (table 2) (Liu et al., 2015; 
Maesner et al., 2016). Of note, some of these markers, such as CD34, are expressed in 
mouse satellite cells but not in human satellite cells (Péault et al., 2007).  
Positive 
markers 
Negative 
markers 
SCs isolated Starting 
muscles 
References 
VCAM1 CD31, CD45, 
SCA-1.  
Quiescent 
and 
activated 
Hind limb 
muscles, 
diaphragm 
(Liu et al., 2013)  
SM/2.6 CD45.  Quiescent Hind limb 
muscles 
(Fukada et al., 2007)  
CXCR4  
Integrin-β1 
CD45, MAC1, 
SCA-1.  
Quiescent Hind limb 
muscles 
(Sherwood et al., 
2004)  
CD34 CD45, SCA-1.  Quiescent Hind limb 
muscles, 
diaphragm 
(Montarras et al., 
2005)  
CD34 CD31, CD45, 
SCA-1.  
Quiescent Hind limb 
muscles 
(Joe et al., 2010)  
Integrin-α7 CD31, CD45, 
SCA-1.  
Activated Hind limb 
muscles 
(Joe et al., 2010)  
CD34 
Integrin-α7 
CD31, CD11b, 
CD45, SCA-1.  
Quiescent Tibialis anterior (Sacco et al., 2008; 
Pasut et al., 2012).  
Table 2. Overview of cell surface markers used to isolate mouse satellite cells, types of satellite cells 
isolated and tissue of origin. (From: Liu et al., 2015). 
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1.3.2 MUSCLE REGENERATION AFTER INJURY 
Skeletal muscle contains an enormous regenerative potential in adults, even after a 
massive injury that demolishes muscle structure. As previously indicated, satellite cells 
control this regeneration process. These cells are quiescent under resting conditions, 
but following muscle injury they activate, migrate to the site of the injury, proliferate 
and differentiate into skeletal muscle, regenerating the damaged tissue. This process is 
tightly controlled through the sequential expression of MRFs (figure 10). Importantly, a 
subset of activated satellite cells returns to quiescence, replenishing the satellite cell 
pool (Kuang et al., 2007). This way, skeletal muscle is able to retain its regenerative 
potential to confront subsequent muscle injuries. 
Quiescent satellite cells express Pax7 and Myf5 (except for the Myf5-negative satellite 
stem cell population, referred below). Once activated, most satellite cells commit to 
differentiation, and they express Pax7 and MyoD1, with variable expression of Myf5. 
These cells are known as myoblasts, which later exit the cell cycle to become myocytes. 
At this stage of the differentiation, expression of Pax7 and Myf5 is reduced whereas 
Mrf4 and myogenin are induced. Finally, these myocytes fuse to each other or to 
damaged fibers, downregulating MyoD1, while sarcomeric proteins such as myosin 
heavy chain (MyHC) are expressed in terminally differentiated myotubes (Reviewed by 
Dumont et al., 2015a). The balance between Pax7 and MyoD1 levels seems to 
importantly impact satellite cell fate. Thus, high Pax7:MyoD1 ratios appear to promote 
satellite cell quiescence and medium ratios allow satellite cell proliferation, while low 
Pax7:MyoD1 ratios induce their differentiation (Olguin et al., 2007). 
 
 
Figure 10. Sequential MRF and myogenic gene expression in terminally differentiating satellite cells. 
(Adapted from: Dumont et al., 2015). 
Although all adult satellite cells can be detected based on Pax7 expression, different 
satellite cell types have been identified based on MRF expression patterns and their role 
during muscle regeneration. Among them, a subset of satellite cells has been described 
as satellite stem cells, characterized by the lack of Myf5 expression both during 
development and after birth. This population, which has been estimated as 10% of the 
total satellite cell pool in mice, possesses higher self-renewal and engraftment potential 
and a lower tendency to differentiate into skeletal muscle, compared to Myf5-
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expressing satellite cells. Importantly, these Myf5-negative cells exert a key role in the 
maintenance of the muscle regenerative capacity, due to their ability to perform 
asymmetric divisions, leading to a Myf5-positive committed satellite cell and a Myf5-
negative satellite stem cell (Kuang et al., 2007). 
1.3.3 REGULATION OF SATELLITE CELL PERFORMANCE 
Satellite cell quiescence and activation are tightly regulated processes, due to their 
impact in the maintenance of the muscle regenerative capacity. Although the overall 
RNA content of quiescent satellite cells is notably reduced when compared to activated 
satellite cells, more than 500 genes have been shown to be upregulated in quiescent 
satellite cells (Fukada et al., 2007). Many of these genes are involved in common 
processes such as inhibition of cell cycle, proliferation and myogenesis, or they encode 
proteins participating in cell to cell adhesion, formation of extracellular matrix, copper 
and iron homeostasis, and lipid transportation (Fukada et al., 2007). Moreover, these 
and other studies have identified proteins specifically expressed in quiescent satellite 
cells but not in activated satellite cells, such as calcitonin receptor (Fukada et al., 2007; 
Gnocchi et al., 2009).  
It is worth noting the role of broadly expressed proteins, such as the proteins of the 
Notch pathway and the retinoblastoma tumor suppressor protein (Rb), in the regulation 
of satellite cell quiescence and activation. The Notch pathway is active in quiescent 
satellite cells (Bjornson et al., 2012; Philippos et al., 2012), likely due to the interaction 
of Notch receptors found in the satellite cell membrane with the Notch ligand delta1 
expressed at the fiber membrane. Importantly, loss of Notch signaling in quiescent 
satellite cells induces their activation and differentiation (Kuang et al., 2007; Bjornson 
et al., 2012; Philippos et al., 2012), whereas sustained activation of Notch signaling 
prevents satellite cell activation (Wen et al., 2012). Additionally, Rb is highly expressed 
in quiescent satellite cells, but it is phosphorylated and inactivated in proliferating 
satellite cells. Next in the myogenic differentiation process, Rb is dephosphorylated 
again, inducing the cell cycle withdrawal required for terminal myogenic differentiation 
(Hosoyama et al., 2011). Additional proteins involved in the regulation of the cell cycle, 
such as the negative regulator of the fibroblast growth factor 2 (FGF2) signaling pathway 
sprouty-1 and the cyclin-dependent kinase inhibitor p27kip1, are also enriched in 
quiescent satellite cells (Chakkalakal et al., 2012). 
As previously mentioned, there are several proteins that prevent satellite cell activation 
during homeostasis. Similarly, a quiescent satellite cell’s determination to activate is 
affected by numerous extracellular and intracellular factors. For example, several 
factors released following muscle injury induce satellite cell activation. Among them, 
FGF2 induces satellite cell proliferation (Kastner et al., 2000; reviewed by Fu et al., 2015) 
by activating the p38-MAPK pathway (Jones et al., 2005). Similar to FGF2, other factors 
such as hepatocyte growth factor (HGF) (Tatsumi et al., 1998) and tumor necrosis factor 
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α (TNF-α)(Li, 2003) are released following muscle injury and induce satellite cell 
activation. 
Recently, several studies have attempted to determine if the age-dependent loss of 
regenerative capacity of muscular tissue is due to the progressive reduction of satellite 
cells’ intrinsic regenerative potential or due to age-dependent changes in the satellite 
cell niche that directly affect their performance. It remains unclear whether the number 
of satellite cells declines with aging (Shefer et al., 2006) or remains relatively constant 
(Brooks et al., 2009). Importantly, satellite cells in aged organisms seem to have 
increased cycling activity in resting conditions, likely due to their reduced capacity to 
return to quiescence following activation and self-renewal (Chakkalakal et al., 2012). 
Age-dependent changes in the satellite cell microenvironment clearly affect satellite cell 
performance. Conboy and colleagues (Conboy et al., 2005) demonstrated this with 
heterochronic parabiosis experiments. The results demonstrated that exposure of aged 
satellite cells to young serum rescues their regenerative potential. Similarly, age-
dependent increases of certain circulating factors appear to act on these cells. For 
example, reduced self-renewal capacity of satellite cells in aged organisms is potentially 
caused by increased amounts of FGF2 in their microenvironment. p38, which is activated 
by FGF2 signaling and localizes asymmetrically in committed progenitor cells, is also 
elevated in aged satellite cells (Bernet et al., 2014), leading to increased myogenic 
differentiation and reduced self-renewal of the satellite cell pool. Importantly, 
pharmacological inhibition of p38 effectively rescues the regenerative potential of aged 
satellite cells (Cosgrove et al., 2014; Bernet et al., 2014). Additionally, the JAK/STAT 
pathway is involved in the age-dependent reduction of satellite cell self-renewal. This 
signaling pathway is more active in aged satellite cells when compared to young satellite 
cells, perhaps due to increased serum IL-6 levels in aged organisms (Tierney et al., 2014). 
Overactivation of JAK/STAT signaling pushes satellite stem cells to undergo asymmetric 
divisions instead of symmetric divisions, thereby decreasing the satellite stem cell self-
renewal (Price et al., 2014). Similarly, age-dependent increases of muscle transforming 
growth factor beta (TGF-β) levels activate mothers against decapentaplegic homolog 3 
(Smad3), which in turn inhibits Notch signaling, impairing satellite cell self-renewal 
(Carlson et al., 2008). Age-dependent increases of Wnt signaling in aged satellite cells 
could also impact muscle regeneration since it antagonizes Notch signaling in satellite 
cells (Brack et al., 2008) and favors the conversion of myogenic cells into fibrotic cells 
(Brack et al., 2007).  
As previously mentioned, there is evidence demonstrating the activation of cell-intrinsic 
age-dependent mechanisms that induce the loss of regenerative capacity. Sousa-Victor 
and colleagues (Sousa-Victor et al., 2014) reported that satellite cells in 30 month-old 
mice retain a reduced regenerative capacity since quiescent satellite cells switch to 
irreversible senescence, losing their ability to activate following injury. The cell cycle 
inhibitors p16INK4a and p19Arf were highly expressed in these senescent satellite cells, 
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which were not able to recover their regenerative potential even when exposed to a 
young microenvironment (Sousa-Victor et al., 2014). 
Therefore, both cell intrinsic factors and environmental changes seem to contribute to 
the age-dependent loss of muscle regenerative potential.  
1.3.4 OTHER CELL TYPES WITH SKELETAL MUSCLE REGENERATIVE 
POTENTIAL 
Besides satellite cells, several other cell types found outside of the basal lamina have 
been shown to have in vitro myogenic potential, as well as the ability to contribute to 
muscle regeneration in vivo. These cells have attracted the attention of the scientific 
community, which has tested their potential for the development of cell 
transplantation-based therapies to treat muscle pathologies.  
One of these cell types are neural stem cells (NSC), which are able to differentiate into 
skeletal muscle in vitro when cocultured with myoblasts, as well as in vivo following 
intramuscular transplantation (Galli et al., 2000). Similarly, it has been shown that bone 
marrow-transplanted cells also contribute to muscle regeneration following muscle 
injury in mice (Ferrari et al., 1998). This fact has been confirmed in humans through the 
detection of donor-derived cells in the muscles of bone marrow-transplanted Duchenne 
muscular dystrophy (DMD) patients (Gussoni et al., 2002). Additionally, therapeutic 
approaches have been tested by concentrating this myogenic progenitor-enriched 
fraction, termed side population (SP), prior to transplantation (Gussoni et al., 1999; 
Ferrari et al., 2001). The myogenic potential of pericytes has also been tested for the 
treatment of DMD (Dellavalle et al., 2007). Likewise, CD133-positive circulating stem 
cells have been shown to express early myogenic markers. CD133-positive cells have 
also been isolated from muscle, and their therapeutic potential has been tested for the 
treatment of DMD (Torrente et al., 2004; Benchaouir et al., 2007). However, each of 
these therapeutic approaches have failed to translate into treatments for affected 
humans since the frequency of the myogenic contribution of these cells is not high 
enough to functionally benefit the patients. Additional cell types have also shown 
myogenic potential, such as mesoangioblasts (Sampaolesi et al., 2003), bone marrow 
stromal cells (Dezawa et al., 2005) and myoendothelial cells (Zheng et al., 2007). 
Multipotent adipose-derived stem cells (MADSCs) also have myogenic potential that can 
be enhanced by the transient expression of MYOD1 (Goudenege et al., 2009).  
During the last decade, embryonic stem (ES) cells and induced pluripotent stem (iPS) 
cells have been investigated and appear promising for future cell-transplantation 
therapies for muscular dystrophies. Numerous protocols have been published 
describing the myogenic induction of these pluripotent stem cells, both in vitro and in 
vivo (Awaya et al., 2012; Darabi et al., 2012; Chal et al., 2015, 2016; Maffioletti et al., 
2015; Shoji et al., 2015; Iovino et al., 2016), which involve culturing the cells in specific 
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conditions, selection of myogenic cells through FACS and/or transient expression of 
exogenous genes (reviewed by Kodaka et al., 2017). 
2. MUSCULAR DYSTROPHIES, LGMD2A AND CALPAIN 3 
2.1 MUSCULAR DYSTROPHIES 
Muscular dystrophies are a heterogeneous group of inherited disorders affecting 
skeletal muscle (Emery, 2002). From a clinical point of view, these diseases induce a 
progressive muscular degeneration that leads to muscle weakness. Each type of 
muscular dystrophy shows a specific pattern of predominantly affected muscles, 
progression rate and age of onset of the symptoms. Importantly, respiratory, cardiac 
and facial muscles may also be affected in some specific muscular dystrophies. 
Myotonic dystrophy (DM), or Steinert’s Disease, is the most common form of muscular 
dystrophy in adults. DM1, the most frequent form of DM, is caused by a pathological 
(CTG) triplet expansion in the 3' untranslated region (UTR) of the dystrophia myotonica 
protein kinase (DMPK) gene. These patients suffer a progressive muscular weakness, 
atrophy and myotonia, as well as other clinical manifestations such as cardiomyopathy, 
cognitive decline, insulin resistance and cataracts, resembling an accelerated aging 
phenotype (Reviewed by Mateos-Aierdi et al., 2015). 
As for muscular dystrophies affecting children, Duchenne muscular dystrophy (DMD) 
and its more benign form known as Becker muscular dystrophy (BMD), are the most 
common and severe forms of dystrophy. These diseases are caused by mutations in the 
dystrophin-coding gene located in the X chromosome. DMD symptoms appear in the 
early childhood and muscle degeneration progresses fairly quickly. Cardiac 
abnormalities and respiratory difficulties lead to problems to the affected patients. 
Although there is no cure for these diseases, palliative care such as physiotherapy and 
assisted ventilation have effectively increased the life expectancy of patients from the 
teen years up to the 40’s or 50’s (Carter et al., 2012).  
To date, the genetic origin of most muscular dystrophies has already been elucidated 
(Kaplan and Hamroun, 2014). However, further investigation is still required to 
understand the pathogenic mechanism of many of these diseases. The disease-causing 
mutated genes encode proteins involved in a wide range of biological processes, such 
as dystrophin, which binds the sarcomere with the sarcolemma (Hoffman et al., 1987), 
emerin (Bione et al., 1994) and lamin A/C (Bonne et al., 1999), located in the nuclear 
envelope, mannosiltransferases POMT1 (D’Amico et al., 2006) and POMT2 (Biancheri et 
al., 2007), which perform post-translational glycosylation, and RNA-binding proteins, 
such as Poly(A)-binding protein PABP2 (Brais et al., 1998). Noticeably, these mutations 
affect both ubiquitously expressed and muscle-specific genes. The following figure 
(figure 11) represents proteins that lead to muscular dystrophies when mutated. 
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Figure 11. Representation of a myofiber section, where different dystrophy-related proteins are 
indicated. (Adapted from: www.afm-telethon.com).  
2.1.1 MUSCLE REGENERATION AND SATELLITE CELLS IN MUSCULAR 
DYSTROPHIES 
It is evident that muscle regeneration mechanisms are not sufficient to repair the muscle 
wasting in patients with muscular dystrophy. Several studies have shown that satellite 
cells are involved in the pathophysiology of various muscular dystrophies (reviewed by 
Randolph and Pavlath, 2015). One of the most evident cases was described by Sacco and 
colleagues (Sacco et al., 2010), who demonstrated that muscle stem cells in a DMD 
mouse model lose their regenerative potential due to their exhaustion. Next, it was 
shown that the number of satellite cells is increased in young mdx mice (a DMD mouse 
model), but however, as the disease progresses, loss of Notch signaling leads to the 
depletion of the satellite cell population, impairing the muscle regenerative potential 
(Jiang et al., 2014). In vitro studies have also reported that DMD patient-derived 
myoblasts have a considerably shortened lifespan (Webster and Blau, 1990). However, 
contrary to what is expected, some authors have reported increased satellite cell 
number in DMD patients (Kottlors and Kirschner, 2010). Similar defects have also been 
described in satellite cells in other dystrophies, such as LGMD2H (Kudryashova et al., 
2012) and myotonic dystrophy (Thornell et al., 2009). 
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Overall, this deficient satellite cell performance in muscular dystrophies may derive from 
two different causes. On the one hand, the chronic muscle degeneration occurring in 
muscular dystrophies could induce satellite cells to be constantly activated to confront 
the sustained regenerative demands of the affected tissues, leading to satellite cell 
exhaustion. On the other hand, satellite cell-intrinsic defects could emerge if the 
mutated genes that cause the dystrophy are expressed in these cells, playing a specific 
role (Morgan and Zammit, 2010).  
One example of this second cause of satellite cell impairment has been described in a 
recent study (Servián‐Morilla et al., 2016), which has identified the first case of muscular 
dystrophy due to mutations in the POGLUT1 gene. This disease presents an autosomal 
recessive inheritance pattern with late onset and has been classified as limb-girdle 
muscular dystrophy (LGMD). The genetic mutation induces a dramatic reduction of 
Notch signaling in muscle satellite cells, causing their defective self renewal and 
increased differentiation that ultimately leads to satellite cell depletion. Loss of 
adequate Notch signaling in satellite cells is also implicated in the physiopathology of 
DMD (Jiang et al., 2014). Importantly, overexpression of the Notch activator protein 
Jagged1 in dystrophin-deficient dogs has been shown to notably ameliorate dystrophic 
symptoms (Vieira et al., 2015).  
Since both the regenerative requirements, as well as satellite cell performance, appear 
to differ among different muscles (Ippolito et al., 2012; reviewed by Randolph and 
Pavlath, 2015), the implication of satellite cells in muscular dystrophies could partially 
clarify why each muscular dystrophy affects a specific subset of muscles (Reviewed by 
Randolph and Pavlath, 2015).  
2.2 LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2A 
Limb-girdle muscular dystrophy type 2A (LGMD2A) or calpainopathy (OMIM: 253600) is 
a genetically defined muscular dystrophy that presents an autosomal recessive 
inheritance pattern. LGMD2A patients develop a slowly progressive muscular weakness 
affecting both scapular and pelvic girdles, as well as proximal lower limb muscles 
(Fardeau et al., 1996a; Fardeau et al., 1996b; Kawai et al., 1998). Strickingly, two recent 
studies have reported a dominant form of calpainopathy with a similar but milder 
phenotype compared to LGMD2A (Vissing et al., 2016; Martinez-Thompson et al., 2017). 
This fact potentially impacts the study of calpainopathies, as well as the understanding 
of the role of calpain 3 in skeletal muscle. 
2.2.1 EPIDEMIOLOGY 
LGMD2A is one of the most frequent recessive LGMD forms, globally accounting for 
approximately 30% of all recessive LGMD cases (Dinçer et al., 1997; Richard et al., 1997; 
Topaloglu et al., 1997; Chae et al., 2001; de Paula et al., 2002; Zatz and Starling, 2005). 
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It is worth noting that this prevalence is considerably higher in specific regions, such as 
some Amish communities in the USA (Allamand et al., 1995), the Reunion Island, where 
95% of LGMDs correspond to calpainopathies (Fardeau et al., 1996b), and the province 
Gipuzkoa in Spain, where 79% of LGMDs are type 2A (Urtasun et al., 1998). Moreover, 
frequencies in these regions are also the highest ones known across the world, with 48 
cases per million inhabitants in the Reunion Island (Fardeau et al., 1996b), 69 cases per 
million in Gipuzkoa (Urtasun et al., 1998) and 40 cases out of 3000 inhabitants in an 
Amish population (reviewed by Gallardo, et al., 2011).  
2.2.2 CLINICAL FEATURES 
Considerable heterogeneity is observed in LGMD2A disease outcomes, both among 
affected members of the same family and among unrelated patients (Fardeau et al., 
1996a; Fardeau et al., 1996b; Pénisson-Besnier et al., 1998; Zatz et al., 2000; de Paula et 
al., 2002). Initial symptoms usually appear during the second decade of life, although 
some cases report the beginning of symptoms as early as 2 years and as late as 50 years 
of age (Reviewed by Gallardo et al., 2011). Muscle degeneration is progressive and 
patients may show a staggering or tip toe walking. Difficulties to lift weight, climb stairs, 
run and/or get up from a chair or from the floor keep increasing during the progression 
of the disease (Urtasun et al., 1998; Pollitt et al., 2001). Affected individuals become 
wheelchair-bound approximately one or two decades after the beginning of the 
symptoms, depending on the progression rate and age of onset (Fardeau et al., 1996a; 
Fardeau et al., 1996b; Urtasun et al., 1998). To date, there are no effective treatments 
for this disease, and only palliative care, such as physiotherapy, can exert beneficial 
effects in the affected patients. 
Muscle weakness predominantly affects shoulder and pelvic girdles, as well as proximal 
limb muscles. In the majority of patients, weakness begins in the pelvic girdle. However, 
in some cases shoulder girdle muscles are firstly affected, or both girdles suffer a 
simultaneous weakness. Trunk muscles and posterior thigh muscles suffer a prominent 
atrophy, being the adductor magnus and semimembranous muscle two of the 
predominantly affected muscles. A recent study has reported that soleus, vastus 
intermedius and biceps femoralis also suffer a pronounced decline in affected patients 
(Richard et al., 2016). Moreover, magnetic resonance imaging (MRI) has shown that 
some distal muscles, such as the soleus, are also affected in the early stages of the 
disease (Mercuri et al., 2005). Distal lower limb hypertrophy has been described in a 
Brazilian LGMD2A population, although this feature is not shared by most European 
patients (de Paula et al., 2002). Affected individuals may often experience contractures 
in the hips, knees, elbows, fingers, Achilles tendon and backbone area, and they might 
develop shoulder bone protrusions known as scapula alata (Pollitt et al., 2001) (figure 
12).  
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Figure 12. Magnetic resonance images and scapula alata. Magnetic resonance images of a) calves and b) 
thighs of an ambulant LGMD2A patient (kindly provided by Dr. Fernández-Torrón). c) Scapular winging in 
a LGMD2A patient. (From: Urtasun et al., 1998). 
It is worth noting that contrary to some other muscular dystrophies, cardiac and facial 
muscles are not affected in LGMD2A, and patients do not show mental retardation 
(Dinçer et al., 1997; Topaloglu et al., 1997). Some patients may experience mild 
respiratory insufficiency in advanced stages of the disease as a result of abdominal 
muscle weakness (Urtasun et al., 1998). Muscular impairment is slightly more significant 
in men than in women (Richard et al., 2016). 
Patients with the previously described dominant form of calpainopathy show clinical 
symptoms that resemble those of LGMD2A patients, although with an overall milder 
phenotype. Of note, these patients manifest myalgia and back pain as predominant 
symptoms in addition to the LGMD2A-like muscle affectation (Vissing et al., 2016). 
Blood tests show that similar to other muscular dystrophies, patients experience a 
marked increase of their serum creatine kinase (CK) levels (5-80 times increased) in the 
early stages of the disease, but it progressively decreases to normal levels in wheelchair-
bound patients (Urtasun et al., 1998). However, unaltered serum CK levels have been 
reported in several affected members of the same family with various severity (Starling 
et al., 2003). Overall, these CK increases are moderate compared to other muscular 
dystrophies such as DMD, dysferlinopathies and LGMD2I (Gallardo et al., 2011).  
2.2.3 HISTOPATHOLOGICAL FEATURES 
Similar to the clinical features of LGMD2A, muscle biopsies of these patients are greatly 
variable, even among different patients with the same mutations (Chae et al., 2001; 
Fanin et al., 2003). These biopsies display common dystrophic features, such as necrotic 
areas with regenerative regions, fiber size variability and disorganized myofibrils, as well 
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as a variable degree of fibrosis that increases as the disease progresses (figure 13) 
(Fardeau et al., 1996b; Chae et al., 2001; Keira et al., 2007). During the early stages of 
the disease, eosinophilic infiltrations are observed in these biopsies as well as in 
peripheral blood, although they tend to diminish and disappear as the disease 
progresses (Krahn et al., 2006; Amato, 2008; Krahn et al., 2011; Rosales et al., 2013). An 
increased number of apoptotic nuclei compared to other muscle dystrophies have also 
been reported (Baghdiguian et al., 1999). It is remarkable that the amount of satellite 
cells continues to increase as the disease progresses (Rosales et al., 2013).  
 
Figure 13. Hematoxylin-eosin staining of muscle sections of LGMD2A patients at different stages of the 
disease. Images show a) degenerating fibers and blood cell infiltrations, indicative of inflammation, b) 
fiber size variability, centrally nucleated regenerating fibers and fibrosis, c) considerable connective tissue 
(fibrosis) and d) adipose tissue infiltrations. Original magnification (200x) (From: Fanin and Angelini, 2015).  
Staining of muscle sections to detect oxidative enzymatic activity demonstrated that 
lobulated fibers are often found in these biopsies (Guerard et al., 1985; Kawai et al., 
1998; Chae et al., 2001; Hermanová et al., 2006; Keira et al., 2007), as it happens in other 
muscular dystrophies (Guerard et al., 1985; Figarella-Branger et al., 2002). This is 
potentially caused by disorganized mitochondria and myofibrils found in affected fibers 
(Chae et al., 2001). Biopsies of patients with the dominant form of calpainopathy show 
similar, but milder, histological traits with central nucleation and fiber size variability, 
sporadic cell necrosis, ring fibers and increased fibrosis (Vissing et al., 2016). 
As for the differential fiber type-specific affectation, muscle biopsies display different 
outcomes depending on the study sample. For example, a cohort of Japanese patients 
had an increased proportion of type I fibers, but also increased atrophy of these fibers, 
(Chae et al., 2001), whereas a cohort of Czech patients displayed a type II fiber atrophy 
and loss as well as type I lobulated and hypertrophic fibers (Hermanová et al., 2006). 
Other authors have also reported an increased number of type I fibers in muscles of 
patients in advanced disease stages (Fardeau et al., 1996b; Rosales et al., 2013).  
2.2.4 GENETIC CAUSE OF LGMD2A 
Many LGMD forms are caused by mutations in genes that encode structural muscle 
proteins. LGMD2A is caused by mutations in CAPN3 gene, which encodes an enzyme 
known as calpain 3 or p94 (Richard et al., 1995). This non-lysosomal protease is highly 
expressed in skeletal muscles and, despite its protease activity, structural roles have also 
been attributed to this protein.  
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Calpain 3 was first described in 1989, when Sorimachi and colleagues (Sorimachi et al., 
1989) detected the expression of a skeletal muscle-specific transcript that showed high 
homology with the ubiquitously expressed calpain 1 and calpain 2. CAPN3 gene is a 53Kb 
sequence located in chromosome 15q15.1-q21.1. It contains 24 exons of variable length, 
ranging from 12 to 309 nucleotides (Richard et al., 1995). To date, several transcript 
variants have been described, which are generated as a result of the alternative splicing 
of the gene and due to different promoters that can activate its transcription in different 
tissues (Herasse et al., 1999; Kawabata et al., 2003). Among them, the longest and most 
common isoform leads to an 821 amino acid calpain 3 protein.  
Since 1995, when the genetic cause of LGMD2A was discovered, more than 450 
pathogenic mutations have been reported in CAPN3 gene (Reviewed by Kramerova et 
al., 2007; Richard et al., 2016). This includes point mutations that lead to premature stop 
codons, mutations that affect splice sites, mutations that alter the reading frame, or 
even bigger insertions and deletions (http://www.dmd.nl). These mutations induce 
various protein outcomes, such as loss of the protein or the impairment of its enzymatic 
activity (Ono et al., 1998; Fanin et al., 2003). Other mutations do not alter the enzymatic 
activity, but they affect its titin-binding affinity (Ono et al., 1998; Kramerova et al., 2004), 
which suggests that calpain 3 is a multifunctional protein. Interestingly, 20-30% of 
LGMD2A patients present normal muscle calpain 3 levels in Western blot analysis. 
Besides the wide range of pathogenic mutations described, some of them are highly 
prevalent, such as the c.2362_2363delinsTCATCT, also known as the “Basque mutation” 
due to its high prevalence in this population.  
As previously mentioned, LGMD2A phenotypes are variable among different patients 
regarding their severity, age of onset and progression rate. Currently, there are several 
studies aimed to establish a relationship between the mutations observed in CAPN3 
gene in LGMD2A patients and their disease outcomes. Nevertheless, it has not been 
possible to directly correlate the mutations found in different patients and their disease 
severity (Urtasun et al., 1998; de Paula et al., 2002; Sáenz et al., 2005). However, it is 
worth noting that in general, patient with two null mutations in their CAPN3 alleles 
appear to develop a more severe phenotype of the disease with an earlier onset, 
compared to patients that harbor at least one missense mutation (Fardeau et al., 1996a; 
Fardeau et al., 1996b; Chae et al., 2001; de Paula et al., 2002; Sáenz et al., 2005; 
Hermanová et al., 2006; Fanin et al., 2007a). Intermolecular complementation could also 
partially explain this weak genotype:phenotype correlation (Sáenz et al., 2011; Ono et 
al., 2014). As previously mentioned, an autosomic dominant form of calpainopathy 
caused by a 21 bp in-frame deletion has recently been reported, demonstrating a 
comparable, but milder, phenotype than LGMD2A patients. The authors suggest that 
the mutated CAPN3 allele in these patients potentially leads to calpain 3 proteins that 
exert a dominant negative effect (Vissing et al., 2016; Martinez-Thompson et al., 2017).  
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2.2.5 EXPERIMENTAL APPROACHES TO TREAT LGMD2A 
The development of novel therapeutic approaches to treat muscular dystrophies is 
progressing rapidly. A majority of these experimental treatments consist of cell 
transplantation approaches as well as gene therapies aimed at restoring the expression 
of the wild type version of the disease-causing gene in affected tissues. However, many 
of these approaches have failed to reproduce the beneficial effects observed in 
laboratory animals when transferred to humans, primarily due to the great difficulty of 
delivering the treatment (cells, viruses, short oligonucleotide sequences, etc.) to the 
large amount of skeletal muscle tissue found in humans. 
As for calpainopathy, efficacy of adeno-associated virus-mediated gene transfer of 
calpain 3 was tested in an animal model of the disease (Bartoli et al., 2006). The therapy 
induced the expression of a functionally active calpain 3 in the sarcomere, although the 
clinical improvement was modest. Dose increases led to cardiac toxicity, but this 
undesired effect was circumvented when calpain 3 expression was restricted to skeletal 
muscle, preventing cardiac toxicity (Roudaut et al., 2013). 
In an alternative attempt, gene therapy has been studied to halt the progression of 
muscle dystrophy by transferring genes that do not cause the disease if mutated, but 
can still exert a positive effect in this tissue. Myostatin, a negative regulator of muscle 
mass, was inhibited in a mouse model of calpainopathy by overexpressing a mutated 
version of the gene (Bartoli et al., 2007). Blockage of myostatin was able to ameliorate 
the dystrophic phenotype in this animal model. However, this gene therapy was not 
successful to treat α-sarcoglycan deficiency (Bartoli et al., 2007). To date, none of these 
therapeutic approaches have been tested in LGMD2A patients. 
2.3 CALPAIN PROTEASES AND CALPAIN 3 
2.3.1 THE CALPAIN SUPERFAMILY 
Calpains (calcium-dependent papain-like proteases) are a group of non-lysosomal 
proteases whose activity depends on the intracellular calcium ion level (Guroff, 1964; 
reviewed by Goll et al., 2003). Calpains are found in a wide range of species, from 
prokaryotic organisms to mammals. Currently, 15 different calpains have been identified 
in humans, some of them ubiquitously expressed, whereas others show tissue specificity 
(table 3).  
Calpain 1 (CAPN1 or µCL) and calpain 2 (CAPN2 or mCL) are the best understood 
members since they were the first calpains to be discovered and they are both 
ubiquitously expressed. Each of them comprises two subunits: an 80 kDa subunit, where 
the active site is located, and the 28 kDa subunit known as CAPNS1, which regulates the 
activity of the 80 kDa subunit and provides stability to the protein structure, acting as a 
chaperone (reviewed by Goll et al., 2003; Kramerova, et al., 2007; Ono et al., 2016).  
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The study of the protein structure has revealed that the big subunit of calpains 
comprises at least 4 domains whereas the small subunit has at least 2 domains 
(Moldoveanu et al., 2002; Reviewed by Campbell and Davies, 2012). The domains in the 
big subunit are the following: 
Domain I: the propeptide domain.  
Domain II: the catalytic domain, named CysPc, is divided into two subdomains; PC1 
(or domain IIa) and PC2 (or domain IIb). Both subdomains harbor calcium-binding 
sites, as well as amino acids that constitute the catalytic triad.  
Domain III: this is the calcium-binding and phospholipid-binding C2 domain (Tompa 
et al., 2001), nowadays named as CBSW (Calpain-type Beta-SandWich domain). 
Domain IV: it is the C-terminal calcium-binding domain, which harbors five EF 
sequences (penta-EF, PEF). 
The small subunit consists of two domains:  
Domain V: a glycin- and proline-rich domain.  
Domain VI: an EF sequence-containing region similar to domain IV.  
Although the small subunit of calpains is ubiquitously expressed, only calpain 1 and 
calpain 2 bind this subunit in vivo (Ono and Sorimachi, 2012). Both subunits bind non-
covalently to each other through the EF domains located in their C-terminal region 
(reviewed by Goll et al., 2003; Kramerova et al., 2007; Ono et al., 2016). 
Some members of the calpain superfamily contain domains I to IV and therefore, are 
known as classical calpains, whereas other calpains that lack one or more of these 
domains are termed non-classical calpains (figure 14).  
 
Figure 14. Schematic representation of the structure of human calpains. NS, N-terminus sequence; IS1, 
Insertion Site 1; IS2, Insertion Site 2; N, N-terminus domain; GR, Gly-rich domain; MIT, microtubule 
interacting and transport motif; C2, protein C conserved domain 2; Zn, zinc-finger motif; SOL, small optic 
lobes product homology domain; IQ, calmodulin (CaM)-interacting motif. (Adapted from: Ono et al., 
2016).  
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Activity of calpains is implicated in multiple pathologies, such as cataracts (Biswas et al., 
2004) and brain ischemia (Bartus et al., 1994). Similarly, calpain deficiency can lead to 
pathological conditions, known as calpainopathies. Table 3 summarizes the expression 
preference of calpain genes and the phenotypes derived from its deficiency.  
Gene Expression preference Deficiency phenotype 
Capn1 Most cells Platelet dysfunction 
Capn2 Most cells Embryonic lethal 
CAPN3, Capn3 Skeletal muscle Muscular dystrophy 
CAPN5, Capn5 Most cells Vitreoretinopathy 
Capn6 Embryonic muscle Hypergenesis 
Capn7 Most cells Under investigation 
Capn8 Gastrointestinal tract Gastric ulcer 
Capn9 Gastrointestinal tract Gastric ulcer 
CAPN10 Most cells Type 2 diabetes 
Capn11 Testis Under investigation 
Capn12 Hair follicle Under investigation 
Capn13 Most cells No information  
CAPN14 Esophagus Eosinophilic esophagitis 
CAPN15/SOLH Most cells No information 
Capn16/Adgb/C6orf103 Testis Under investigation 
Table 3. Expression preference of calpain genes in humans (genes in capital letters) and mice (genes in 
lower case) and the phenotypes derived from their deficiency. (From: Ono and Sorimachi, 2012).  
2.3.2  CALPAIN 3 
2.3.2.1 STRUCTURE 
Calpain 3 contains the four domains found in classical calpains. Domains I-IV show more 
than 50% homology with other calpains. Importantly, calpain 3 also harbors three 
unique sequences named (1) NS, a 47 amino acid sequence located in the N-terminal 
domain, (2) IS1, a 48 amino acid sequence in domain II, and (3) IS2, a 77 amino acid 
sequence between domains III and IV, which contains a nuclear localization motif (figure 
15). Among them, IS1 and IS2 sequences are only found in calpain 3, which suggests that 
these two regions could perform calpain 3-specific roles. In particular, it has been shown 
that IS1 contains the autocatalytic activity of the enzyme (Kinbara et al., 1998).The three 
key amino acids that constitute the active site are located adjacent to IS1: Cys-105 
(located in PC1), His-262 and Asn-286 (located in PC2) (Sorimachi and Suzuki, 2001; 
Moldoveanu et al., 2002). This region itself could block the active site of calpain 3 until 
it is proteolyzed, avoiding substrates to access the active site (García-Diaz et al., 2004). 
Conversely, IS2 enables the interaction between calpain 3 and titin in the cytoplasm 
(Sorimachi et al., 1995) and it could also control the subcellular localization of calpain 3 
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since it contains a nuclear localization signal (Sorimachi et al., 1993, 1995), as well as 
exerting fodrinolytic activity (Herasse et al., 1999).  
Contrary to conventional calpains, which associate with the smaller subunit CAPNS1, 
calpain 3 molecules potentially bind in pairs through their penta-EF domains, forming 
homodimers (Kinbara et al., 1998; Ravulapalli et al., 2005; Partha et al., 2014). However, 
homodimerization of full-length calpain 3 molecules has not been reported yet, likely 
because this dimerization might be sensitive to calcium ion levels (Ono et al., 2016).  
 
Figure 15. Schematic representation of the structure of conventional calpains and calpain 3 (From: Ojima 
et al., 2005).  
2.3.2.2 EXPRESSION AND ISOFORMS 
CAPN3 is basally expressed in almost all tissues. Nonetheless, this gene is predominantly 
expressed in skeletal muscle tissue, where its expression level is ten times higher than 
that of the ubiquitous calpains (Sorimachi et al., 1989). Of note, calpain 3 levels appear 
to be higher in type IIa and type IIb fibers compared to type I fibers in porcine muscle 
extracts (Jones et al., 1999). 
Different calpain 3 isoforms have been detected in several tissues, such as the lens (Ma 
et al., 2000), retina (Azuma et al., 2000), cornea (Nakajima et al., 2001), brain and 
smooth muscle (Herasse et al., 1999), which lack one or more of the mentioned unique 
domains. Alternative promoters may also activate the transcription of calpain 3 in 
specific tissues, leading to different calpain 3 isoforms (Kawabata et al., 2003).  
Similarly to tissue-specific isoforms, different splicing variants of calpain 3 have been 
detected during embryonic muscle development, some of them lacking the exons that 
encode the IS1 region (exon 6) and/or the IS2 sequence (exons 15 and 16), or variants 
including a newly generated exon located in intron 16 (Herasse et al., 1999). These 
“immature” calpain 3 isoforms are found during embryonic development and the 
perinatal stage. However, in adult mice, they are only found in regenerating skeletal 
tissue, which suggests that IS1 and IS2 exert specific roles during adulthood (Herasse et 
al., 1999). Importantly, overexpression of the calpain 3 variant lacking IS1 region 
(encoded by exon 6) in adult mice induces centrally nucleated fibers with variable 
diameter. This phenotype has been linked to lack of proper maturation of the fibers 
rather than a defect in the regenerative process, since skeletal muscles in these mice do 
not show regenerative areas, elevated serum CK levels, or cell membrane damage 
(Spencer et al., 2002).  
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These immature isoforms are more stable than the full-length calpain 3, which is rapidly 
autolyzed both following in vitro overexpression and in muscle homogenates (Sorimachi 
et al., 1993; Kinbara et al., 1998; Guyon et al., 2003). This increased stability could be 
due to reduced sensitivity to calcium. Importantly, calpain 3 can also be activated 
through a calcium-independent mechanism (Kinbara et al., 1998).  
CAPN3 expression has also been studied in human embryos by in situ hybridization. It 
has been reported that this gene is also expressed in cardiac tissues at early 
developmental stages, but later, its expression is limited to skeletal muscle (Fougerousse 
et al., 1998). Immature CAPN3 isoforms are detected in fetal muscles beginning at 10-
12 weeks, which follow specific distribution patterns (Fougerousse et al., 1998). This 
differential splicing of CAPN3 during the embryonic development, postnatal growth and 
adulthood suggests that CAPN3 isoforms play specific roles during muscle development 
and regeneration (Kramerova et al., 2007). 
2.3.2.3 ACTIVATION MECHANISM 
The fact that full-length calpain 3 is extremely unstable in muscle extracts as well as in 
most cell lines has hampered the study of its structure and its activation mechanism 
(Sorimachi et al., 1993). Therefore, more stable mutant versions and isoforms lacking 
one or several exons have been expressed using in vitro gene expression systems and 
cell cultures to elucidate its enzymatic mechanism (Federici et al., 1999; Herasse et al., 
1999, Ono et al., 2006, 2007).  
The rapid calpain 3 degradation could be caused by its sensitivity not only to calcium 
ions, but also to sodium ions (Ono et al., 2010). Using in vitro expression systems, it has 
been determined that calpain 3 is activated at 100 mM sodium ion concentration, and 
at 0.01 mM calcium ion level. Nevertheless, these activation concentrations decrease 
substantially when both ions are added at the same time, making calpain 3 a very 
unstable protein (Ono et al., 2010). However, these values can differ in skeletal muscle 
tissue, where binding of calpain 3 to myogenic proteins could make it more resistant to 
activation. In this regard, is has also been reported that calpain 3 is only activated after 
prolonged periods of increased cytosolic calcium levels, but not after normal exercise, 
which only causes short calcium increases (Murphy and Lamb, 2009).  
Based on these and other experimental evidence, a two-step activation mechanism for 
calpain 3 has been suggested. According to this mechanism, binding of calcium ions to 
calpain 3 causes a conformational change in the proteolytic domain. Consequently, the 
three key amino acids, known as the catalytic triad, move closer to each other, forming 
the active site (García-Díaz et al., 2006). This step is known as intramolecular activation. 
Next, caIpain 3 is autolyzed at the IS1 region. As a result, the three key amino acids of 
the active site are distributed in the two resulting 31 kDa and 58 kDa fragments, but 
calpain 3 retains its enzymatic activity as long as these two fragments remain together. 
Subsequently, proteolysis of the IS2 region leads to enzymatic inactivation. Binding of 
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calpain 3 to muscle proteins, such as titin, through its IS2 region appears to prevent its 
activation (Ono et al., 2006). Recently, a protein named PLEIAD has also been found to 
interact with calpain 3, suppressing its protease activity (Ono et al., 2013). 
Phosphorylation of the IS2 region might also prevent calpain 3 autolysis in differentiated 
muscle cells, allowing calpain 3 to perform a structural role (Ojima et al., 2014).  
Importantly, Ono and colleagues have reported that calpain 3 activity of two mutated 
versions of the protein can be rescued when the two mutations are distributed in both 
protein fragments derived from IS1 autolysis. This is attributed to the intermolecular 
complementation of the two wild type fragments of the proteins (Ono et al., 2014). This 
phenomena could contribute to understanding the weak genotype:phenotype 
correlations observed among LGMD2A patients (Sáenz et al., 2011; Ono et al., 2014). 
2.3.2.4 ROLE OF CALPAIN 3 IN THE PATHOGENIC MECHANISM 
Currently, the pathogenic mechanisms that explain how mutations in CAPN3 gene cause 
LGMD2A are still unknown. Since calpain 3 potentially proteolyzes a wide range of 
proteins in vivo, it could participate in several cellular processes, such as apoptosis 
(Baghdiguian et al., 1999), myogenic differentiation and sarcomere formation 
(Kramerova et al., 2004) and maintenance of calcium homeostasis (Toral-Ojeda et al., 
2016). The fact that calpain 3 has been detected in several subcellular compartments, 
such as the M line and the Z disk of the sarcomere (Kramerova et al., 2004, 2005), 
subsarcolemmal membrane (Huang et al., 2005, 2008), the triad-associated protein 
complex (Kramerova et al., 2008), or the nucleus (Sorimachi et al., 1993; Baghdiguian et 
al., 1999; Richard et al., 2000; Benayoun et al., 2008), reinforces its multifunctionality.  
As previously mentioned, calpain 3 comprises several domains and each of them 
contributes one or more specific roles to this protein: autolytic activity, proteolytic 
activity, calcium and/or sodium sensitivity, dimerization ability, etc. It is striking that 
mutations in CAPN3 gene found in LGMD2A patients are distributed all along the entire 
gene (figure 16), and thus, each mutation would theoretically disrupt one or more 
functions of calpain 3 depending on its location and the effect (e.g., protein 
modification, protein degradation) of each specific mutation on the protein outcome. 
For example, it has been shown that the proteolytic activity of calpain 3 is normal in 32% 
of LGMD2A patient-derived biopsies (Milic et al., 2007). Therefore, alterations of 
additional calpain 3-specific functions that do not implicate its proteolytic activity also 
lead to LGMD2A.  
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Figure 16. Distribution of pathogenic mutations in CAPN3 reported in LGMD2A patients, and their 
relative frequency. (From: www.calpain.org and Ono et al., 2016). 
In addition to all the information provided by patients’ biological samples and in vitro 
systems, several mouse models of calpainopathy have been created to determine the 
role of calpain 3 in muscle biology and muscular dystrophy.  
The first knockout mouse model was developed by Richard and colleagues (Richard et 
al., 2000). The authors replaced exons 2 and 3 of the Capn3 gene with a neomycin 
resistance cassette. As a result, mRNA of Capn3 gene was nearly undetectable in skeletal 
muscles of these animals, and calpain 3 protein was absent. However, in vitro studies 
demonstrated that the neomycin resistance cassette was eliminated during the 
maturation of Capn3 mRNA, and the resulting recombinant protein preserved the titin-
binding ability in the N2A region, although contrary to wild type calpain 3, it was not 
able to perform autolysis nor fodrin proteolysis. The knocked Capn3 gene was preserved 
in the pure 129Sv mouse background, as well as in a mixed C57BL/6 - 129Svter 
background. Both mice displayed a similar dystrophic affectation observed as centrally 
nucleated fibers, necrotic and regenerative areas, inflammatory cell infiltrates and 
splitted fibers. Importantly, this phenotype was muscle-specific; psoas, soleus, and 
deltoid were predominantly affected, whereas tibialis anterior (TA) and biceps showed 
a mild phenotype and the quadriceps, gastrocnemius, and triceps brachii did not seem 
to be affected. Furthermore, these dystrophic signs were evident at two months of age 
in the 129Sv background, whereas the mixed-background strain did not develop the 
phenotype until 6 months of age. This strongly suggests that additional genetic traits 
play a role in the genotype:phenotype correlation in calpainopathy (Richard et al., 
2000b).  
Four years later, Kramerova and colleagues (Kramerova et al., 2004) developed a full 
Capn3 knockout (C3KO) mouse model. These mice were smaller than their wild type 
counterparts and had reduced muscle mass. C3KO mice developed a muscle-specific 
phenotype with reduced fiber size, inflammation and necrotic and regenerative areas 
were observed in cross-sections of gastrocnemius, soleus, TA and diaphragm. The soleus 
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and the diaphragm were the most affected muscles. The authors also discovered that 
lack of calpain 3 led to delayed myofibrillogenesis and reduced maturity of the fibers.  
Another knockout model of calpain 3 was developed by Laure and colleagues by 
targeting the exon 1 of Capn3 gene with an IRES-LacZ-Lox-PGK-Hygro-lox cassette that 
prevented its expression (Laure et al., 2009). Soleus and psoas were the most affected 
muscles in this C3-null mouse model at 7-8 months of age, whereas extensor digitorum 
longus (EDL) and TA were slightly affected and the quadriceps was unaffected.  
In combination with knockout models of the disease, in 2000 Tagawa and colleagues 
published a transgenic mouse model of calpainopathy, which ubiquitously expressed a 
mutant version of the Capn3 gene that led to a calpain 3 protein containing a single 
amino acid substitution (C129S). This mutation turned calpain 3 into a proteolytically 
inactive molecule, despite preserving its structure. Importantly, this mouse model also 
expressed the wild type calpain 3. Mutant calpain 3 expression increased with aging, 
while muscle strength decreased progressively. However, histological abnormalities 
were essentially absent in EDL and soleus muscles at 40 weeks of age, and only some 
slight dystrophic features were observed in muscles of 2 year-old transgenic mice 
(Tagawa et al., 2000). Thus, accumulation of the mutated calpain 3 might exert a toxic 
gain of function effect in skeletal muscles of this mouse model.  
In 2010, Ojima and colleagues developed a knockin model of calpainopathy (Ojima et 
al., 2010), in which the endogenous Capn3 was replaced with the previously described 
proteolitically inactive calpain 3 (C129S). This strain developed several dystrophic 
features that were detected in histological analyses, such as centrally nucleated fibers 
and necrotic and regenerative areas. This phenotype was exacerbated with aging and 
exercise. 
Each of these animal models of calpainopathy has provided valuable data to determine 
the role of calpain 3 in skeletal muscle. However, lack of functional calpain 3 in these 
mice leads to minor phenotypic traits that are far from representing the muscle 
degeneration observed in LGMD2A patients.  
Despite these mouse models of calpainopathy, Capn3 overexpression models have been 
created to assess the toxicity of calpain 3 in potential gene therapies. In this regard, 
Spencer and colleagues established three mouse models overexpressing wild type 
Capn3, as well as the developmental isoforms lacking exon 6 or exon 15, under the 
control of the skeletal muscle-specific promoter α-actin (Spencer et al., 2002). These 
models proved that wild type calpain 3 had no toxic effects when overexpressed in vivo 
in these animals. Importantly, overexpression of the developmental isoforms led to 
immature muscles, suggesting that wild type calpain 3 might play a role in the 
maturation of skeletal muscle. 
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Numerous studies have been performed to decipher the physiopathology of LGMD2A. 
These studies involve the mentioned mouse models of calpainopathy, cellular models, 
patient-derived samples and in vitro overexpression systems. Based on the results, 
multiple roles have been attributed to calpain 3, which are described below.  
2.3.2.4.1 Calpain 3 and NFkB-mediated apoptosis 
One of the earliest attempts to decipher the pathophysiology of LGMD2A associated the 
lack of calpain 3 with an altered nuclear factor kappa B (NFkB) signaling pathway, leading 
to myonuclear apoptosis (Baghdiguian et al., 1999). The common NFkB protein 
comprises two subunits known as p65 and p50, which tend to locate in the cytoplasm of 
cells due to their interaction with inhibitors of kappa B (IkB) (Baldwin, 1996). Upon 
activation by a wide range of signals, IkB proteins are degraded, allowing the 
translocation of p65 to the nucleus, which activates the expression of anti-inflammatory 
genes and cell survival genes. Therefore, this is considered as an anti-apoptotic signaling 
pathway. 
Immunofluorescence analysis of deltoid muscle sections of LGMD2A patients and 
healthy subjects revealed that IkBα tends to accumulate in patients’ fibers, retaining 
NFkB in the cytoplasm of the cells. This suggests that lack of functional calpain 3 in 
patients could prevent the degradation of this inhibitor, leading to its accumulation and 
therefore, steadily inhibiting the NFkB signaling pathway (Baghdiguian et al., 1999). In 
parallel, the number of apoptotic myonuclei observed in LGMD2A biopsies was 100 
times higher when compared to healthy controls and other muscular dystrophies. These 
TUNEL-positive cells also accumulated high IkBα levels. Therefore, the study concluded 
that inhibition of NFkB, caused by a lack of functional calpain 3, prevented the 
expression of antiapoptotic genes activated by the NFkB pathway, increasing cellular 
apoptosis (Baghdiguian et al., 1999). Indeed, a subsequent study demonstrated that 
mRNA and protein levels of the anti-apoptotic factor cellular-FLICE inhibitory protein (c-
FLIP), which is induced by the NFkB signaling pathway, were downregulated in LGMD2A 
biopsies (Benayoun et al., 2008). However, the overall number of apoptotic nuclei in 
LGMD2A muscle sections, besides being significantly higher than in other dystrophies, 
remained lower than 0.5% of total myonuclei (Baghdiguian et al., 1999), which casts 
doubts about this apoptosis rate being causative of the muscle degeneration seen in 
LGMD2A patients.  
One year later, Richard and colleagues (Richard et al., 2000) tested this hypothesis in 
their newly generated knockout mouse model of calpainopathy. The study detected 
some apoptotic myonuclei that colocalized with IkBα. NFkB displayed a subsarcolemmal 
localization in half of the fibers, whereas the other half showed a normal pattern in the 
myonuclei. Thus, the authors concluded that calpain 3 deficiency alone was not 
sufficient to induce an abnormal localization of NFkB, suggesting that an activator signal, 
such as oxidative or mechanical stress, might be necessary to clearly visualize the 
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phenotype derived from calpain 3 deficiency. Importantly, c-FLIP expression was also 
reduced in affected muscles of these mice (Benayoun et al., 2008). Apoptotic TUNEL-
positive nuclei were also detected in the C3KO mouse model (Kramerova et al., 2004), 
but contrary to previous findings, these cells were located outside of the sarcolemmal 
membrane and co-stained for CD11b, indicating that the apoptotic cells were, in fact, 
immune cells instead of myogenic cells (Kramerova et al., 2004).  
The role of the NFkB signaling pathway in calpainopathy remains controversial, since its 
constitutive activation in mice leads to muscle degeneration (Cai et al., 2004), whereas 
its inactivation in transgenic mice makes these animals resistant to atrophy (Mourkioti 
et al., 2006). In accordance with this, Rajakumar and colleagues (Rajakumar et al., 2013) 
determined that oxidative stress and protein ubiquitinylation were increased in 
calpainopathic muscles, potentially leading to the activation of the NFkB that was 
represented as nuclear translocation of the p65 subunit in patient-derived biopsies but 
not in control samples (Rajakumar et al., 2013). Consequently, these authors suggest 
that inhibition of NFkB signaling might be beneficial for LGMD2A patients. 
2.3.2.4.2 Calpain 3, titin and sarcomere remodeling 
Titin or connectin is a giant protein found in the sarcomeres, connecting the Z disks to 
the M lines, as shown in figure 3. Yeast two-hybrid studies performed in the nineties 
showed that calpain 3 was able to bind titin in two different sites, the N2 region and the 
C-terminal region of titin, which is located in the M line of the sarcomeres (figure 17) 
(Sorimachi et al., 1995; Kinbara et al., 1997).  
Since calpain 3 is highly stable in muscular tissue, but is rapidly proteolyzed in muscle 
homogenates and in vitro cellular models, it has been suggested that binding of calpain 3 
to titin potentially stabilizes this protein in its inactive state, preventing its degradation 
(Haravuori et al., 2001; Garvey et al., 2002). Titin would also directly control calpain 3 
activity by limiting its access to different substrates. It is worth noting that during 
myogenesis, titin is one of the first proteins to be synthesized, even before myosin, actin 
and nebulin (Fürst, 1989). This could be important for the quick stabilization of calpain 3 
during myogenic differentiation.  
To determine the relevance of calpain 3 binding to titin in the pathophysiology of 
LGMD2A, Ono and colleagues tested the titin-binding ability of several mutant calpain 3 
proteins harboring missense mutations found in LGMD2A patients (Ono et al., 1998). 
Interestingly, it was reported that even though each of the mutations affected the 
fodrinolytic activity of calpain 3, some of them did not alter its titin-binding ability, 
suggesting that loss of titin binding ability does not play a crucial role in the muscle 
wasting. However, Ermolova and colleagues demonstrated that calpain 3 mutants that 
preserve proteolytic activity, but lack titin-binding ability, were extremely unstable and 
caused muscle dystrophy (Ermolova et al., 2011). Thus, the interaction between 
  INTRODUCTION 
79 
  
calpain 3 and titin appears necessary, but is not sufficient to prevent muscle 
degeneration.  
Along with titin-binding ability, it has been found that calpain 3 is able to cleave titin in 
vitro. Therefore, calpain 3 may participate in sarcomere remodeling by cleaving titin 
molecules when required. This is supported by the fact that C3KO mice display abnormal 
sarcomere organization in affected muscles, although titin molecules are correctly 
distributed in the sarcomeres (Kramerova et al., 2004). In addition, overexpression of 
the calpain 3 isoform lacking IS1 (exon 6) or IS2 (exon 15) prevents the correct 
maturation of the myofibers (Spencer et al., 2002), supporting that calpain 3 participates 
in myofiber architecture. Moreover, in vivo induced sarcomere remodeling in C3KO mice 
shows ubiquitination deficiencies during remodeling, consistent with the formation of 
protein aggregates that presumably exert a cytotoxic effect in calpain 3-deficient 
muscles (Kramerova et al., 2005). Altered in vitro differentiation has also been reported 
in LGMD2A patient-derived myotubes, consistent with an inefficient replacement of 
integrin β1A expression by integrin β1D expression that occurs during regular myogenic 
differentiation (Jaka et al., 2017). Importantly, deficient induction of integrin β1D in 
patient-derived myotubes is rescued by silencing frizzled-related protein (FRZB), as well 
as following pharmacological administration of LiCl, indicating a basis for a potential 
treatment for LGMD2A patients (Jaka et al., 2017).  
Taken together, the data suggests that calpain 3 is necessary for sarcomere remodeling 
and myogenic maturation.  
2.3.2.4.3 Calpain 3 and signal transduction 
Numerous studies suggest that proteins located in the sarcomeres, as well as in the 
sarcolemma, actively participate in mechanical sensing and response of myofibers 
(Granzier and Labeit, 2004). Calpain 3 likely participates in this signal transduction 
process since it is located in both subcellular locations. 
As for sarcomeric proteins, calpain 3 has been detected in three different locations: in 
the N2 region and the M-line, interacting with titin as previously indicated, and also in 
the Z-disks, associated with α-actinin (figure 17) (Ojima et al., 2010). These three sites 
are the regions where signaling molecules, such as muscle RING finger proteins (MURFs) 
and muscle ankyrin repeat proteins (MARPs), interact with structural sarcomeric 
molecules. Therefore, calpain 3 could participate in this signal transduction via its 
interaction with signaling proteins found in these locations (Ojima et al., 2005).  
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Figure 17. Representation of the sarcomeric proteins and signaling molecules found in the M line, Z 
disks and N2A regions. (From: Ojima et al., 2005). 
Indeed, these interactions have been reported in the N2A region, where MARP2/Ankrd2 
competes with calpain 3 for binding titin in this site. Interestingly, calpain 3 also 
proteolyzes these signaling proteins (Hayashi et al., 2008).  
As for membrane proteins, calpain 3 directly interacts with the transmembrane protein 
dysferlin in vitro (Huang et al., 2005). Dysferlin participates in vesicle transportation and 
cell membrane repair. An interaction between calpain 3 and dysferlin is presumed since 
some LGMD2B patients (caused by mutations in the dysferlin-coding gene) display a 
secondary calpain 3 deficit (Anderson et al., 2000), whereas secondary dysferlin 
deficiency has been detected in some LGMD2A patients (Chrobáková et al., 2004). 
However, C3KO mice do not develop membrane alterations, which excludes the 
participation of calpain 3 in membrane repair processes. The link between calpain 3 and 
dysferlin seems to involve AHNAK, a member of the dysferlin protein complex that 
participates in the subsarcolemmal architecture of the cytoskeleton and membrane 
repair processes. AHNAK is a substrate of calpain 3 and once it is proteolyzed, it is not 
able to interact with dysferlin. Moreover, AHNAK is accumulated in muscles of LGMD2A 
patients, which could explain secondary deficiencies of calpain 3 and dysferlin found in 
LGMD2B and LGMD2A patients, respectively (Huang et al., 2008). 
Calpain 3 is additionally able to degrade alternative membrane proteins, such as M-
cadherin and membrane-associated β-catenin, which are accumulated in C3KO fibers 
(Kramerova et al., 2006). However, it is still unknown whether these protein interactions 
contribute to LGMD2A physiopathology.  
2.3.2.4.4 Calpain 3 in the regulation of the cytoskeleton 
In vitro assays have shown that calpain 3 is able to proteolyze several cytoskeletal 
components, such as filamin C (Guyon et al., 2003), filamin A (Taveau et al., 2003; Ono 
et al., 2007), talin, vinexin and erzin (Taveau et al., 2003). Therefore, calpain 3-mediated 
proteolysis might be necessary to modify the structure of muscle fibers. However, 
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despite all the efforts, it has not been confirmed that any of these and other cytoskeletal 
proteins are proteolyzed in vivo by calpain 3. 
2.3.2.4.5 Calpain 3 and calcium homeostasis 
As previously mentioned, calcium released from the sarcoplasmic reticulum to the 
cytosol of the fibers activates muscle contraction. The signal for calcium release comes 
from motor neurons, which induce a membrane depolarization that activates DHPRs 
that couple with RyR1 in skeletal muscle. These RyR1 channels are able to rapidly 
transport millions of calcium ions from the sarcoplasmic reticulum to the cytosol of the 
fibers. Following contractions, muscles are relaxed due to the SERCA pumps that 
reuptake calcium into the sarcoplasmic reticulum. This mechanism ensures the 
maintenance of calcium homeostasis in skeletal muscle tissue, which has been found 
altered in several muscular dystrophies (Reviewed by Vallejo-Illarramendi et al., 2014).  
Calpain 3 was found to proteolyze RyR1 in skeletal muscle (Shoshan-Barmatz et al., 
1994). This cleavage was thought to enhance calcium ion effluxes from the sarcoplasmic 
reticulum to the cytosol. However, contrary to the expectations, RyR1 was already 
cleaved in calpain 3-deficient myotubes (Dayanithi et al., 2009), which suggests that 
ubiquitous calpains may also cleave RyR1 in skeletal muscle (Verburg et al., 2009). 
Calcium release from the sarcoplasmic reticulum showed significant impairment in 
calpain 3-deficient myotubes following caffeine-induced RyR1 activation (Dayanithi et 
al., 2009). Additionally, it was significantly reduced in C3KO mouse-derived myotubes 
(Kramerova et al., 2008) and isolated fibers (Difranco et al., 2016). These authors 
reported that calpain 3 interacts with the glycolytic enzyme aldolase A (AldoA) and with 
RyR1 in the triads. Therefore, calpain 3-deficiency leads to inefficient recruitment of 
AldoA and RyR1 to the triads, consistent with reduced calcium effluxes (Kramerova et 
al., 2008). Calpain 3 was described in the triad in the knockin mouse model of calpain 3 
(Ojima et al., 2011). In line with previous results, calpain 3 interacted with RyR, 
calsequestrin, SERCA1a and phosphofructose kinase muscle type (PFKM), although none 
of these were proteolyzed by calpain 3. Moreover, calcium effluxes were regular in these 
mice, which indicates that calpain 3 performs a non-proteolytic role in the sarcoplasmic 
reticulum (Ojima et al., 2011).  
Importantly, a recent study has shown that calpain 3 interacts with SERCA proteins, 
which suggests that calcium impairment in LGMD2A patients does not only derive from 
deficiencies in RyR-related calcium release from the sarcoplasmic reticulum, but also 
from altered calcium reuptake to sarcoplasmic reticulum by SERCA pumps. Involvement 
of SERCA proteins in LGMD2A pathophysiology is supported by diminished amounts of 
SERCA2 and small ankyrin 1 (a SERCA1-binding protein) in LGMD2A muscle extracts, 
while they remain unaltered in other muscular dystrophies (Toral-Ojeda et al., 2016). 
Considerably reduced calpain 3 mRNA and protein levels in inclusion body myositis (IBM) 
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muscles, which also show altered calcium levels, reinforce the idea that calpain 3 plays 
a critical role in calcium homeostasis (Amici et al., 2017).  
Absence of calpain 3 in skeletal muscle also alters the calcium-calmodulin protein 
kinase-II signaling pathway, which in healthy mice promotes the expression of the slow 
form of myosin following exercise. Therefore, C3KO mice do not show this adaptive 
switch of fiber types, which could partially explain the fiber type-specific affectation of 
muscles in LGMD2A patients and mouse models of calpainopathy (Kramerova et al., 
2012). Recently, this adaptive failure has been correlated with a defective induction of 
genes involved in lipid metabolism and energy production after exercise, suggesting that 
calpain 3 deficiency leads to defective oxidative metabolism (Kramerova et al., 2016). 
Altered oxidative metabolism following exercise has also been reported in a small cohort 
of LGMD2A patients (Siciliano et al., 2015), and studies have suggested a correlation 
between CAPN3 variants and serum lipid content in specific populations (Guo et al., 
2017). 
2.3.2.4.6 Calpain 3 and mitochondria 
Lack of calpain 3 in skeletal muscles correlates with abnormal structure and distribution 
of mitochondria in C3KO mice, besides reduced ATP production in mitochondria and 
elevated oxidative stress, leading to increased protein modifications by free radicals 
(Kramerova et al., 2009). These abnormalities have been confirmed in LGMD2A patient 
muscles, which also show deficient levels of mitochondrial antioxidant enzymes such as 
superoxide dismutase 1 (SOD1) protein, as well as increased lipid peroxidation (Nilsson 
et al., 2014). Therefore, mitochondrial dysfunction seems to be involved in LGMD2A 
pathophysiology.  
2.3.2.4.7 Calpain 3 and maintenance of muscle stem cells 
Only a few studies have suggested that calpain 3 participates in the maintenance of 
muscle stem cells. Using a murine cellular model of myogenesis, CAPN3 expression was 
observed to be upregulated in reserve cells (a population of undifferentiated and 
quiescent satellite cell-like cells found in myoblast cultures) compared to proliferating 
myoblasts (Stuelsatz et al., 2010). Importantly, authors report that calpain 3 reduced the 
transcriptional activity of MYOD1, although a direct MYOD1 proteolysis by calpain 3 was 
not expected due to the different subcellular location of both proteins (Stuelsatz et al., 
2010). If this regulation of MYOD1 activity by calpain 3 is also consistent in human 
muscle progenitors, lack of functional calpain 3 in LGMD2A patients would lead to an 
inefficient maintenance of the quiescent satellite cell population due to an increased 
MYOD1 activity. However, the number of PAX7-positive cells in LGMD2A muscle biopsies 
increases as the disease progresses, and it is the highest in fibrotic tissues (Rosales et 
al., 2013). Therefore, these authors suggested that satellite cells in LGMD2A patients 
may have difficulties switching from proliferation to differentiation, leading to 
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inefficient muscle regeneration (Rosales et al., 2013). Of note, the number of type II 
fiber-associated satellite cells is reduced with aging (Verdijk et al., 2014), but this 
tendency is reversed in LGMD2A patients, who show increased Pax7-positive cell 
numbers primarily associated with type II fibers (Rosales et al.,2013). Considering this 
experimental data, satellite cells might be implicated in the pathophysiology of 
LGMD2A, although a direct role of calpain 3 in satellite cells has not been reported to 
date.  
2.3.2.4.8 Capain 3 and control of cell cycle 
Several studies have implicated calpain 3 in control of the cell cycle progression in 
different cell types. For example, it has been reported that calpain 3 participates in the 
differentiation of myeloid precursor cells into granulocytes by cleaving cyclin A (Welm 
et al., 2002). Calpain 3 isoforms have been implicated in the development of different 
tumors. For example, calpain 3 is downregulated in very aggressive and metastatic 
melanoma cells compared to treatment-responding melanoma cells, suggesting that 
calpain 3 potentially exerts a pro-apoptotic effect over these tumor cells (Moretti et al., 
2009). Contrarily, Roperto and colleagues suggested that activated calpain 3 could 
promote the proliferation of tumor cells in urothelial tumors in cattle (Roperto et al., 
2010). Indeed, calpain 3 appears to regulate the amount of the tumor suppressor 
protein p53 by promoting its degradation (Tao et al., 2013; Guan et al., 2016). However, 
overexpression of the calpain 3 isoform hMp84 in melanoma cells may induce p53 
stabilization and reduce cell proliferation (Moretti et al., 2015). Therefore, different 
calpain 3 isoforms potentially exert antagonistic roles in a wide range of cell types with 
regard to the regulation of cell cycle progression.  
Currently, it is unknown whether calpain 3 participates in the regulation of the cell cycle 
in skeletal muscle cells. Since this tissue is predominantly constituted by post-mitotic 
cells, this hypothetical role may be performed in muscle satellite cells, which require a 
strict proliferative control to retain their regenerative potential over time. 
  
  
 
  
  
  
 
 
 
 
 
 
 
 
GOALS AND 
HYPOTHESES 
 
 
  
  
GOALS AND HYPOTHESES 
87 
  
This project aims to explore the potential role of calpain 3 in the early stages of muscle 
regeneration and myogenesis, in order to contribute to the understanding of the 
pathophysiology of LGMD2A. This project will test the following hypotheses:  
 
I. It is possible to establish LGMD2A patient-specific iPSC-derived cellular 
models of the disease.  
 
II. In vitro modeling of LGMD2A through myogenic differentiation of patient-
specific iPSCs will allow investigation into the role of calpain 3 in different 
stages of the myogenic differentiation process.  
 
a. iPSC-derived PAX7-expressing muscle progenitor cells, similar to 
activated satellite cells, can be used to study the role of calpain 3 in the 
early stages of myogenesis. 
 
b. Terminal differentiation of PAX7-expressing muscle progenitor cells will 
lead to myotube cultures, which may be used to study the role of 
calpain 3 in more advanced, or even terminal, stages of myogenesis.  
 
c. Comparative study of LGMD2A- and healthy control-derived cultures will 
establish calpain 3-specific phenotypes at different stages of the 
myogenic differentiation process.  
 
III. Mutations in CAPN3 will affect the regenerative potential of iPSC-derived 
PAX7-expressing myogenic progenitors upon intramuscular transplantation.  
 
IV. CAPN3 is expressed in murine satellite cells.  
 
V. Calpain 3 plays a role in the activation, proliferation, differentiation and/or 
return to quiescence of murine satellite cells.  
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BACKGROUND AND HYPOTHESIS  
The study of the physiopathology of LGMD2A endures several challenges due to multiple 
features of this disease. One of the difficulties originates from its rare condition. 
Consequently, the number of patients providing clinical data is reduced compared to 
other diseases. Moreover, currently its genetic diagnosis is performed in blood samples 
(Blázquez et al., 2008). Therefore, the amount of muscle biopsies that were originally 
performed with diagnostic purposes and then used for research purposes has 
dramatically reduced in recent years. Thus, patient-derived muscle samples are limited 
and greatly appreciated to study the physiopathology of the disease. 
An additional difficulty when studying the role of calpain 3 in skeletal muscle lies on its 
autolytic activity, which makes it a highly unstable protein with a very short half-life 
(Fanin et al., 2007b). As a result, it has not been possible to crystalize the entire protein 
to determine its three-dimensional structure. Lack of calpain 3-specific antibodies 
suitable for immunodetection has also slowed the study of calpain 3.  
As previously reviewed, a considerable number of roles have been attributed to 
calpain 3 in skeletal muscle tissue (Kinbara et al., 1997; Baghdiguian et al., 2001; Taveau 
et al., 2003; Kramerova et al., 2004; Ojima et al., 2005, 2010; Stuelsatz et al., 2010; 
Rosales et al., 2013; Nilsson et al., 2014; Toral-Ojeda et al., 2016;). Nevertheless, to date 
none of these functions appear to explain how mutations in the calpain 3-coding gene 
lead to the muscle degeneration observed in LGMD2A patients, which predominantly 
affects a specific subset of muscles and induces progressive muscle wasting that is not 
evident in newborns, but appears in the teen years. In this regard, the large range of 
mutations observed in affected patients along with the lack of a clear 
genotype:phenotype correlation makes it more difficult to elucidate the role of calpain 3 
in skeletal muscle. 
To evade some of these obstacles in the study of the physiopathology of LGMD2A, 
several mouse models of calpainopathy have been generated (Richard et al., 2000; 
Kramerova et al., 2004; Laure et al., 2009; Ojima et al., 2010). These mice, despite 
providing valuable information about the role of calpain 3 in skeletal muscle, fail to 
reproduce the muscle wasting that occurs in LGMD2A patients. This fact suggests that 
these mouse models have compensatory mechanisms that alleviate the muscle 
degeneration caused by a lack of calpain 3 in humans. Each of these hurdles led to the 
idea that a patient-derived in vitro model of LGMD2A would be highly useful to study 
the physiopathology of the disease and to elucidate the role of calpain 3 during 
myogenesis.  
Patient-derived myoblasts, as well as healthy donor-derived myoblasts, have been 
broadly used to study the physiopathology of muscular dystrophies as well as to test the 
efficacy of molecules with possible therapeutic potential (Delaporte et al., 1990; Volonte 
et al.,2003; Petrov et al., 2006; Bou Saada et al., 2016). However, a muscle biopsy is 
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required to get this patient-specific material, which is usually uncomfortable for the 
donors and can negatively affect their daily life for several weeks following the biopsy. 
Moreover, these biopsies offer a limited amount of cells. Thus, in order to maximize this 
material, several authors have chosen to immortalize myoblasts, despite the fact that 
this process can slightly alter their properties (Mamchaoui et al., 2011; Yoon et al., 
2013). 
Alternatively, researchers have been investigating for other easy-access cell types with 
myogenic potential to establish patient-specific cellular models. In this regard, skin-
derived fibroblast transdifferentiation into myotubes through exogenous MYOD1 
expression has been very useful to establish myogenic in vitro models of a wide range 
of muscular dystrophies (Choi et al., 1990; Cooper et al., 2007). 
The development of mouse (Takahashi and Yamanaka, 2006) and human (Takahashi et 
al., 2007) induced pluripotent stem (iPS) cell lines from somatic cells has been one of 
the most important recent breakthroughs in regenerative biology and medicine. In 2006, 
the Nobel Prize winner Shinya Yamanaka and his colleague Kazutoshi Takahashi, 
described a protocol to reprogram differentiated somatic cells into an undifferentiated 
state (induced Pluripotent Stem Cells or iPSCs) via the induced expression of four 
transcription factors, referred to as Yamanaka factors: OCT4, SOX2, KLF4 and cMYC. Cell 
reprogramming provides subject-specific undifferentiated cells with unlimited 
proliferative capacity, as well as with differentiation potential to practically any cell type. 
Therefore, despite their considerable applicability to cell therapies, iPSCs are 
additionally being used to establish patient-specific cellular models of diseases 
(Ravulapalli et al., 2005; Campbell et al., 2015; Hashimoto et al., 2015; Torrent et al., 
2015; Mungenast et al., 2016; Ueki et al., 2017). These iPSC-derived patient-specific 
cellular models are useful to study the physiopathology of the diseases, as well as to test 
the efficacy of potential therapies.  
Thus, we pursued to establish patient-specific iPSC-derived myogenic cellular models of 
LGMD2A, in order to determine the role of calpain 3 during the myogenic differentiation 
process, as well as to investigate how different mutations found in LGMD2A patients 
alter this process. In particular, we wanted to study 1) the differential myogenic 
potential of healthy donor- and LGMD2A patient-derived iPSCs, 2) expression of CAPN3 
during myogenic differentiation of iPSCs and 3) in vitro and in vivo phenotypes caused 
by mutations in CAPN3 gene. 
To accomplish this, LGMD2A and healthy control-derived fibroblasts were 
reprogrammed to pluripotency. These newly established cell lines were subjected to a 
battery of characterization tests in order to assess their pluripotency. Myogenic 
differentiation was achieved following a protocol that involved the transient expression 
of exogenous PAX7, which drives pluripotent cells into muscle progenitor cells that 
afterward can be terminally differentiated into multinucleated myotubes (Darabi et al., 
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2012), leading to patient-specific myogenic cultures. Intramuscular transplantations of 
muscle progenitor cells into immunosuppressed mice were also performed to assess the 
role of calpain 3 in the in vivo regenerative potential of muscle progenitor cells (figure 
18). 
 
Figure 18. Workflow for the generation of patient-specific iPSC-derived cellular models of LGMD2A, and 
assessment of the in vivo regenerative potential of healthy and calpain 3-deficient muscle progenitor 
cells. Med.: medium.  
The previously mentioned difficulties to obtain patient muscle biopsies, as well as the 
lack of optimized protocols to isolate human satellite cells, challenges the study of the 
potential role of calpain 3 in human satellite cells and/or during early myogenesis. 
Therefore, we considered that these patient-specific iPSC-derived muscle progenitors, 
which express surface markers described in murine satellite cells (CD56, M-cadherin, 
integrin-α7, integrin-β1) and mesenchymal stem cells (CD105, CD90, and CD13) (Darabi 
et al., 2012), and their subsequent terminal differentiation may potentially contribute 
to understanding the role of calpain 3 during myogenesis.  
 
MATERIALS AND METHODS 
Selection of samples to be reprogrammed. Five LGMD2A patients evaluated at the 
Neurology Service of the Donostia University Hospital were selected to participate in 
this study. Inclusion was based on the mutations in CAPN3 gene and their disease 
phenotype, classified as mild, intermediate, advanced or severe by the physicians that 
examined these patients. Patients were graded according to an adapted version of the 
Vignos and Archibald Scale, as indicated in table 4 (From: Walton, 1981). 
Hereafter, patients were classified into different phenotypes according to their clinical 
grade and age, as shown in table 5.  
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Genetic diagnosis was performed by the Neurogenetics research group of the 
Experimental Unit located at the Donostia University Hospital, under the supervision of 
Dr. López de Munain and Dr. Amets Sáenz. Additionally, the theoretical effects of the 
mutations in the protein outcomes were determined by the same experts. Two age- and 
sex-matched healthy donor derived fibroblasts were obtained from the Basque Biobank 
and used as controls for this study. Absence of mutations in the CAPN3 gene was 
ascertained in these two samples. 
Grade Clinical data 
0 hyperCKemia, all activities normal.  
1 Normal gait, unable to run freely, myalgia. 
2 Incapacity to walk on tiptoes, wadding gait.  
3 Evident muscular weakness, steppage and climbing stairs with banister.  
4 Difficulty to rise from the floor, Gowers’ sign.  
5 Incapacity to rise from the floor.  
6 Medical incapacity to climb stairs.  
7 Incapacity to rise from a chair.  
8 Unable to walk unassisted.  
9 Unable to eat, drink or sit without assistance.  
Table 4. Modified Vignos and Archibald Scale (MVA) (From: Walton, 1981). 
 
 Age <24 Age 24-34 Age 35-44 Age >44 
Mild 0-1 0-2 0-3 0-4 
Intermediate 2 3 4 5 
Advanced 3 4 5 6 
Severe 4 or more 5 or more 6 or more 7 or more 
Table 5. Classification of LGMD2A patients into mild, intermediate, advanced or severe phenotypes 
according to their age and grade of disability assessed using the modified Vignos and Archibald Scale.  
Establishment of patient-specific fibroblast cultures. Selected patients were invited to 
participate in this study. Following acceptance, participants signed an informed consent 
prior to the sample collection. Skin samples were obtained with a punch biopsy and 
processed by the Cell Culture Platform at Biodonostia Research Institute. Skin was 
collected in RPMI 1640 medium containing 200 U/ml penicillin and 200 μg/ml 
streptomycin. Once in the cell culture hood, fatty tissue was removed from the biopsy 
using a sterile scalpel. The remaining tissue was washed with fresh medium, chopped 
into 2-3mm3 pieces and placed in culture flasks previously rinsed with MEM medium 
supplemented with 13% of newborn calf serum, 40 U/ml penicillin, 40 μg/ml 
streptomycin and 2mM L-glutamine. Flasks were incubated vertically for three hours in 
a cell incubator to favor the attachment of biopsy pieces to the flasks, and then placed 
horizontally. The medium was replaced twice a week until fibroblasts were observed in 
CHAPTER 1: Materials and methods 
95 
  
the flasks. Fibroblasts were cultured in DMEM medium containing 10% FBS, 100 U/ml 
penicillin and 100 μg/ml streptomycin, and expanded for 3-4 passages using 0.25% 
trypsin. 
Cell reprogramming: production of retroviruses expressing the 4 reprogramming 
factors. pMSCV-based retroviral vectors expressing FLAG-tagged OCT4, SOX2, KLF4 and 
cMYCT58A were packaged using Phoenix Amphotrophic cells. A GFP-expressing vector was 
used as a positive control. The day prior to the transfection, 4.5 million cells were plated 
in each of the five P100 dishes. The following day, 9 µg of each plasmid were diluted in 
Optimem together with X-tremeGene9 DNA Transfection reagent. Following a 
25- minute incubation at room temperature, each of these cocktails was spread, drop 
by drop, in one of the plates containing the Phoenix Amphotrophic cells, and incubated 
overnight at 37°C. The following day, the medium of the plates was replaced with 
10.5 ml of DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml 
streptomycin and cells were incubated at 32°C to favor retroviral production. The 
following day, supernatants were collected and filtered through a low protein-binding 
0.45 µm pore filter, and used for the first fibroblast infection. An additional 10.5 ml of 
medium were added to each of the retrovirus-producing plates and these were 
incubated at 32°C for a second round of retroviral production. The next day, the 
supernatants were collected and filtered as indicated previously and culture dishes used 
for retroviral production were discarded. The workflow is illustrated in figure 19. 
Cell reprogramming: infection of fibroblasts with retroviral vectors. One day prior to 
the first infection, 100 000 fibroblasts of the selected samples were plated in a well of a 
six well plate. The day of the infection, cell supernatants containing retroviruses carrying 
OCT4, SOX2, KLF4 and cMYC genes were collected and filtered, as previously mentioned. 
Polybrene was added to the supernatants at a final concentration of 1 μg/ml, and these 
were combined by mixing equal volumes of each or them, which led to the infectious 
supernatant containing the four reprogramming retroviruses. In parallel, an additional 
100 000 fibroblasts from each sample were infected with the GFP-expressing retroviral 
vector and used as a positive control. Fibroblasts were spin-infected at 700 x g for 45 
minutes at 32°C. Finally, cells were incubated at 37°C for 24 hours. The following day, 
fibroblasts were infected for the second time, following the same protocol described for 
the first infection. The workflow is illustrated in figure 19. 
Cell reprogramming: cell culture during the reprogramming process. Three days 
following the second infection, the infected fibroblasts were seeded on top of non-
proliferating (irradiated) human foreskin fibroblasts (HFFs), also known as feeder cells. 
These feeder cells were previously generated by expanding CRL-2429 cells in DMEM 
medium supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin 
for three passages (up to passage 12), then irradiated with ionizing radiation at a dose 
of 40 Gy and frozen in 90% FBS/10% DMSO. Irradiated feeder cells were thawed and 
seeded in matrigel-coated dishes in DMEM medium supplemented with 10% FBS, 
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100 U/ml penicillin and 100  μg/ml streptomycin at a density of 65 000 cells/cm2, two 
days prior to seeding the infected fibroblasts on top of them. Two days after seeding the 
infected fibroblasts on top of feeder cells, the medium was switched to human 
embryonic stem cell medium (hES medium), which consisted of knockOut DMEM 
medium supplemented with 20% knockOut Serum Replacement, 2 mM GlutaMAX, 1x 
non-essential amino acids (NEAA) solution, 50 μM 2- mercaptoethanol, 100 U/ml 
penicillin, 100 μg/ml streptomycin and 10 ng/ml FGF2. This medium was replaced daily 
until colonies of reprogrammed cells appeared on top of the feeder cell layer. The 
workflow is illustrated in figure 19. 
 
Figure 19. Workflow of retroviral production, infection of donor-derived fibroblasts and culture during 
reprogramming.  
Cell reprogramming: establishment of iPSC clones, culture and expansion. In order to 
establish different reprogrammed cell lines (i.e., clones) from each sample, up to 6 
colonies from each reprogramming plate were independently picked, seeded, cultured 
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in feeder cell-coated dishes and expanded on hES medium. Feeder cells were seeded 
two days prior to passaging the reprogrammed cells, in matrigel-coated wells using 
DMEM medium supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml 
streptomycin, at a density of 65 000 cells/cm2. The following day, culture medium was 
switched to hES medium. Cell passages were performed mechanically, using a stripper 
pipette with 100 μm tips. Reprogrammed cells at early passages were mechanically 
detached and frozen in freezing medium (90% FBS/10% DMSO) to generate a frozen 
stock of the newly generated cell lines.  
Cell reprogramming: establishment and maintenance of pure (feeder-free) 
reprogrammed cell cultures. Reprogrammed cells growing over feeder cells at passage 
6 or higher were mechanically picked and seeded on matrigel-coated wells. These cells 
were cultured in hES medium that had been previously exposed to irradiated CD1-
murine embryonic fibroblasts (CD1-MEFs) for 24 hours (known as conditioned medium). 
A stock of irradiated MEFs was created following the same steps previously described 
for generating feeder cells. Alternatively, matrigel-adapted reprogrammed cells were 
cultured using the commercially available mTeSR1 medium supplemented with 
100  U/ml penicillin and 100 μg/ml streptomycin. Cell medium was replaced daily. Cells 
proliferated and formed colonies. Colonies were passaged using Trypsin-EDTA 0.05%, 
ReLeSR reagent or StemPro Accutase, depending on the purpose. Cells were seeded in 
culture medium supplemented with 5 μM Y-27632 rock inhibitor for 24 hours to improve 
cell survival following passaging. Similar to feeder-dependent reprogrammed cells, a 
stock of frozen matrigel-adapted reprogrammed cells was generated for future 
experiments. 
Characterization of reprogrammed cell lines. Once a stock of reprogrammed cells was 
created for each of the established cell lines, characterization tests were performed to 
assess their pluripotency. 
As summarized in figure 20, the characterization process began by testing alkaline 
phosphatase (AP) activity in each of the clones established per reprogrammed sample. 
Cell lines that positively stained for AP activity were further characterized by analyzing 
the gene expression rates of reprogramming transgenes and a set of endogenous 
pluripotency genes. Based on transgene silencing criteria and the induction of 
pluripotency genes, two cell lines per sample were chosen for further characterization. 
Thereafter, Southern blot analysis of transgenes allowed to verify the clonal 
independence of each pair of cell lines analyzed per sample, and one of them was 
selected for final characterization tests. These final characterization tests consisted of 
the detection of pluripotency markers, in vitro differentiation into cell types derived 
from the three embryonic germ layers, epigenetic reprogramming and verification of 
karyotype stability. In the case of karyotype abnormalities detected in a subpopulation 
of cells, these cell lines were subcloned and karyotyped again to ensure the absence of 
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genomic alterations. Following these characterization tests, cell lines that met all the 
characterization criteria were used for following differentiation experiments.  
 
Figure 20.  Schematic representation of the characterization workflow.  
Characterization: detection of alkaline phosphatase activity. AP activity was assessed 
using the alkaline phosphatase blue membrane substrate solution kit. Reprogrammed 
cell colonies grown over feeder cells were fixed by incubating them in 3.7% 
formaldehyde for 2.5 minutes. Following fixation, cells were washed twice with PBS and 
incubated in a mixture of substrate A and B (1:1) from the staining kit for 25 minutes at 
room temperature, protected from light. After the incubation, the staining solution was 
replaced with PBS and AP-expressing colonies were observed as blue colonies under an 
optic microscope.  
Characterization: gene expression analysis of pluripotency markers through qPCR. RNA 
was extracted from reprogrammed cell lines (clones) following the classical trizol-
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chloroform protocol. 1 μg of RNA was retrotranscribed using the SuperScript III kit, 
following manufacturer’s instructions. Expression of endogenous OCT4, SOX2, KLF4, 
cMYC, NANOG, CRIPTO and REX1, and transgenic OCT4, SOX2, KLF4 and cMYC 
pluripotency genes was determined through qPCR, using specific primer pairs for each 
of the genes (Aasen et al., 2008) (table 6) and SYBR green real-time master mix, in an 
Applied Biosystems StepOnePlus Real-Time PCR Machine. 
Target Forward primer Reverse primer 
Trans-OCT4 5′-TGGACTACAAGGACGACGATGA-3′ 5′-CAGGTGTCCCGCCATGA-3′  
Trans-SOX2 5′-GCTCGAGGTTAACGAATTCATGT-3′ 5′-GCCCGGCGGCTTCA-3′ 
Trans-KLF4 5′-TGGACTACAAGGACGACGATGA-3′ 5′-CGTCGCTGACAGCCATGA-3′ 
Trans-cMYC 5′-TGGACTACAAGGACGACGATGA-3′ 5′-GTTCCTGTTGGTGAAGCTAACGT-3′ 
Endo-OCT4 5′-GGGTTTTTGGGATTAAGTTCTTCA-3′ 5′-GCCCCCACCCTTTGTGTT-3′ 
Endo-SOX2 5′-CAAAAATGGCCATGCAGGTT-3′ 5′-AGTTGGGATCGAACAAAAGCTATT-3′ 
Endo-KLF4 5′-AGCCTAAATGATGGTGCTTGGT-3′ 5′-TTGAAAACTTTGGCTTCCTTGTT-3′ 
Endo-cMYC 5′-CGGGCGGGCACTTTG-3′ 5′-GGAGAGTCGCGTCCTTGCT-3′ 
NANOG 5′-ACAACTGGCCGAAGAATAGCA-3′ 5′-GGTTCCCAGTCGGGTTCAC-3′  
CRIPTO 5′-CGGAACTGTGAGCACGATGT-3′ 5′-GGGCAGCCAGGTGTCATG-3′ 
REX1 5′-CCTGCAGGCGGAAATAGAAC-3′ 5′-GCACACATAGCCATCACATAAGG-3′ 
GAPDH 5′-GCACCGTCAAGGCTGAGAAC-3′ 5′-AGGGATCTCGCTCCTGGAA-3′ 
Table 6. Primers used during gene expression analysis of pluripotency genes. In order to distinguish 
endogenous and transgenic expression of reprogramming genes, gene names are indicated with trans- 
(transgenic) and endo- (endogenous) prefixes.  
Characterization: detection of transgene insertions through Southern blot. Genomic 
DNA from two clones of each sample was isolated using the QIAamp DNA mini kit, and 
concentrated following a classical sodium acetate and ethanol-based protocol. 10 μg of 
each DNA sample were digested overnight with 50 U of HindIII and an additional 10 μg 
with 50 U of PstI, in a final volume of 50 μl. The following day, 3 μl of the digestion 
product were run on a small 1% agarose gel to verify complete digestion. If the digestion 
was incomplete, additional 20 U of the corresponding restriction enzyme were added to 
the samples and digestion was hold for 3 more hours. Once the digestion was successful, 
samples were electrophoresed in a large 1% agarose gel using fresh TAE buffer, 
denaturalized in 1.5 M NaCl/0.5 M NaOH solution for 30 minutes, washed once with 
distilled water, neutralized in 1.5 M NaCl/0.5 M Tris/0.001 EDTA, pH 6.9, for 30 minutes, 
washed once with distilled water and incubated again in neutralizing solution for 15 
minutes, washed in distilled water and transferred to a hybond nylon membrane 
overnight through capillarity.  
The next day, the membrane was washed in 1.5 M NaCl/0.17 M sodium citrate, pH 7.0, 
for 5 minutes, dried using whatman paper, and DNA was cross-linked by incubating the 
membrane for 75 seconds under UV light. Then, membranes were placed in 
hybridization tubes, wet with milliQ water, prehybridized with preheated CHURCH 
buffer (0.5 M NaPi, 7% SDS, 0.001 M EDTA) for 30 minutes at 68°C, and hybridized 
overnight at 68°C with DIG-dUTP-labeled probes 1:10 diluted in preheated CHURCH 
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buffer: the membrane containing HindIII-digested samples was incubated with the cMYC 
probe, whereas the membrane with PstI-digested samples was incubated with the KLF4 
probe. These probes were previously generated through PCR using the PCR DIG probe 
synthesis kit, the reprogramming plasmids as template and primers specified in table 7.  
The following day, membranes were washed twice in preheated 0.04 M NaPi/0.01% SDS 
buffer for 8 minutes at room temperature, followed by two more 8 minute washes in 
0.1 M maleic acid/0.15 M NaCl/0.3% tween at room temperature. Subsequently, 
membranes were blocked using the blocking reagent for 1 hour at room temperature, 
incubated with the AP-conjugated anti-DIG antibody (1:25 000 diluted in blocking 
reagent) for 1 hour at room temperature, washed again for 30 minutes in 0.1 M maleic 
acid/0.15 M NaCl/0.3% tween followed by a final 5 minute wash in 0.1 M NaCl/0.1 M 
Tris, and developed with CDP-Star chemilluminiscent substrate. Next, membranes were 
stripped by incubating them for 10 minutes in 0.5 M NaOH/1.5 M NaCl, followed by a 1 
minute wash in milliQ water and a 2 minute incubation in 50 mM NaPi. Finally, 
membranes were hybridized with the probes generated against OCT4 (membrane 
containing HindIII-digested samples) and SOX2 (membrane containing PstI-digested 
samples).The southern blot was completed similarly for cMYC and KLF4 detection. 
Primary fibroblasts of each sample were used as a negative control. 
 Forward primer Reverse primer 
SOX2 5’-AGTACAACTCCATGACCAGC-3’ 5’-TCACATGTGTGAGAGGGGC-3’ 
OCT4 5’-TAAGCTTCCAAGGCCCTCC-3’ 5’-CTCCTCCGGGTTTTGCTCC-3’ 
KLF4 5’-AATTACCCATCCTTCCTGCC-3’ 5’-TTAAAAATGCCTCTTCATGTGTA-3’ 
cMYC 5’-TCCACTCGGAAGGACTATCC-3’ 5’-TTACGCACAAGAGTTCCGTAG-3’ 
Table 7. Primers used to generate probes against the indicated targets: SOX2, OCT4, KLF4 and cMYC. 
(From: Aasen et al., 2008) 
Characterization: immunodetection of pluripotency markers. To assess the expression 
of a panel of pluripotency markers comprising the nuclear transcription factors OCT4, 
SOX2 and NANOG, the glycolipid antigens SSEA3 and SSEA4, and the keratin sulfate 
antigens TRA-1-60 and TRA-1-81, immunofluorescence detection was performed on 
reprogrammed cell colonies cultured on top of feeder cells, following the protocols 
described by Martí and colleagues (Martí et al., 2013). Cells were fixed in 4% 
paraformaldehyde for 20 minutes and stored in tris-buffered saline (TBS) at 4°C until 
immunofluorescence was performed. For immunofluorescence detection, cells were 
washed three times in TBS/0.1% triton-X100 for 15 minutes, and blocked in TBS/0.5% 
triton-X100/6% donkey serum for 2 hours at room temperature. Hereafter, samples 
were incubated with the corresponding primary antibody combinations, diluted in 
TBS/0.1% triton-X100/6% donkey serum, for 72 hours at 4°C: A) Anti-OCT4 + anti-SSEA3, 
B) Anti-SOX2 + anti-SSEA4 + anti-TRA-1-60 and C) anti-NANOG + anti-TRA- 1-81 (table 8). 
Next, samples were washed three times with TBS/0.1% triton-X100, blocked for 1 hour 
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in TBS/0.1% tritonX-100/6% donkey serum, and incubated with the corresponding 
secondary antibody combinations diluted in TBS/0.5% triton-X100/6% donkey serum, 
for two hours at room temperature, protected from light: A) goat-anti-mouseIgG-Cy2 + 
goat-anti-ratIgM-Cy3, B) donkey-anti-RabbitIgG-Cy2 + goat-anti-mouseIgG-Cy3 + goat-
anti-mouseIgG-Cy5, C) donkey-anti-goatIgG-Cy2 + donkey-anti-mouseIgM-Cy3 (table 8). 
Finally, samples were washed 3 more times, incubated for 10 minutes in 100 ng/ml 4',6-
diamino-2-fenilindol (DAPI), washed twice in TBS and mounted in 2.5% DABCO mounting 
medium. Samples were imaged with a Leica SP5 confocal microscope. 
Table 8. Antibody combinations and dilutions for multiple detection of pluripotency markers in 
reprogrammed cells. (From: Martí et al., 2013). 
Characterization: in vitro differentiation of reprogrammed cells. Differentiation of 
reprogrammed cells into cell types derived from each of the three primordial germ 
layers of the embryo was achieved by culturing matrigel-adapted cells in specific culture 
media. Differentiation was initiated by culturing reprogrammed cells in suspension in 
conditioned medium until cell aggregates known as embryoid bodies (EBs) were visible 
after 5-7 days. Mesoderm differentiation was induced by seeding the EBs in 0.1% 
gelatin-coated plates and culturing them with KO-DMEM medium supplemented with 
10% FBS, 1x NEAA, 2 mM GlutaMAX, 50 μM 2-mercaptoethanol and 100 μM ascorbic 
acid for 3-4 weeks. For endodermal differentiation, EBs were cultured in KO- DMEM 
medium supplemented with 10% FBS, 1x NEAA, 2mM GlutaMAX and 50 μM 2-
mercaptoethanol for 3-4 weeks. Ectodermal differentiation was induced by culturing the 
EBs in suspension for 10 more days in N2B27 medium, which consisted of a 1:1 
combination of DMEM/F12 medium and neurobasal medium, supplemented with 0.5x 
B-27 supplement, 0.5x N-2 supplement, 2 mM GlutaMAX, 100  U/ml penicillin, 100 μg/ml 
streptomycin and 10  ng/ml FGF2, followed by their culture in matrigel-coated plates in 
N2B27 medium without FGF2 for 3-4 weeks. All media were replaced every 2-3 days.  
The differentiation rate was assessed by immunofluorescence analysis of lineage-
specific markers. Cells were fixed in 4% paraformaldehyde for 20 minutes, washed 3 
times in TBS/0.1% triton X-100 for 15 minutes and blocked in TBS/0.5% triton X-100/6% 
 Primary antibodies Secondary antibodies 
Target Dilution Antibody Dilution 
A 
OCT4 
SSEA3 
1:60 
1:3 
Goat-anti-mouseIgG-Cy2 
Goat-anti-ratIgM-Cy3 
1:200 
1:200 
B 
SOX2 
SSEA4 
TRA-1-60 
1:100 
1:3 
1:200 
Donkey-anti-RabbitIgG-Cy2 
Goat-anti-mouseIgG-Cy3 
Goat-anti-mouseIgM-Cy5 
1:200 
1:200 
1:200 
C 
NANOG 
TRA-1-81 
1:50 
1:200 
Donkey-anti-goatIgG-Cy2 
Donkey-anti-mouseIgM-Cy3 
1:200 
1:200 
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donkey serum for 2 hours at room temperature. Next, samples were incubated with the 
corresponding primary antibody combinations, diluted in TBS/0.1% triton X- 100/6% 
donkey serum, for 48 hours at 4°C: A) for endoderm differentiation: anti-AFP + anti-
FOXA2, B) for ectoderm differentiation: anti- TUJ1 + anti-GFAP, and C) for mesoderm 
differentiation: anti-α-SMA + anti-GATA4 (table 9). Then, samples were washed 3 times 
in TBS/0.1% triton X-100 for 15 minutes, blocked in TBS/0.5% triton X- 100/6% donkey 
serum for 1 hour at room temperature and incubated with the corresponding secondary 
antibody combinations diluted in TBS/0.5% triton X-100/6% donkey serum, for 2 hours 
at room temperature, protected from light: A) anti-rabbit-IgG-Cy2 + anti-goat-IgG-Cy3,  
B) anti-mouse-IgG-Cy2 + anti-rabbit-IgG-Cy3, and C) anti-mouse-IgG-Cy2 + anti-rabbit-
IgG-Cy3 (table 9). Finally, samples were washed 3 more times, incubated for 10 minutes 
with 100 ng/ml DAPI, washed twice in TBS and mounted in 2.5% DABCO mounting 
medium. Samples were imaged using a Leica SP5 confocal microscope. 
Table 9. Antibody combinations for multiple detection of lineage-specific markers in reprogrammed 
cells. (From: Martí et al., 2013) 
Characterization: study of the methylation profile of OCT4 and NANOG promoters. The 
methylation profile of CpG islands located in the promoter region of two pluripotency 
genes, OCT4 and NANOG, was studied to verify that cell reprogramming was also 
effective at the epigenetic level. To establish this pattern, genomic DNA was extracted 
from reprogrammed cells and mutagenized using the Methylamp DNA modification kit, 
which converts unmethylated cytosine bases into uracil bases. The two promoter 
sequences were amplified by double PCR (Freberg et al., 2007) (table 10), 
electrophoresed in a 1% agarose gel, purified using the QIAquick gel extraction kit and 
cloned into the pCRII vector. Cloning products were transformed into competent TOP10 
bacteria and seeded onto LB agar plus ampicillin plates, where IPTG was previously 
added in order to activate the expression of LacZ. Plates were incubated overnight at 
37°C and the following day, 10 white colonies (presumably containing the plasmid with 
a cloned PCR product insert) were picked and grown in 3 ml of LB medium. Correct 
cloning of the PCR product was verified through PCR. Plasmids were purified using a 
QIAprep spin miniprep kit and sequencing reactions were set using the BigDye 3.1 kit. 
 Primary antibodies Secondary antibodies 
Target Dilution Antibody Dilution 
Endoderm 
AFP 
FOXA2 
1:400 
1:50 
anti-rabbit-IgG-Cy2 
anti-goat-IgG-Cy3 
1:200 
1:200 
Mesoderm 
α-SMA 
GATA4 
1:400 
1:50 
anti-mouse-IgG-Cy2 
anti-rabbit-IgG-Cy3 
1:200 
1:200 
Ectoderm 
TUJ1 
GFAP 
1:500 
1:1000 
anti-mouse-IgG-Cy2 
anti-rabbit-IgG-Cy3 
1:200 
1:200 
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The sequencing results were aligned with the wild type sequence of the amplified region 
and CpG islands were studied to detect C>T conversions, indicative of demethylation.  
 Forward primer Reverse primer 
OCT4  5’-TTAGGAAAATGGGTAGTAGGGATTT-3’ 5’-TACCCAAAAAACAAATAAATTATAAAACCT-3’ 
NANOG  5’-AGAGATAGGAGGGTAAGTTTTTTTT-3’ 5’-ACTCCCACACAAACTAACTTTTATTC-3’ 
Table 10. Primers used to amplify the promoter region of OCT4 and NANOG genes. (From: Freberg et 
al., 2007).  
Characterization: karyotype analysis. Karyotype analysis was performed on highly 
proliferating reprogrammed cell cultures to maximize the number of cells arrested in 
the metaphase stage. This is important because it is when chromosomes are condensed 
and chromosomal abnormalities can be detected under the microscope. Cells were 
incubated in conditioned medium supplemented with 20 ng/ml colcemid for 45 
minutes, washed twice in PBS, detached using 0.25% trypsin to ensure maximal cell 
separation, neutralized and washed with PBS again. The cell pellet was detached from 
the bottom of the tube, and 10 ml of previously warmed hypotonic solution (0.075 M 
KCl) was added to the cells drop wise, while the cells were being vortexed. Samples were 
incubated at 37°C for 10 minutes, and then 1 ml of chilled Carnoy’s fixative solution 
(methanol:acetic acid, 3:1) was also added to the cells drop wise, while vortexing. 
Finally, cells were pelleted by centrifugation and resuspended in 10 ml of chilled 
Carnoy’s fixative solution, and stored at -20°C until karyotype analysis was performed 
through the G-banding method by a cytogeneticist at the Donostia University Hospital. 
Karyotypes of 20 metaphases were analyzed per each cell line. If chromosomal 
abnormalities, such as trisomies or loss of chromosomes, were detected, cells were 
subcloned three times and karyotype analysis was repeated to select a subclone that 
was free of karyotype abnormalities. 
Myogenic differentiation: production of lentiviruses harboring the two components of 
the PAX7-inducible system. rtTA-FUGW and hPAX7-pSAM2 vectors that comprise the 
doxycycline-inducible PAX7 system (figure 21) were packaged in 293T cells using VSV-G 
and Delta-8.9 plasmids as coating and packaging plasmids, respectively (plasmids were 
kindly provided by Dr. Perlingeiro, University of Minnesota). Each vector was packaged 
in separated plates and the supernatants of both virus-producing plates were combined 
prior to iPSC (induced Pluripotent Stem Cell) infection. Viral production was initiated by 
seeding 106 293T cells in two 60mm-tissue culture plates in DMEM medium 
supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. The 
following day, each plate was simultaneously transfected with a combination of 3 
plasmids (5 μg of rtTA-FUGW or hPAX7-pSAM2 + 2  μg of VSV- G + 3 μg of Delta 8.9) 
using Lipofectamine LTX with Plus reagent as transfection reagent, as described by 
Darabi and Perlingeiro (Darabi and Perlingeiro, 2014). Twenty-four hours following 
transfection, culture media was replaced with 5 ml of mTeSR1. Forty-eight hours 
following transfection, the supernatants of the virus-producing plates were harvested 
and used for iPSC infection, and an additional 5 ml of mTeSR1 were added to the virus-
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producing plates for the second viral production. Seventy-two hours following 
transfection, culture supernatants were harvested and used to infect iPSCs for a second 
time, and virus-producing plates were discarded. 
 
Figure 21. Maps of the plasmids comprising the doxycycline-inducible PAX7 expression system. 
Myogenic differentiation: infection of iPSCs with rtTA-FUGW- and hPAX7-pSAM2-
carrying lentiviruses. Matrigel-adapted iPSCs were harvested using accumax to 
maximize cell disaggregation prior to infection. Between 5x105 and 7x105 cells were 
seeded in a well of a matrigel-coated 6 well-plate in mTeSR1 medium supplemented 
with 100 U/ml penicillin, 100 μg/ml streptomycin and 10 μM of Y-27632 ROCK inhibitor. 
The following day, iPSCs, which were at 40-50% confluence, were infected using the 
virus-containing supernatants. To this effect, hPAX7-pSAM2 and rtTA-FUGW lentivirus-
containing supernatants were combined by mixing equal volumes of each supernatant, 
filtered through a low protein-binding filter and supplemented with polybrene to a final 
concentration of 1 μg/ml. The medium of iPSCs to be infected was aspirated and 5 ml of 
this viral supernatant were added to the well. Cells were spin-infected at 2 500 rpm for 
90 minutes at 33°C. Following infection, the medium was replaced with mTeSR1. The 
following day, the same iPSCs were infected again with the second viral supernatant, 
following the protocol described as for the first infection. From that point on, mTeSR1 
was replaced daily. 
Myogenic differentiation: analysis of infection efficiency. Once the infected cells 
reached 70-80% confluence, they were expanded in two T25 matrigel-coated flasks, and 
a small aliquot was plated in two 24-well matrigel-coated wells. Cells seeded in the T25 
flasks were cultured until they reached 70% confluence, and frozen to generate a stock 
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of infected iPSC vials. Infection efficiency was determined by estimating the percentage 
of GFP-positive cells by flow cytometry, after incubating the cells seeded in one of the 
P24 wells with 1  μg/ml doxycycline for 24 hours. Only the cells infected with the two 
viral vectors and incubated with doxycycline are able to induce the expression of PAX7 
and its GFP reporter. Cells seeded in the other well were used as a negative control. 
Infection rates over 15% were considered sufficient to proceed with the myogenic 
induction of the iPSCs.  
Myogenic differentiation: induction of iPSCs into muscle progenitor cells. iPSCs 
infected with the rtTA-hPAX7 system and cultured in a T25 flask at 70% confluence were 
harvested using accumax and plated in 6 P60mm plates, non-treated for tissue culture 
to avoid their attachment, in 5 ml mTeSR1 medium supplemented with 10 μM ROCK 
inhibitor. These plates were incubated in a 5% CO2 incubator and 100% humidity for 2 
days, on top of an orbital shaker at 20 rpm. After 2 days, homogeneous EBs formed in 
the culture dishes. At that point, culture medium was switched to EB medium (IMDM 
medium supplemented with 15% FBS, 10% horse serum, 1% chick embryo extract, 2 mM 
GlutaMAX, 50 μg/ml ascorbic acid, 4.5 mM monothioglycerol, 100 U/ml penicillin and 
100 μg/ml streptomycin) supplemented with 5 μM ROCK inhibitor, and plates were 
incubated shaking for another 3 days. At day 5 of the induction protocol, the medium of 
the plates was replaced with 5 ml of EB medium supplemented with 5 μM ROCK 
inhibitor, and EBs were incubated shaking for two more days. At day 7 of the induction 
protocol, EBs formed in each P60mm dish were transferred to a gelatinized T75 flask 
containing 12 ml of EB medium supplemented with 5 ng/ml FGF2. Flasks were incubated 
for 3 days in the incubator, with special care to avoid their movement to maximize EB 
attachment to the surface. Following those three days (day 10 of the protocol), when 
cell outgrowths were visible, expression of PAX7 was induced by switching the culture 
medium to EB medium supplemented with 1  μg/ml doxycycline and 5 ng/ml FGF2. Cells 
were cultured in these conditions for 4 more days, replacing their medium on day 12 of 
the protocol. At day 14, cultures were harvested using 0.25% trypsin, and taken to the 
cell sorting facility in sorting buffer (PBS supplemented with 0.5% BSA, 25 mM HEPES 
and 5 mM EDTA, pH 7.2). Figure 22 represents the induction protocol. Cells were sorted 
in a BD FACSAria III sorting cytometer, and GFP-positive cells were plated in gelatin-
coated dishes in EB medium supplemented with 1  μg/ml doxycycline and 10 ng/ml FGF2 
(and 5 μM ROCK inhibitor during the first 24 hours) at a density of 50 000 cells/cm2. Cells 
were cultured for 2-3 days, until they reached 90% confluence. At that point, they were 
split 1:5 in order to get the maximum number of cells. At passage 1 and 2 following 
sorting, GFP-positive cells were considered myogenic precursors and they were frozen 
for future experiments. 
Due to recent publications claiming that GSK3β inhibition activates the canonical Wnt 
signaling pathway, promoting the mesodermal differentiation of stem cells (van der 
Velden et al., 2007; Xu et al., 2013), transient inhibition of GSK3β was assessed as a 
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potential optimization of the induction protocol. To do so, the previously described EB 
medium was supplemented with 5 μM GSK3β inhibitor CHIR99021 between day 2 and 
day 3 (24-hour inhibition) or between day 2 and day 4 (48-hour inhibition), as indicated 
in figure 22. The effect of transient GSK3β inhibition was assessed by checking the 
morphology of EBs and the percentage of GFP-positive cells at day 14 of the induction 
protocol. Moreover, these progenitors were differentiated for 5 days in 15% KOSR 
medium (detailed below) and differentiation efficiencies were assessed by comparing 
the frequency of sarcomeric myosin-positive cells in culture. 
 
Figure 22. Schematic representation of the myogenic induction protocol. EBs were formed in agitation 
in mTeSR1 medium supplemented with 10 μM ROCK inhibitor (Y-27632). At day 2 of the protocol, cells 
were switched to EB medium supplemented with 5 μM ROCK inhibitor, and at this point, the GSK3β 
inhibitor CHIR99021 (CHIR) was added at a final concentration of 5 μM and kept for 24 or 48 hours 
(represented in yellow). At day 7, EBs were seeded in 0.1% gelatin-coated flasks in EB medium, and PAX7 
expression was induced at day 10 of the protocol by adding doxycycline (DOXY) to the culture medium. 
At day 14, PAX7-expressing muscle progenitors were sorted according to their GFP expression. (Adapted 
from Darabi and Perlingeiro, 2014).  
Myogenic differentiation: terminal differentiation of PAX7-expressing iPSC-derived 
myogenic progenitors into myotubes. iPSC-derived myogenic precursors at passage 3 
or 4 post-sorting were cultured on 0.1% gelatin-coated wells or chambers in EB medium 
supplemented with 10 ng/ml FGF2 and 1 μg/ml doxycycline until they reached 80-100% 
confluence. At that point, cells were washed once with DPBS and terminal 
differentiation medium was added to the cultures. Several terminal differentiation 
media were tested: A) 2% HS medium (low glucose DMEM supplemented with 2% HS, 
100 U/ml penicillin and 100  μg/ml streptomycin) (Darabi and Perlingeiro, 2014), B) 20% 
KOSR medium (KO- DMEM supplemented with 20% KOSR, 1x NEAA, 2mM GlutaMAX, 
100 U/ml penicillin and 100 μg/ml streptomycin) , C) conditioned medium (2% HS 
medium or 20% KOSR medium exposed to differentiating C2C12 cultures for 24 hours 
and filtered) and D) 15% KOSR medium (high glucose DMEM supplemented with 15% 
KOSR, 2 ng/ml IGF1 and 10 ng/ml HGF) (Chal et al., 2016). Differentiations were 
performed in 24- well plates for RNA and Western blot analysis, and in 4-well chamber 
slides for immunofluorescence detection, using 700 μl of differentiation medium per 
well/chamber. In the sandwich coating, an additional layer of 1:3-diluted matrigel was 
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added on top of the cells to be differentiated (200 μl per well), and incubated for 30 
minutes in the incubator at 37°C (Toral-Ojeda et al., unpublished data). Next, 700 μl of 
the corresponding differentiation medium were added to each well. Comparative 
differentiations were performed, where two differentiation media were tested in each 
differentiation test, as detailed below:  
Test 1: 2% HS medium versus conditioned 2% HS medium. Control 1 and patient 1-
derived progenitors at passage 4 post sorting were cultured up to 80% confluence. Next, 
cells were washed once with DPBS and cultured in HS medium or conditioned 2% HS 
medium for 12 days. Culture media were replaced every two days. Myogenic 
differentiation was assessed through immunofluorescence at day 12 of differentiation, 
based on the density of sarcomeric myosin-positive cells found in the cultures. 
Test 2: 2% HS medium versus 20% KOSR medium. Control 1 and patient 4-derived muscle 
progenitor cells at passage 4 were cultured up to 100% confluence and then switched 
to 1:1 induction-differentiation medium without doxycycline for 24 hours. Thereafter, 
cells were washed once with DPBS, switched to differentiation medium and cultured for 
4 more days. Myogenic differentiation was assessed through immunofluorescence 
based on the density of sarcomeric myosin-positive cells found in the differentiated 
cultures, as well as on the expression rates of a set of myogenic genes (PAX7, desmin, 
myogenin and dystrophin) assessed through qPCR. 
Test 3: 20% KOSR medium versus 15% KOSR medium, with regular coating versus the 
sandwich coating. Control 1-derived myogenic progenitors were cultured up to 100% 
confluence, washed with DPBS, switched to the corresponding differentiation medium 
and incubated for 5 days (regular coating). In parallel, for the sandwich coating, 
myogenic progenitors were cultured up to 100% confluence, washed once with DPBS 
and coated with a layer of 1:3-diluted matrigel (approximately 200 μl per well). Finally, 
cultures were incubated at 37°C for 30 minutes and 700 μl of the corresponding 
differentiation media were added to each well and cultured in differentiation media for 
5 days. Myogenic differentiation was assessed through immunofluorescence detection 
of sarcomeric myosin-positive cells. 
Once terminal differentiation conditions were optimized, differentiated cultures were 
used for gene expression analysis through qPCR, protein expression through Western 
blot or immunofluorescence analyses. 
Myogenic differentiation: gene expression analysis through qPCR. Cells at day 0 and 
day 5 of differentiation were washed once with DPBS and harvested on ice using cell 
scrapers and 700 μl of QIAzol lysis reagent. Samples were stored at -80°C until RNA 
extraction was performed. Total RNA was extracted using the RNeasy Mini kit and the 
QIAcube extraction system, following manufacturer’s instructions. 1 μg of RNA from 
each sample was retrotrascribed using the High Capacity cDNA Reverse Transcription 
Kit, following manufacturer’s instructions. Finally, gene expression was assessed 
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through qPCR in a CFX384 Touch Real-Time PCR Detection System (Biorad), using 
TaqMan probes and TaqMan gene expression master mix. TATA-binding protein (TBP) 
or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as endogenous 
controls, and gene expression levels were represented relative to TBP or GAPDH 
expression, which were considered as 100%. Gene expression differences between 
healthy control-derived cultures and patient-derived cultures were analyzed using 
GraphPad Prism 5 (Mann-Whitney test with a 0.05 significance level). 
Analysis of CAPN3 maturation along the differentiation process of healthy control 
samples was performed at day 0, 2 and 5 of differentiation. Expression results were 
normalized to 100%, which was calculated by summing the expression rate of the 
immature isoform (lacking exon 6, delta exon 6) and the mature isoform (probe for 
exons 5-6) at each timepoint. Evolution of expression rates of each isoform along the 
myogenic differentiation were analyzed using GraphPad Prism 5 (Friedman test with a 
0.05 significance level). 
Myogenic differentiation: Western blot analysis. Cells at day 0 and day 5 of 
differentiation were washed once with DPBS and harvested on ice using cell scrapers 
and 150 μl of protein extraction buffer per cm2 of tissue culture area. The buffer 
consisted on 20 mM Tris HCl, pH 8, 0.1 mM EDTA, 1 mM DTT, 28 μM E-64, 20 μg/ml 
soybean trypsin inhibitor and 2 mM PMSF supplemented with 5% 2-mercaptoethanol 
and 1x loading buffer. Samples were transferred to eppendorf tubes, incubated at 95°C 
for 5 minutes and stored at -80°C. For Western blot analysis, protein extracts were 
heated at 95°C for 3 minutes, and 20-40 μl of each protein extract were loaded into 6% 
or 8% acrylamide gels. Human muscle protein extracts were used as a positive control, 
and the Precision Plus Kaleidoscope Prestained Protein ladder was used as a protein size 
marker. Gels were run at 50V-80V and proteins were transferred to Hibond 
Nitrocellulose membranes using the Mini Trans-Blot Electrophoretic Transfer system for 
1 hour at 400 mA. Membranes were stained with Ponceau S solution to ensure adequate 
protein transfer, washed out shaking with tap water, and blocked with 5% skimmed milk 
diluted in TBST solution (0.05 M Tris, 0.2 M NaCl, 1% triton X-100 in distilled water, pH8) 
shaking for 1 hour at room temperature. Subsequently, membranes were incubated 
overnight in rollers in presence of primary antibodies diluted in 5% BSA in TBST (table 
11). The following day, membranes were washed three times in TBST (5 minutes per 
wash) and incubated in secondary antibody (table 11) diluted in 5% skimmed milk in 
TBST. Finally, membranes were washed three times in TBST (5 minutes per wash) and 
proteins were detected by chemilluminescence using the SuperSignal West Dura kit as 
substrate. Protein levels were assessed using Image Studio Lite 5.2, and standardized to 
GAPDH protein levels.  
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Primary antibodies Secondary antibodies 
Target Reference Dilution Reference Dilution 
Calpain 3  COP-080049 (IS2), Cosmobio  1:1 000 P0449, Dako 1:2 000 
Calpain 3 NCL-CALP-12A2, Novocastra  1:15 P0447, Dako 1:2 000 
GAPDH 2118, Cell Signaling Technology 1:10 000 P0448, Dako 1:10 000 
PAX7 NBP1-69130, Novusbio 1:50 P0448, Dako 1:5 000 
SERCA2 sc-376235, Santa Cruz Biotech 1:500 P0447, Dako 1:1 000 
Table 11. Primary and secondary antibodies used for protein detection through Western blot. 
Myogenic differentiation: immunofluorescence analysis. Cells were fixed in 4% PFA for 
10 minutes at room temperature and permeabilized with PBS/0.3% triton X-100 for 20 
minutes at room temperature. Next, samples were blocked in PBS/10% donkey 
serum/0.01% triton X-100 diluted in PBS, for 1 hour at room temperature, and then 
incubated with the primary antibody (table 12) diluted in PBS/0,3% triton X-100 
overnight at 4°C. The following day, cells were washed twice with DPBS and incubated 
with the secondary antibody (table 12) diluted 1:500 in DPBS for 1 hour at room 
temperature, protected from light. Finally, samples were washed twice with DPBS, 
incubated for 3 minutes in 1  μg/ml Hoechst diluted in PBS, and washed again twice with 
DPBS, once with distilled water and once with deionized water. Finally, samples were 
mounted using the fluorogel mounting medium. 
Primary antibodies Secondary antibodies 
Target Reference Dilution Antibody Reference Dilution 
Myogenin DSHB, F5D 1:50 DαM-af555 Invitrogen, A-31570 1:500 
PAX7 DSHB, PAX7 1:50 DαM-af555 Invitrogen, A-31570 1:500 
Sarcomeric 
myosin 
DSHB, MF20 1:50 DαM-af488 
DαM-af555 
Invitrogen, A-21202 
Invitrogen, A-31570 
1:500 
1:500 
Table 12. Primary and secondary antibodies used for immunofluorescence analysis. Abbreviations: Alexa 
fluor (af), anti (α), donkey (D), mouse (M). 
Transplantation of iPSC-derived muscle progenitor cells. Ten 7 week-old NSG (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) mice were purchased from Charles River and housed in the 
animal facility. All procedures were performed following the guidelines and approval 
provided by Biodonostia Animal Care Committee and the Regional Government of 
Gipuzkoa (Donostia, Spain), in accordance with the Spanish Royal Decree (53/2013), the 
European Directive 2010/63/EU and the guidelines established by the National Council 
on Animal Care. At 8 weeks of age, tibialis anterior (TA) muscles were injured one day 
prior to cell transplantation. To do so, mice were anesthetized by inhaled isoflurane 
(Forane), administered at 5% concentration for induction and at 3% concentration for 
maintenance during surgery. Muscles were injured by injecting 7.5 μl of cardiotoxin from 
Naja mossambica mossambica at 100 μM in both TA muscles of each mouse, using a 
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beveled 26G needle. The following day, control 2- and patient 1-derived 106 progenitor 
cells at passage 4 post-sorting were transplanted into the right TA of each animal (cells 
from each sample were transplanted into 5 mice) in 15 μl of final volume. 15 μl of DPBS 
were injected into the left TA of each mouse and these were used as negative controls. 
Mice were housed in the animal facility for 30 days, to allow muscle regeneration. Thirty 
days following transplantation, mice were sacrificed by inhalation of 5% isoflurane 
followed by inhalation of CO2. 
Detection of transplanted cells in TA muscle sections. Immediately following sacrifice, 
TA muscles were extracted and frozen in nitrogen-chilled isopentane, embedded in 
O.C.T. Serial 7 μm-thick sections were cut using the cryostat and slides were stored at 
- 80°C until immunofluorescence analysis was performed. 49 μm-spaced sections (one 
every 7 sections) were used to assess the engraftment and regenerative potential of 
transplanted cells. To do so, double immunofluorescence detections were performed, 
which allowed for the detection of human cell nuclei (detection of human lamin 
A/C- positive nuclei) and fibers generated by the transplanted human cells (detection of 
human Dystrophin-positive fibers). To proceed with immunofluorescence analysis, 
slides were incubated at room temperature for 30 minutes to allow samples to thaw. 
Next, sections were rehydrated in DPBS for 5 minutes, permeabilized in DPBS/0.3% 
triton X-100 for 20 minutes, washed in DPBS for 5 minutes, and blocked in 3% BSA in 
DPBS for 1 hour at room temperature. Then, samples were incubated overnight at 4°C 
with the primary antibody against human dystrophin diluted in blocking solution. The 
following day, samples were incubated for 1 hour at room temperature with the second 
primary antibody, anti-human-lamin A/C, diluted in blocking solution. Thereafter, 
samples were washed 3 times in DPBS (5 minutes per wash), and then incubated for 45 
minutes at room temperature with secondary antibodies (table 13) diluted in blocking 
solution and protected from light. Finally, samples were washed twice in DPBS (5 
minutes per wash), incubated with 1  μg/ml Hoechst for 3 minutes to stain cell nuclei, 
and washed again twice in DPBS, once in distilled water and once in deionized water (2 
minutes per wash). Samples were covered with a coverslip using fluorogel as mounting 
medium, and stored at 4°C until they were visualized in the fluorescence microscope.  
Primary antibodies Secondary antibodies 
Target Reference Dilution Antibody Reference Dilution 
h-Dystrophin Leica, NCL-
DYS3 
1:20 DαM-
af555 
Invitrogen, A-31570 1:500 
h-Lamin A/C Abcam, 
ab108595 
1:500 DαR-af488 Invitrogen, A-21206 1:500 
Table 13. Primary and secondary antibodies used for immunofluorescence analysis. Abbreviations: 
human (h), alexa fluor (af), anti (α), donkey (D), mouse (M), rabbit (R).  
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Differences in the number of human lamin A/C-positive cells (indicative of cell 
engraftment) and human dystrophin-positive fibers (indicative of muscle regeneration) 
detected in TAs transplanted with healthy control- and patient-derived samples were 
analyzed using GraphPad Prism 5 (Mann-Whitney test with a 95% confidence interval). 
RESULTS 
Selection of samples to be reprogrammed. Five LGMD2A patients were chosen as 
representative samples of the wide genetic and phenotypic variability found among 
LGMD2A patients examined at the Donostia University Hospital. Patients 2, 3 and 5 
carried the most commonly found mutation among the Basque population of LGMD2A 
patients, which is located in exon 22. Importantly, patient 5 harbored this mutation in 
homozygosis, whereas the other two patients carried this mutation in combination with 
a mutation in exon 11 leading to a single amino acid substitution (patient 2) or an 
intronic mutation in intron 14 that generates a neoexon (patient 3). Patient 1 had an 
entire deletion of one of the CAPN3 alleles whereas the other allele harbored a mutation 
in exon 24. Patient 4 carried a mutation in exon 5 in one of the CAPN3 alleles, leading to 
a single amino acid substitution, and a mutation in exon 16 in the other allele, leading 
to a shift in the codon reading frame that theoretically produced a truncated calpain 3 
protein (table 14, figure 23). Next, two age- and sex-matched fibroblasts from healthy 
donors were selected as controls of the study. One of these primary fibroblast cultures 
was derived from a female in her late forties, thus being a sex-matched control for 
patients 1, 3 and 5, and an age-matched control for patients 3 and 5. The second control 
was derived from a male in his twenties, and was a control sample for patients 2 and 4 
accordinng to their sex, and patient 1, 2 and 4 regarding their age. 
Patients disability was assessed at the moment of the biopsy according to the modified 
MVA scale (table 4), and disease phenotype was determined based on the MVA grade 
and age, according to table 5. Patient 3 and 5 were wheelchair-bound, being classified 
as grade 8 and thus, with a severe phenotype. Patient 1 and 2 had difficulties to rise 
from the floor and thus were classified as grade 4. Therefore, according to their age, 
they were classified as severe and advanced phenotypes, respectively. Patient 4 
displayed a grade 3 disability and was classified as an intermediate phenotype.  
Table 14 summarizes the data available about the sample donors. Figure 23 represents 
the location of the mutations found in CAPN3 gene (blue scheme) and the predicted 
effect on the synthesized calpain 3 protein (green scheme). Single amino acid 
substitutions appear to produce a 94 kDa calpain 3 protein that could be detected 
through Western blot, whereas mutations leading to frame-shifts or loss of the stop 
codon lead to truncated calpain 3 proteins, which might be more prone to further 
degradation. 
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Figure 23. Schematic representation of CAPN3 exons (in blue, from 1 to 24) and calpain 3 protein (in 
green). The different domains and calpain 3-specific regions are indicated in green. Mutations found in 
patients are indicated in orange over the blue scheme, whereas the predicted protein modifications 
caused by the mutations are also indicated in orange over the green scheme. Numbers on top of the blue 
scheme of the wild type allele indicate the amino acids encoded by each exon. 
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Establishment of patient-specific fibroblast cultures. Patient-specific primary fibroblast 
cultures were established as previously described, and frozen at early passages (passage 
5 or lower). Healthy donor-derived fibroblasts were obtained from the Basque Biobank 
and expanded in the same way as patient-derived fibroblasts. Cultures were highly 
proliferative and displayed no evident morphologic differences among patient- and 
control-derived cells. 
Induction of cell reprogramming. Fibroblasts at early passages (passages 3-5) were 
infected with retroviral vectors expressing the four Yamanaka factors: OCT4, SOX2, KLF4 
and cMYC. Three to six weeks after seeding the infected fibroblasts over feeder cells and 
culturing them in hES medium, colonies of cells resembling the morphology of 
embryonic stem cells (i.e., homogeneous surface of the colonies with smooth and well 
defined edges) were visible. Six colonies from each plate were selected and 
independently seeded over feeder cells to establish clonally independent cell lines. 
However, only 3 colonies were observed in the patient 5-specific reprogramming plate, 
and therefore, only three colonies could be picked. Most of the selected colonies led to 
stable cultures that could be passaged over time for more than 20 passages. Five clones 
were established for each of the control-derived samples, 6 clones were obtained from 
patients 2, 3 and 4 and only three clones were established for patient 1 and 5.  
These cell lines were mechanically expanded over feeder cells, and they were also 
adapted to feeder-free culture conditions by culturing them on matrigel-coated dishes, 
as previously described. Reprogrammed cells cultured in both conditions were used to 
test their pluripotency following a set of characterization tests. These tests enabled the 
selection of one specific clone per reprogrammed sample that met all the 
characterization requirements to be considered as a pluripotent cell line, and thus as an 
iPSC line.  
Characterization of reprogrammed cells 
 AP staining. AP-positive colony formation has been reported as a sensitive indicator 
of embryonic stem cells (O’Connor et al., 2008). Thus, detection of AP activity in 
reprogrammed samples is considered as an indicator of pluripotency (Martí et al., 
2013). AP staining was assessed in each of the clones established from each sample, 
and consistent AP activity was detected in all the clones tested (figure 24), as shown 
by the blue staining of the colonies.  
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Figure 24. Representative picture of an AP-stained colony from each cell line, captured with an 
optical microscope. The blue color indicates AP activity, as a result of the colorimetric reaction 
occurred when colonies were incubated with the AP Blue Membrane Substrate Solution. Numbers in 
the pictures indicate the clones (clonal cell line) established for each reprogrammed sample. Grey 
squares represent colonies that were picked to establish a clone but failed to lead to a stable cell line. 
 
 Silencing of transgenes and induction of pluripotency genes. The second 
characterization test assessed the expression of pluripotency genes. Currently, it is 
widely accepted that the correct reprogramming of cells implies the silencing of 
reprogramming transgenes (Brambrink et al., 2008; Aasen et al., 2008), as well as the 
induction of endogenous pluripotency genes. Therefore, expression of a set of 
pluripotency genes and the transgenes used for cell reprogramming were assessed 
by qPCR (figure 25.a, 25.b and 25.c). Transgene silencing was considered successful 
if only the expression level of each of the four transgenes was clearly downregulated. 
In this study, expression levels lower than 0.5% of that of GAPDH were considered 
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optimal. Induction of endogenous pluripotency genes was considered successful if 
their expression was detectable and not higher than GAPDH expression.  
Based on these results, two clones per sample were selected for further 
characterization. Control 1-derived cell lines successfully induced the expression of 
endogenous pluripotency genes.However, clones 1, 2 and 3 failed to clearly silence 
transgene expression. Therefore, clones 4 and 5 were selected for further 
characterization. As for control 2, induction of pluripotency genes and transgene 
silencing were achieved by all the cell lines, and thus, clones 2 and 5 were selected 
for further characterization because these two clones showed the most consistent 
transgene silencing. Among the three cell lines derived from patient 1, endogenous 
pluripotency genes were induced in the three clones established, but transgenic KLF4 
expression was not silenced in clone 2 and thus, clones 1 and 6 were selected for 
further characterization. Similarly, based on transgene silencing data, clones 1 and 6 
were selected for patient 2. As for patient 3, endogenous pluripotency genes were 
not induced in clone 1, and transgenic OCT4 was not silenced for clones 2 and 3. 
Therefore, clones 5 and 6 were selected for further characterization. Transgenes 
were not silenced in clones 3, 4, 5 and 6 of patient 4, and moreover, endogenous 
OCT4 expression level was abnormally high in clones 5 and 6. Hence, clones 1 and 2 
were selected for further characterization. Finally, clones 2 and 3 of patient 5 were 
analyzed and only clone 2 met the transgene silencing criteria. However, clone 3 was 
also included in the following characterization tests due to the lack of alternative 
clones for this specific patient. 
 
 
 
 
Figure 25.a. Expression rates of transgenic and endogenous pluripotency genes quantified by qPCR 
and represented relative to GAPDH expression (100%) in C1-derived reprogrammed cells.  
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Figure 25.b. Expression rates of transgenic and endogenous pluripotency genes quantified by qPCR 
and represented relative to GAPDH expression (100%) in C2, P1 and P2-derived reprogrammed cells.  
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Figure 25.c. Expression rates of transgenic and endogenous pluripotency genes quantified by qPCR 
and represented relative to GAPDH expression (100%) in P3, P4 and P5-derived reprogrammed cells.  
 
 Determination of clonal independence. Southern blot analysis was performed to 
detect the number of transgene insertions in the two clones selected for each sample 
based on gene expression results. Fibroblast-derived DNA from each sample was 
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used as a negative control. The number of transgene inserts was determined by 
comparing the number and size of the bands detected in reprogrammed samples 
versus their corresponding fibroblasts. The different number and/or size of bands 
(corresponding to transgenes) found between the two clones selected for each 
sample confirmed their independent origin. Detection of cMYC (figure 26) and OCT4 
(figure 27) through Southern blot analysis provided adequate information to confirm 
that the two reprogrammed cell lines selected for each donor had an independent 
origin. The data was inconclusive with regards to the Southern blot results for KLF4 
and SOX2 transgene insertions.  
    
Figure 26. Southern blot images show bands corresponding to endogenous cMYC (Green asterisks), 
and transgenic cMYC (red asterisks). Samples are indicated as F (fibroblasts) and reprogrammed cell 
clones (#).  
     
Figure 27. Southern blot images show bands corresponding to endogenous OCT4 (Green asterisks), 
and transgenic OCT4 (red asterisks). Samples are indicated as F (fibroblasts) and reprogrammed cell 
clones (#). 
Following verification of clonal independence, one clone per sample was selected for 
further characterization. These clones were the following: Clone 4 for control 1, clone 
5 for control 2, clone 6 for patient 1, clone 1 for patient 2, clone 6 for patient 3, clone 
1 for patient 4 and clone 2 for patient 5. The selection performed was based on 
previous gene expression data, as well as discarding the cell lines that displayed an 
elevated number of transgene insertions, such as clone 1 of patient 1 and clone 5 of 
patient 3.  
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 Detection of pluripotency markers in reprogrammed samples. Expression of a set of 
seven pluripotency markers was studied by immunofluorescence: OCT4, NANOG, 
SOX2, SSEA-3, SSEA-4, TRA1-60 and TRA1-81.  
 
Figure28. Multiple immunofluorescence images of pluripotency markers. Images in column 1 prove 
the expression of OCT4 (green) and SSEA-3 (red). Images in column 2 show the expression of NANOG 
(green) and TRA1-81 (red). Images in column 3 and 4 correspond to a triple immunodetection of SOX2 
(green), TRA1-60 (red) and SSEA-4 (cyan). Cell nuclei are shown in blue in all the images. Scale bars: 75 
μm. 
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Fully reprogrammed cell lines are expected to express the entire set of markers 
(Martí et al., 2013). As shown in figure 28, all the selected cell lines stained intensely 
for each of the seven markers detected by multiple immunofluorescence.  
 
 In vitro differentiation potential of reprogrammed cell lines. Once the expression 
of pluripotency markers was proven, the next characterization test intended to 
demonstrate that these cells had the potential to differentiate into cell types derived 
from the three primordial germ layers found in the embryo. Therefore, 
reprogrammed cells were cultured in specific culture conditions to induce their 
differentiation into these cell types. Immunofluorescence detection of lineage-
specific markers was used to verify their successful differentiation. Expression of at 
least one of the lineage-specific markers was sufficient to validate that cells had 
differentiated into each of the three lineages.  
As for the directed differentiation towards ectoderm, expression of the neuron-
specific class III beta-tubulin (TUJ1) was detected in each of the cell lines, whereas 
glial fibrillary acidic protein (GFAP) was only detected in some samples (figure 29).  
As for the differentiation into mesoderm lineage, α-smooth muscle actin (α-SMA) 
was broadly expressed in each of the differentiated samples, whereas the 
transcription factor GATA4, known to be essential during cardiac development, was 
detected in most, but not all the samples (figure 29). 
As for endoderm differentiation, the transcriptional activator of liver-specific genes 
FOXA2 was detected in all the samples, whereas expression of α-fetoprotein (AFP), 
considered as the fetal form of serum albumin, was only detected in some samples 
(figure 29). 
Therefore, these results indicate that the reprogrammed cell lines possessed the 
potential to differentiate into cell types derived from the three primordial cell layers, 
providing strong evidence of their pluripotency. 
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Figure 26. Multiple immunofluorescence images of lineage-specific markers. Images in column 1 
show the detection of TUJ1 (green) and GFAP (red), used as ectoderm markers. Images in column 2 
show the expression of α-SMA (green) and GATA4 (red), used as mesoderm markers. Images in column 
3 correspond to a double immunodetection of the endoderm markers AFP (green) and FOXA2 (red). 
Cell nuclei are shown in blue in all the images. Scale bars: 75 μm. 
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 Epigenetic reprogramming. Methylation of CpG islands located in the promoter 
regions is considered to be a strong epigenetic modification that represses gene 
transcription. Consistent with this, promoters of the pluripotency genes OCT4 and 
NANOG have been found to be highly methylated in differentiated cell types, such 
as fibroblasts (Freberg et al., 2007), preventing their expression. Since 
reprogramming induces the expression of these and other pluripotency genes, their 
promoters are expected to be considerably demethylated in fully reprogrammed 
iPSC lines.  
Therefore, we studied their methylation status through bisulfite sequencing and 
found that CpG islands located in the promoter regions of these genes were highly 
demethylated. Overall, 98.3% of the CpG islands analyzed in the promoter region of 
OCT4 were found unmethylated (figure 30), whereas 86.9% of the CpG islands found 
in the NANOG promoter region were unmethylated (figure 31). These unmethylation 
percentages are substantially higher compared to the percentage of non-methylated 
CpG islands found in some of our fibroblast cell lines analyzed (data not shown) and 
those percentages found in differentiated cells that have been reported in the 
literature (Freberg et al., 2007). 
 
 
Figure 30. Schemes representing the methylation pattern of CpG islands in the OCT4 promoter 
region. Five bacterial clones, each one representing the promoter region of one reprogrammed cell, 
were sequenced for each reprogrammed cell line. Circles in each line correspond to the methylation 
status of five CpG islands located in this promoter region in each of the bacterial clones studied. White 
circles represent a demethylated CpG island whereas black circles represent a methylated CpG island. 
#: clone (reprogrammed cell line).  
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Figure 31. Schemes representing the methylation pattern of CpG islands in the NANOG promoter 
region. Between 4 and 6 bacterial clones, each one representing the promoter region of one 
reprogrammed cell, were sequenced for each reprogrammed cell line. Circles in each line correspond 
to the methylation status of five CpG islands located in this promoter region in each of the bacterial 
clones studied. White circles represent a demethylated CpG island whereas black circles represent a 
methylated CpG island. #: clone (reprogrammed cell line). 
 Karyotype stability. Cell reprogramming using integrative vectors, as well as the 
extensive culture of the cells, facilitates the emergence of chromosomal 
abnormalities. To circumvent chromosomal abnormalities in our newly generated 
cell lines, karyotype analysis through G-banding was performed in each of the cell 
lines. This analysis detected chromosomal abnormalities in control 1 clone 4, patient 
2 clone 1 and patient 5 clone 2 cell lines, such as loss of a chromosome or appearance 
of trisomies. Importantly, these abnormalities affected less than 20% of the 
metaphases analyzed (data not shown). Therefore, these cell lines were subcloned 
for three passages over feeder cells, establishing 6 subclones for each clone (e.g., 
Control 1 clone 4 a-f), and these subclones were karyotyped again to ensure the 
absence of chromosomal abnormalities in each of the cell lines (figure 32). Newly 
established subclones displayed no chromosomal abnormalities and were named as 
control 1 subclone 4a, patient 2 subclone 1d and patient 5 subclone 2f. These cell 
lines were used in following myogenic differentiation experiments, together with 
control 2 clone 5, patient 1 clone 6 and patient 4 clone 1 cell lines.  
The patient 3-derived cell line (patient 3 clone 6) met each of the characterization 
requirements to be considered as a fully reprogrammed cell line. However, it showed 
a strong tendency to spontaneously differentiate after 4-5 passages growing in pure 
(matrigel-adapted) culture conditions. This fact raised doubts regarding the degree 
of pluripotency acquired by this cell line and consequently, it was excluded from the 
following myogenic differentiation tests.  
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Figure 32. Representative karyotype images for each of the reprogrammed cell lines analyzed, once 
further subcloning was performed in the cell lines in which karyotype abnormalities were previously 
detected. 
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Infection of iPSCs with lentiviruses comprising the doxycycline-inducible PAX7 
expression system. Matrigel-adapted iPSCs were infected with the PAX7-rtTA vector 
system and infection efficiencies were determined by assessing the percentage of 
GFP- expressing cells by flow cytometry.  
Overall, the infection efficiencies were high (over 25% of cells infected) for some of the 
cell lines, such as control 1 and patient 1, whereas other cell lines appeared to be 
especially resistant to infection, such as control 2 and patient 5. However, several 
infection attempts performed with some of the cell lines indicated that infection 
efficiency was greatly influenced by other technical factors, such as cell confluence at 
the time of infection, quality of the viral production and cell disaggregation reagent used 
when seeding the iPSCs to be infected (data not shown). Figure 33 shows histograms 
representing the analysis of the infection efficiency performed on the six iPSC lines of 
the study. 
Myogenic induction of PAX7-rtTA-infected iPSC lines and selection of GFP-positive 
progenitors. Myogenic induction of the six iPSC lines was performed as previously 
described. Each of the iPSC lines grown on matrigel displayed a very similar morphology 
both before and after being infected with the PAX7-rtTA system. During the myogenic 
induction process, minor differences were visible among the different cell lines with 
regards to EB size and morphology (figure 34). However, since these differences were 
also observed in different inductions performed for each cell line, they could be 
attributed to small variations in the number of cells plated at the beginning of the 
induction, rather than to cell line-specific features.  
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Figure 33. Representative histograms showing the infection efficiencies achieved for each of the iPSC 
lines infected with the PAX7-rtTA vector system. Histograms in the left column represent the 
fluorescence detected in iPSCs that had not been incubated with doxycycline, and were used to determine 
the GFP-negative region (R1). Histograms in the right column correspond to infected cell lines incubated 
with doxycycline to induce the expression of PAX7-GFP. GFP-positive events are detected in the R2 region. 
Percentages of events located in the R2 region determine the infection efficiency.  
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Figure 34: Representative light microscopy images of the two cell lines (control 1 and patient 1) before, 
during and after the induction process. Pictures illustrate iPSCs cultured on matrigel before the induction 
protocol was initiated, EB cultures at day 2, 5 and 7 of the induction process, adherent cultures at day 14 
of the induction protocol, and sorted GFP-positive cells at passage 3 post-sorting. Scale bars: 100 μm. 
 
FACS plots of cell separations performed on day 14 of the myogenic induction protocol 
also indicate that there was considerable variability among the six cell lines regarding 
cell size and granularity (figure 35, SSC-A vs. FSC-A plots). Importantly, sorted GFP+ cells 
(green events) were fairly homogeneous regarding their size, granularity and shape of 
the population (figure 35, green events). 
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Figure 35. FACS plots corresponding to the isolation of GFP-positive cells at day 14 of the myogenic 
induction protocol. Plots in the first column represent the staining of the cells with the viability marker 
TO-PRO-3. TO-PRO-3-negative events (live cells) were gated and represented according to their size and 
granularity (second column). The second gate selected events corresponding to cells, and small events, 
likely corresponding to cell debris, were not selected. Finally, events were plotted according to their GFP 
signal and GFP-positive events (in green in all the plots) were gated and sorted. #: clone (reprogrammed 
cell line).  
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Optimization of the myogenic induction protocol of iPSCs. Based on publications that 
report that GSK3β inhibition promotes the differentiation of pluripotent cells into 
mesodermal progenitors (Bakre et al., 2007; Borchin et al., 2013), we aimed to test the 
effect of transiently inhibiting GSK3β during the previously described induction protocol. 
Addition of 5 μM of the GSK3β inhibitor CHIR99021 during the myogenic induction of 
patient 2-derived iPSCs slightly modified the size and morphology of the EBs (figure 
36.a), these looking somewhat smaller and rougher following a 24 hour-inhibition. 
However, no evident morphologic differences were detected following a 48 hour-
inhibition. Importantly, the addition of CHIR99021 increased the percentage of GFP-
positive cells at day 14 of the induction process, suggesting that inhibition of GSK3β 
promotes the proliferation of myogenic progenitor cells. However, this increase was 
evident when GSK3β was inhibited for 24 hours (from 38% to 52.4%) but it was 
diminished when GSK3β inhibition was sustained for 48 hours (from 38% to 42.1%) 
(figure 36.b). This result indicates that long lasting GSK3β inhibition might negatively 
impact cell proliferation. 
Despite transient inhibition of GSK3β clearly performed over our regular myogenic 
induction process, terminal differentiation of GFP-positive progenitor cells did not 
improve, as evidenced by the frequency of sarcomeric myosin-positive cells observed in 
these cultures (figure 36.c). Moreover, progenitor cells derived from cells treated with 
CHIR99021 for 48 hours during the induction process showed a reduced differentiation 
potential compared to the myogenic cultures differentiated following the regular 
protocol. Therefore, transient GSK3β inhibition in our protocol was not found to 
improve myogenic differentiation of iPSCs. Thus, this additional step was not included 
in the myogenic induction protocol. 
Optimization of the terminal differentiation protocol of iPSC-derived PAX7-positive 
muscle progenitor cells. Several differentiation protocols were evaluated to establish 
the optimal conditions to terminally differentiate iPSC-derived PAX7-positive progenitor 
cells into myotubes. First, we pursued the terminal differentiation of progenitor cells 
from control 1 and patient 1 by following the protocol described by Darabi and 
colleagues (Darabi et al., 2012), with minor modifications. Briefly, progenitors were 
cultured on gelatin-coated wells until they reached 80% confluence. Next, cells were 
switched to 2% HS differentiation medium or conditioned 2% HS differentiation medium. 
Differentiation media were replaced every two days through day 12. At that time point, 
no myotubes were visible under a light microscope. Immunofluorescence detection of 
sarcomeric myosin displayed a few sporadic myosin-positive cells that were not 
multinucleated in most cases (figure 37). However, overall, no myogenic differentiation 
of cultures was achieved with either type of differentiation media tested. Nevertheless, 
it should be noted that conditioned 2% HS medium appeared to induce a higher 
maturation rate of the myogenic cells, since striations were frequently visible in myosin-
positive cells differentiated with this medium, compared to differentiations performed 
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with 2% HS medium. Visually, no major differences were detected among healthy 
control- and patient-derived myogenic cultures.  
 
Figure 36. Effect of transient GSK3β inhibition during the induction of iPSCs towards GFP-positive 
myogenic progenitor cells. a) Light microscopy images of EBs during the myogenic induction following the 
regular protocol (left column), CHIR99021-supplemented for 24 hours (second column) and CHIR99021-
supplemented for 48 hours (third column). b) Plots corresponding to the isolation of GFP-positive events 
by FACS at the end of each induction protocol. c) Immunofluorescence images of sarcomeric myosin 
detection (in green) and cell nuclei (in blue) at day 5 of differentiation. Scale bars: 100 μm.  
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Figure 37. Immunofluorescence detection of sarcomeric myosin (green) in PAX7-positive progenitor-
derived cultures on day 12 of differentiation. Control 1-derived cells (a,b) and patient 1-derived cells (c,d) 
were differentiated with 2% HS medium (a, c) or conditioned 2% HS medium (b,d). Cell nuclei are stained 
in blue. Scale bars: 100 μm. 
Since these two differentiation protocols were not successful on driving PAX7-positive 
progenitors into myotubes, we evaluated alternative myogenic differentiation 
protocols. In the second test, cells were cultured for 5 days in differentiation conditions. 
This was established because the authors of the original myogenic differentiation 
protocol (Darabi et al., 2012; Darabi and Perlingeiro, 2014) claimed that the highest 
differentiation rate of PAX7-positive muscle progenitor cells was achieved at day 5-6 of 
differentiation. Therefore, we cultured PAX7-positive progenitor cells from control 1 and 
patient 4 up to 100% confluence and then switched to 1:1 induction-differentiation 
medium for 24 hours. Finally, cells were differentiated in 2% HS medium for an 
additional 4 days. Alternatively, cells were also differentiated in 20% KOSR medium, as 
suggested by the authors of the original differentiation protocol. Gene expression 
analysis of the myogenic genes myogenin, desmin, dystrophin and PAX7 on day 5 of 
differentiation indicated that in the majority of the cases, 20% KOSR medium induced 
higher myogenic gene expression rates when compared to 2% HS medium, both in 
control 1- and patient 4-derived cultures (figure 38). However, these gene expression 
differences were modest. Similarly, there were no substantial differences between 
cultures differentiated with 2% HS medium and 20% KOSR medium regarding myosin 
expression detected by immunofluorescence, as displayed in figure 38. Overall, the 
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differentiation rate achieved for both control- and patient-derived cultures was not 
considered successful.  
 
Figure 38. Assessment of myogenic terminal differentiation by gene expression analysis and 
immunofluorescence detection of sarcomeric myosin. (a-d) Gene expression rates at day 5 of 
differentiation relative to TBP expression (100%), in control 1-derived cultures (green bars) and patient 4-
derived cultures (blue bars) differentiated with 2% HS medium (dark bars) or 20% KOSR medium (light 
bars). (e-h) immunofluorescence detection of sarcomeric myosin (green) in control 1-derived and patient 
4-derived cultures after 5 days of differentiation in 2% HS medium (e,g) or 20% KOSR medium (f,h). Cell 
nuclei are stained in blue. Scale bars: 100 μm.  
Finally, the last optimization attempt consisted of inducing the terminal myogenic 
differentiation of PAX7-positive progenitors using the 15% KOSR medium (Chal et al., 
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2015). Moreover, an alternative coating system was also tested, referred to as sandwich 
coating, due to the two layers of coating used during the differentiation process: 0.1% 
gelatin underneath the cells and a 1-mm thick matrigel layer on top of the cells. This 
double coating has been reported to improve myogenic differentiation and maturation 
since it provides a tridimensional scaffold to the differentiating myogenic cells (Toral-
Ojeda et al., unpublished data). Control 1-derived cells were differentiated in these four 
conditions. As shown in the following image, the frequency of myosin-positive cells in 
culture was considerably increased when differentiations were performed with 15% 
KOSR medium (figure 39.b and d), compared to 20% KOSR medium (figure 39.a and c). 
As for the sandwich coating, this system led to more heterogeneous cultures, where the 
frequency of myosin-positive cells was high in some areas but low in other areas (figure 
39.d). Therefore, 15% KOSR medium and 0.1% gelatin coating were considered to be 
optimal conditions to drive the terminal myogenic differentiation of iPSC-derived PAX7-
expressing progenitor cells.  
 
Figure 39. Immunofluorescence images of control 1-derived myogenic progenitor cells at day 5 of 
differentiation. Sarcomeric myosin (in green) is detected in the four differentiation conditions. Cell nuclei 
are stained in blue. Scale bars: 100 μm.  
 
Characterization of iPSC-derived myogenic cultures. To determine the myogenic 
differentiation potential of iPSC-derived cells, myogenic progenitors at passage 3-4 were 
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cultured up to 100% confluence and then differentiated for 5 days using 15% KOSR 
medium. 
Immunofluorescence analyses showed that frequency of myotubes, detected through 
sarcomeric myosin-expression, was highest in patient 1 (P1)-derived cells, followed by 
control 1 (C1)-derived cells. Differentiation rates were lower in control 2 (C2) and patient 
4 (P4)-derived cultures, and minimal or even abset in patient 2 (P2) and patient 5 (P5)-
derived cultures (figure 40.a). Myogenin-positive nuclei displayed a concomitant 
frequency in these differentiated cultures (figure 40.b).  
 
Figure 40. Immunofluorescence detection of a) sarcomeric myosin (red) and b) myogenin (red) in cell 
cultures at day 5 of differentiation. Cell nuclei are stained in blue. Scale bars: 100 μm.  
 
Consistent with the immunofluorescence results, myogenic gene expression in cultures 
before (day 0, progenitors) and after terminal differentiation (day 5, differentiated) 
showed that certain cell lines, such as C1 and P1, were able to induce myogenic gene 
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expression upon differentiation. Other cell lines had a limited (C2 and P4), or even very 
reduced (P2 and P5), differentiation potential (figure 41). Embryonic myosin heavy chain 
(MYH3) and adult myosin heavy chain (MYH2) displayed a similar induction pattern, 
being considerably induced in C1 and P1 cell lines after 5 days of differentiation, and to 
a lower extent in C2 and P4. Only basal expression was detectable in P2 and P5 cells. It 
is noteworthy that adult myosin heavy chain levels were considerably lower than 
embryonic myosin heavy chain rates for each of the cell lines, suggesting that these 
differentiated cultures could potentially further differentiate and mature. Expression of 
MYOD1 and MYOG were consistent with myosin expression, demonstrating the highest 
expression rates in C1 and P1 differentiated cultures, moderate expression rates in C2 
and P4-derived cultures and basal rates in P2 and P5-derived cultures (figure 41).  
 
 
Figure 41. Gene expression of myogenic markers in differentiated cultures. Bar graphs indicate GAPDH-
relative expression rates of myogenic genes (MYH3, MYH2, MYOD1 and MYOG) in undifferentiated 
(progenitors, day 0) and differentiated (day 5) cultures. Bars represent mean values and standard 
deviations of 3 experimental replicates.* (p<0.05). 
 
There were no statistically significant differences found on differential gene expression 
rates between patient- and control-derived cell lines for any of the genes evaluated 
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except for embryonic myosin in muscle progenitor cells, whose expression was 
increased in patient-derived progenitor cells compared to control-derived cells. 
Overall, the variable differentiation potential of the established cellular models did not 
correlate with mutations in CAPN3. In other words, the variable differentiation potential 
of the cultures did not depend on whether the cell line was derived from a healthy 
control or a patient. 
Expression of PAX7 was also assessed in these myogenic cultures. As expected, total 
PAX7 levels (endogenous and exogenous PAX7) were the highest at day 0 of 
differentiation, which is consistent with the presence of doxycycline in the culture 
medium that activated the expression of exogenous PAX7 (figure 42.a). These PAX7 
mRNA levels decreased significantly at day 5 due to doxycycline withdrawal. No 
statistically significant differences were observed between healthy control- and patient-
derived progenitors or differentiated cultures.  
PAX7 protein levels followed a similar trend. Therefore, PAX7 protein detected at day 5 
of differentiation may primarily correspond to endogenous PAX7 expression (figure 42.b 
and c). Importantly, the frequency of PAX7-positive cells at day 5 of differentiation was 
still considerably high, except for P5-derived cultures, where practically no PAX7-
positive cells were detected (figure 42.d). 
CAPN3 and calpain 3 expression in iPSC-derived myogenic cultures. qPCR analysis 
results demonstrated that CAPN3 expression was induced following differentiation. 
Interestingly, CAPN3 rates for each cell line varied greatly and they did not correlate 
strictly with the differentiation efficiency of each cell line (figure 43.a). Notably, CAPN3 
expression in P5-derived cells was higher than in C2, P2 and P4-derived cultures, despite 
its poor myogenic differentiation. CAPN3 levels were considerably high in P1-derived 
cultures, which only has one CAPN3 allele. No statistically significant differences were 
detected between control- and patient-derived cultures regarding CAPN3 expression 
rates. 
Calpain 3 protein levels were assessed by Western blot (figure 43.b and c) using two 
antibodies that recognize different epitopes. As previously mentioned, commercial 
antibodies against calpain 3 are not fully specific and unexpected bands are detected by 
these antibodies. Some of these bands potentially correspond to calpain 3 proteolytic 
products, whereas other bands are considered nonspecific. Therefore, we assessed 
calpain 3 levels in differentiated cultures using antibodies against different epitopes of 
calpain 3 and we focused our attention on the 94 kDa band corresponding to full-size 
calpain 3. 
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Figure 42. Analysis of PAX7 mRNA and PAX7 protein expression. a) Bar graph showing GAPDH-relative 
expression rates of total PAX7 (endogenous and exogenous) in undifferentiated (progenitors, day 0) and 
differentiated (day 5) cultures. Bars represent mean values and standard deviations of 3 experimental 
replicates. b) Western blot detection of PAX7 (upper blot) and GAPDH (lower blot) in undifferentiated 
(day 0) and differentiated (day 5) cultures. c) Quantification of PAX7 protein levels detected in (b) through 
densitometry and normalized to GAPDH protein levels. d) Immunofluorescence detection of PAX7 protein 
(in red) and cell nuclei (in blue) in differentiated cultures. Scale bars: 100 μm. 
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Both antibodies proved the presence of full-size calpain 3 in each of the terminally 
differentiated cultures, except for P5-derived cultures (figure 43.b and c). Calpain 3 
protein levels were greatly variable among the different cell lines. The calpain 3 protein 
levels detected with two different antibodies did not exactly correlate. Considering both 
Western blots, the 94 kDa band found in C1- and C2-derived cultures was attributed to 
wild type calpain 3. The low intensity of these bands could be due to its autocatalytic 
activity. P1, P2 and P4 also expressed full-size calpain 3. Importantly, P2 and P4 harbor 
one missense mutation in one of the CAPN3 alleles, which likely led to these 94 kDa 
bands. Moreover, these amino acid substitutions may confer resistance to degradation 
to calpain 3, resulting in intense 94 kDa bands upon Western blot analysis with both 
antibodies. P1 has only one CAPN3 allele and the mutation located in this allele would 
synthesize a 101 kDa calpain 3 protein, which might not be distinguishable from the 94 
kDa bands observed in these blots. Finally, P5, which contains the Basque mutation in 
homozygosis, resulted in practically no 94 kDa calpain 3 bands, despite its considerable 
expression at the mRNA level. This is consistent with the absence of the 94 kDa calpain 3 
band in muscle extracts of a patient with the Basque mutation in homozygosis (data not 
shown). Notably, very low CAPN3 expression rates appear to be sufficient to synthesize 
calpain 3 protein. 
These data provide evidence that calpain 3 is expressed in myogenic cultures upon 
differentiation. Interestingly, calpain 3 is also detected in poorly-differentiating cell lines 
at day 5 of differentiation, such as P2 and P4.  
In addition to studying CAPN3 mRNA and full-size calpain 3 levels in differentiated 
cultures, expression of different CAPN3 isoforms along terminal myogenic 
differentiation was also assessed. As previously described, several splicing variants 
lacking exon 6 and/or exon 15 and exon 16 are detected during developmental stages, 
as well as during regenerative processes. This switch from immature to mature isoforms 
is recapitulated during in vitro myogenic differentiation (Herasse et al., 1999). Therefore, 
we studied the proportion of immature calpain 3 (lacking exon 6) and mature calpain 3 
(including exon 6) isoforms at day 0, 2 and 5 of the terminal differentiation process in 
C1- and C2-derived cells, as well as in the H9 human embryonic stem (ES) cell line, which 
was included as a positive differentiation control. As shown in figure 44.a, total CAPN3 
expression was significantly induced upon differentiation in C1- and H9-derived cells. 
However, this induction was very limited, although still significant, in poorly 
differentiating C2-derived cells. 
As for CAPN3 isoforms, the proportion of the immature isoform (lacking exon 6) was 
progressively reduced, while the mature form (including exon 6) increased as 
differentiation proceeded in C1 and H9-derived cells (figure 44.b and d). However, this 
switch from immature to mature isoforms was only statistically significant (p<0.05) in 
C1-derived cultures. Importantly, this change from the immature to the mature form 
CHAPTER 1: Results 
140 
  
was absent in C2-derived cells, which only presented a limited differentiation potential 
(figure 44.c). 
 
Figure 43. CAPN3 expression and Calpain 3 levels in iPSC-derived myogenic cultures. a) Bar graph 
illustrating GAPDH-relative CAPN3 expression rates (probe for exon 1-2) in undifferentiated (progenitors, 
day 0) and differentiated (day 5) cultures. Bars represent mean values and standard deviations of 3 
experimental replicates. b) Western blot of calpain 3 protein detection using the IS2 antibody, and GAPDH 
as endogenous control (lower blot). c) Western blot of calpain 3 protein detection using the 12A2 
antibody, and GAPDH as endogenous control (lower blot). d and e) Quantification of full size (94 kDa, 
pointed with arrows) calpain 3 levels detected with IS2 and 12A2 antibodies, respectively, and normalized 
to GAPDH levels. M: human muscle extract. 
CHAPTER 1: Results 
141 
  
 
Figure 44. Study of total CAPN3 expression and its immature and mature isoforms during terminal 
differentiation of iPSC-derived progenitor cells. a) Bar graph illustrating the quantification of total CAPN3 
expression (probe for exon 1-2) during the differentiation of control 1 and control 2 cell lines, as well as 
H9 embryonic stem cells. b, c and d) Bar charts indicate the proportion (%) of immature (lacking exon 6) 
and mature (including exon 6) isoforms of CAPN3 at day 0, 2 and 5 of differentiation. Bars represent mean 
values and standard deviations of 3 experimental replicates. * (p<0.05). 
Expression of dystrophin in iPSC-derived muscle progenitors and terminally 
differentiated cultures. Dystrophin is one of the most thoroughly studied proteins in 
skeletal muscle due to its implication in Duchenne Muscular Dystrophy (DMD). 
Moreover, this protein has been considered as a marker of maturation since its 
expression is highest in late myogenic differentiation stages (Hildyard and Wells, 2014). 
However, it is worth noting that DMD expression levels are also significantly upregulated 
in quiescent satellite cells, whereas its expression decreases significantly upon satellite 
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cell activation (Dumont et al., 2015b). This suggests that dystrophin potentially has 
multiple roles, both at the initial and terminal stages of myogenic differentiation. DMD 
expression was reduced in patient-derived cultures compared to healthy control-
derived cells, both in progenitor and terminal differentiation stages (figure 45). 
 
Figure 45. DMD expression 
in iPSC-derived myogenic 
progenitor cells and 
terminally differentiated 
cultures, relative to GAPDH 
expression (100%). Bars 
represent mean values and 
standard deviations of 3 
experimental replicates. 
*  (p<0.05). 
 
 
Expression of genes encoding extracellular matrix proteins in iPSC-derived muscle 
progenitors and terminally differentiated cultures. Since progressive increase of 
fibrotic tissue is a histological feature of LGMD2A and other muscle dystrophies, 
expression of fibronectin (FN1) and alpha-1 type I collagen (Col1α1) was assessed in 
iPSC-derived muscle progenitors and terminally differentiated cultures. Overall, 
induction of terminal differentiation activated the expression of both genes. Expression 
rates of both genes were higher in healthy control-derived terminally differentiated 
cultures compared to patient-derived cultures, although no statistically significant 
differences were detected (figure 46). Expression trends did not correlate with the 
myogenic differentiation potential of each cell line.  
Figure 46. Expression of extracellular protein-coding genes FN1 and COL1A1 in iPSC-derived myogenic 
progenitor cells and terminally differentiated cultures, relative to GAPDH expression (100%). Bars 
represent mean values and standard deviations of 3 experimental replicates.  
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SERCA2 protein levels in iPSC-derived progenitors and terminally differentiated 
cultures. It has been recently reported that calpain 3 is potentially involved in stabilizing 
the SERCA2 protein (Toral-Ojeda et al., 2016). Thus, SERCA2 protein levels were assessed 
in iPSC-derived cultures. Western blot analysis demonstrated that SERCA2 protein was 
detected in both muscle progenitors and terminally differentiated cells. However, 
SERCA2 protein levels did not correlate with calpain 3 protein levels. Interestingly, 
SERCA2 was absent in terminally differentiated P5-derived cultures, as well as calpain 3. 
SERCA2 protein was also detected in PAX7-expressing progenitors in all the cell lines, 
where expression of CAPN3 was basal (figure 47). 
 
Figure 47. SERCA2 protein levels in iPSC-derived muscle progenitors and terminally differentiated 
cultures. a) Western blots detecting SERCA2 (upper blot) and GAPDH (lower blot) in cell cultures at day 0 
(progenitors) and day 5 of differentiation. b) Quantification of SERCA2 protein levels through 
densitometry, normalized to endogenous GAPDH levels. M: human muscle extract.  
 
In vivo regenerative potential of iPSC-derived progenitor cells. To determine the 
regenerative potential of iPSC-derived muscle progenitor cells, 106 PAX7-expressing cells 
at passage 4 post-sorting were transplanted into cardiotoxin-injured TA muscles. Due to 
the complexity of the experiment, only P1-derived and its age-matched C2-derived cells 
were transplanted. One month after transplantation, muscles were collected and 
analyzed to assess the regenerative potential of the transplanted cells. 
Immunofluorescence detection of human lamin A/C allowed for the visualization of 
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human cell nuclei, which were derived from transplanted cells. This staining was used to 
determine the engraftment potential of C2- and P1-derived progenitor cells. As 
illustrated in figure 48.c, P1-derived cells showed an increased engraftment compared 
to C2-derived cells. Similarly, patient-derived cells generated more human dystrophin-
expressing fibers (figure 48.d), indicative of their greater regenerative potential 
compared to C2- derived cells. Figure 48 a and b display representative images of 
immunofluorescence detection of human cells in mouse TA sections. 
 
Figure 27. Analysis of the in vivo regenerative potential of iPSC-derived muscle progenitor cells. a and 
b) immunofluorescence images of control 2(a)- and patient 1(b)-transplanted TA sections where human 
cell nuclei are visualized in green, and human dystrophin-expressing fibers are seen in red. All nuclei are 
stained in blue. Scale bars: 50 μm c) total number of human lamin A/C-positive nuclei detected in all the 
sections analyzed for each TA, and d) total number of human dystrophin-positive fibers detected in all the 
sections analyzed for each TA. * (p<0.05). 
 
DISCUSSION 
In vitro disease modeling is a valuable and relatively affordable approach to study the 
physiopathology of diseases, as well as to test the efficacy of potential therapies. 
Research on skeletal muscle and the diseases directly affecting this tissue has been 
performed using animal models, patient-derived muscle biopsies, and in vitro myogenic 
cell cultures. Importantly, patient muscle-derived primary cultures have been 
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predominantly used for research purposes since the early 90s and, in vitro culture 
systems have been constantly evolving to optimize their use, as well as to generate 
cultures that closely represent their tissue of origin. In this regard, several disease-
specific myoblasts have been immortalized to extend their utility, and more complex 
extracellular matrixes and three-dimensional setups, as well as specific culture media, 
have been developed to achieve highly mature and long-lasting cultures.  
In recent years, myogenic cell culture systems have developed in parallel with cell 
transplantation approaches to treat muscular dystrophies, which require methods to 
generate large amounts of transplantable myogenic cells in an ex vivo setup. 
Currently, myogenic cultures derived from non-muscle tissues are offering alternative 
patient-specific sources of cells for both therapeutic approaches and in vitro disease 
modeling. Among them, reprogramming of somatic cells to pluripotency offers an 
unlimited source of patient-specific cells that later on can be differentiated into 
myogenic cells. Therefore, we aimed to establish LGMD2A patient-specific iPSC-derived 
myogenic cultures to address the role of calpain 3 in the myogenic differentiation 
process. As a result, this project has demonstrated the feasibility of this approach, while 
highlighting the challenges that are required to be addressed to further optimize the 
system and leverage this newly generated research tool, as discussed below. 
Establishment of LGMD2A patient- and healthy control-derived iPSC lines. Selection of 
samples to be reprogrammed was performed based on the mutations and disease 
severity. Next, two age- and sex-matched healthy samples were selected as controls for 
the study.  
Due to the broad spectrum of mutations observed in LGMD2A patients and their 
variable severity, it was not possible to select samples that directly represented each of 
the patients examined in the Neurology Service of the Donostia University Hospital, nor 
the worldwide population of LGMD2A patients. Among the five patients selected for this 
study, two of them, P3 and P5, had a severe phenotype, being wheelchair-bound in their 
forties. P1 and P2 were in an advanced grade, although still ambulant. Patient 4 
displayed the most benign phenotype among the five patients selected, with an 
intermediate phenotype. As for the mutations, we selected samples with the most 
commonly found mutation in this population (the Basque mutation in exon 22) both in 
homozygosis (P5) and in heterozygosis, combined with a missense mutation (P2) or 
another null mutation (P3). We also selected one sample with a complete deletion of 
one of the CAPN3 alleles (P1), and another sample with two mutations located in exon 
5 and 16 (P4), and thus fulfilling the requirements for a potential intermolecular 
complementation (Ono et al., 2014). In general, as described in the literature, patients 
with at least one missense mutation (P2 and P4) displayed a milder phenotype 
compared to patients with two null mutations (P3 and P5). Importantly, patient 1, which 
has only one CAPN3 allele that generates a mutant calpain 3 protein with a 62 amino 
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acid extension, was not classified as a severe case, suggesting that this CAPN3 allele is 
potentially able to synthesize a partially functional protein. Variable origin of the 
biopsies was not considered a hurdle since fibroblast cultures were obtained following 
the same protocol and cultures were morphologically similar. 
Upon induction of cell reprogramming, each of the cell lines generated a considerable 
number of potentially reprogrammed colonies, except for P5, which only led to three 
colonies (data not shown). Several factors can affect cell reprogramming efficiency, such 
as the age of the biopsy (Trokovic et al., 2015; Lo Sardo et al., 2016), the proliferative 
potential of the fibroblasts (Trokovic et al., 2015) or the infection efficiency achieved 
with the set of reprogramming vectors. In this study, P5 was one of the oldest donors. 
However, its age matched C1 and P3-derived fibroblasts led to a large number of 
colonies. Therefore, this reduced reprogramming rate cannot be directly attributed to 
the age of the donor. Except for P5, the remainder of fibroblasts generated a 
comparable number of colonies in the reprogramming plates. Hence, we conclude that 
mutations in CAPN3 do not alter the reprogramming potential and survival of the 
generated cell lines, as is the case for other disease-specific cell lines, such as Fanconi 
anemia (Raya et al., 2009). Henceforth, variations in the reprogramming rates achieved 
with different fibroblast cultures could be attributed to the stochastic nature of the 
reprogramming process. This is in line with theories that claim that cultured cells are 
heterogeneous, and only a small subpopulation of these cells appear to be in 
energetically favorable positions that facilitate their efficient reprogramming (reviewed 
by Del Sol and Buckley, 2014). Thus, different reprogramming efficiencies could be 
related to the amount of these specific cells that are randomly infected with the 
retroviral vectors. Once ES cell-like colonies emerged in the reprogramming plates, six 
colonies were individually picked and cultured, to establish several clonally-independent 
reprogrammed cell lines derived from each sample. As P5 only generated three colonies, 
only these three colonies were picked. These cell lines were mechanically expanded over 
feeder cells, and then adapted to feeder-free culture conditions and enzymatically 
expanded. Cells grown over feeder cells, as well as matrigel-adapted cells, were used to 
examine their pluripotency. During this process, cell lines that progressively lost the ES 
cell-like morphology (uniform surface and smooth edges) were discarded for 
subsequent characterization tests as it was considered an indicator of lack of 
pluripotency. 
Subsequently, cells were evaluated using a battery of characterization tests that have 
been widely used in the literature (Freberg et al., 2007; Raya et al., 2009; Martí et al., 
2013). The first test focused on the detection of AP activity in the reprogrammed cells, 
which is a feature of ES cells (O’Connor et al., 2008). This was assessed using a specific 
kit that reports AP activity through a colorimetric reaction. Each of the established cell 
lines (clones) from each sample displayed an intense AP staining. Moreover, this staining 
allowed for easier visualization of the morphology of the colonies. In this regard, patient- 
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and control-derived colonies showed a uniform appearance with smooth edges, being 
indistinguishable from ES cell lines cultured in the lab and also from examples reported 
in the literature. Therefore, each of the cell lines were deemed suitable for further 
characterization tests.  
Next, expression of pluripotency genes was evaluated by qPCR. Several studies have 
reported that fully reprogrammed cell lines tend to silence the expression of the 
transgenes used to induce pluripotency, whereas expression of endogenous 
pluripotency genes is simultaneously induced (Brambrink et al., 2008). Therefore, by 
using specific primer pairs, we assessed the expression of transgenic and endogenous 
Yamanaka factors, as well as the expression of CRIPTO, a membrane glycoprotein that 
acts as a growth factor receptor (Fiorenzano et al., 2016), and the pluripotency-related 
transcription factors REX1 and NANOG. Based on the GAPDH-relative expression rates, 
cell lines that demonstrated the lowest expression of the four transgenes, as well as 
induction of pluripotency genes, were selected for further experiments. Cell lines that 
showed high transgene expression rates (above 0.5% relative to GAPDH expression) 
were discarded, since this lack of silencing may potentially be a sign of incomplete 
reprogramming. In the case of patient 4, endo-OCT4 levels above GAPDH expression 
rates were detected in clones 5 and 6. These expression rates were considered 
abnormally high, and consequently, these clones were also discarded from further 
characterization tests. An exception was made for the P5 clone 3 cell line, since only two 
clones were established for this sample. In other words, although clone 3 did not strictly 
meet the transgene silencing criteria, it was included in the following characterization 
step. Regarding the induction of endogenous pluripotency genes, variable induction 
rates were similar to those reported in the literature (Sánchez-Danés et al., 2012). 
Endogenous OCT4 and CRIPTO rates were the highest for each of the reprogrammed 
samples, whereas REX1 and KLF4 levels were very low, or barely detectable.  
The number of clones that efficiently silenced transgene expression and induced 
endogenous pluripotency gene expression did not differ among the patient- and healthy 
control-derived cell lines. These gene expression results indicate that, despite each of 
the established cell lines displaying the typical ES cell morphology and AP staining, a 
more restrictive test based on the quantification of pluripotency gene expression 
allowed the identification of cell lines that did not strictly meet the criteria to be 
considered fully reprogrammed cell lines.  
Once two reprogrammed cell lines (clones) per sample were selected for further 
characterization, the number of transgene insertions in each cell line were analyzed 
through Southern blot. This technique identified bands corresponding to Yamanaka 
factors contained in the genome. By comparing the bands detected in reprogrammed 
samples and non-infected fibroblasts, bands corresponding to transgene insertions were 
identified. Based on these results, variable number or sizes of the bands allowed us to 
confirm the independent clonal origin of each pair of cell lines selected per sample. 
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Generally, between 1 and 3 insertions of each analyzed transgene were detected in the 
reprogrammed samples. When a large number of insertions were detected for a specific 
transgene, such as the 8 bands detected for transgenic OCT4 in P1 clone 1, or the 5 bands 
detected for transgenic cMYC in P3 clone 5, these cell lines were discarded from future 
experiments, since this fact could potentially lead to increased random mutagenesis, 
abnormal reprogramming and/or abnormal differentiation traits. However, due to 
technical challenges, we were not able to determine the number of insertions for 
transgenic SOX2 and KLF4 in each cell line, and therefore, we were unable to test if any 
of the cell lines had a high number of these transgene insertions. Nevertheless, the 
Southern blots obtained for OCT4 and cMYC provided sufficient information to confirm 
the independent clonal origin of the established cell lines. Based on these results, one 
cell line per sample was selected and further characterized. 
Immunofluorescence-based detection of a panel of extensively characterized, and 
widely accepted pluripotency markers, is one of the main characterization tests that 
proves the pluripotency of reprogrammed cell lines. Pluripotency-associated 
transcription factors OCT4, NANOG and SOX2, the stage-specific embryonic antigens 
SSEA-3 and SSEA-4, and podocalyxin-epitopes TRA1-60 and TRA1-81 were detected in 
each of the samples analyzed. Moreover, their expression was detected throughout the 
colonies, although the intensity of the staining varied slightly in some colonies. 
Therefore, it was assumed that the selected clones expressed the entire set of 
pluripotency markers studied, which was indicative of the pluripotency achieved. 
The term ‘pluripotency’ refers to the ability of a cell to differentiate into a wide range of 
cell types. Accordingly, an essential characterization test consists on proving the ability 
of the reprogrammed cell lines to differentiate into several cell types. By culturing 
reprogrammed cells in previously defined conditions, they differentiated into cell types 
derived from the three embryonic germ layers. Finally, immunofluorescence detection 
of lineage-specific markers proved the pursued differentiation. Ectoderm-derived cell 
types include neurons, glial cells and melanocytes. In this differentiation test, TUJ1 and 
GFAP were evaluated as markers of neurons and astrocytes, respectively. Mesoderm 
derivatives include muscle and blood cells, connective tissue and kidneys, among others. 
α-SMA and GATA4, which are expressed in the contractile apparatus and during 
myocardial differentiation, respectively, were detected to prove mesoderm 
differentiation. Finally, endoderm derivatives include the epithelium of lungs, liver, 
pancreas, prostate, vagina and several glands. Therefore, expression of AFP, a 
developmental plasma protein, and FOXA2, a transcriptional activator of liver-specific 
genes, were studied as indicators of endoderm differentiation. Moreover, formation of 
round-shaped structures resembling glands was also considered indicative of endoderm 
differentiation. Each of the differentiated samples expressed at least one out of the two 
lineage-specific markers studied, proving the differentiation of the reprogrammed 
samples into cell types belonging to the three cell lineages. Negative detection of the 
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second lineage-specific marker could be due to different issues. For example, TUJ1 
expression was detected in each of the cultures differentiated into ectoderm lineages, 
but GFAP was only detected on some samples. This suggests that the ectoderm 
induction medium used appears to induce neuronal differentiation better than 
astrocyte differentiation, or that our cell lines potentially had an intrinsic tendency to 
better differentiate into neurons compared to astrocytes. As for endoderm 
differentiation, FOXA2 is expressed in each of the samples, but AFP is absent in some of 
them. This is potentially due to the fact that these markers are expressed at specific 
differentiation stages. FOXA2 is a broadly expressed marker along the endoderm 
differentiation, whereas AFP is only expressed at later stages (Si-Tayeb et al., 2010). 
Thus, detection of one or both endoderm markers depends on the differentiation rate 
achieved by each sample. Therefore, detection of at least one of the two markers tested 
was considered sufficient to prove the differentiation of the reprogrammed samples 
into cell types derived from the three germ lines.  
Epigenetic regulation of gene expression is tightly controlled during cell reprogramming 
and differentiation processes (Guo et al., 2017). Methylation of the CpG islands located 
in promoter sequences is one of the most important modifications that strongly inhibits 
gene expression. In this regard, it has been shown that during differentiation of human 
ES cells, promoters of pluripotency genes such as NANOG and OCT4 are quickly 
methylated upon induction of differentiation, thereby silencing their expression, 
whereas induction of reprogramming of differentiated cells into pluripotency reduces 
their methylation (Freberg et al., 2007; Yeo et al., 2007). Therefore, we evaluated the 
methylation status of the promoter regions of OCT4 and NANOG as part of the 
characterization of the reprogrammed cell lines, and observed that both promoters 
were considerably demethylated (methylation rates below 18%) in each of the 
established cell lines. Thus, we concluded that cell reprogramming led to epigenetic 
modifications required to acquire pluripotency.  
Cell reprogramming using integrative vectors, as well as prolonged in vitro culture of 
reprogrammed cells, often lead to chromosomal abnormalities, which might confer 
selective advantages to the modified cells. To circumvent this, regular karyotype 
analyses are recommended to ensure the genomic stability of the established cell lines. 
Karyotype analyses of the reprogrammed cell lines through G-banding identified 
chromosomal abnormalities in a small percentage of cells in three of the cell lines. 
Subsequent subcloning of these cell lines allowed for derivation of cell lines without 
chromosomal abnormalities. 
In conclusion, this set of characterization tests allowed us to select one pluripotent cell 
line per sample, which were referred to as induced pluripotent stem cells (iPSCs). 
However, further culture of these iPSCs led to consistent spontaneous differentiation of 
patient 3-derived iPSCs after 4 passages in feeder-free conditions. Consequently, this 
cell line was excluded from further experiments, since this spontaneous differentiation 
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raised questions about the incomplete pluripotency that this specific cell line might have 
achieved.  
The fact that one of the cell lines that had passed each of the characterization tests 
displayed signs of incomplete pluripotency, raised doubts about the stringency of the 
set of pluripotency tests selected for the characterization process. Questions that 
require further evaluation include: Is this set of characterization experiments strict 
enough to prove the pluripotency of a cell line? Can we discuss different pluripotency 
degrees in the field of cell reprogramming? Are these characterization tests able to 
detect and differentiate among variable pluripotency status?  
The set of characterization tests performed in this project agreed with the tests required 
by the Spanish National Bank of Cell Lines (Banco Nacional de Líneas Celulares, Instituto 
de Salud Carlos III) to deposit the generated cell lines in this cell bank, which is 
mandatory for any iPSC line generated in any of the Spanish research centers. However, 
our results strongly suggest that these tests are potentially not enough to prove that the 
generated cell lines had acquired full pluripotency. Indeed, many authors perform 
additional characterization tests, such as the in vivo teratoma assay and the reactivation 
of the X chromosome, to further confirm pluripotency of their reprogrammed cells. 
Teratomas are encapsulated tumors that generally contain tissues and organ-like 
structures derived from the three germ layers. In stem cell research, teratoma formation 
is considered to be one of the most demanding tests to prove cell pluripotency. The test 
relies on the transplantation of reprogrammed cells, together with extracellular matrix 
(usually matrigel) into immunosuppressed mice, subcutaneously or into the gonads, to 
allow for teratoma formation. Irradiated feeder cells may be transplanted as well to 
improve teratoma formation (Gropp et al., 2012). Moreover, teratoma formation 
efficiency and the duration of the process appear to depend on the cell number 
transplanted and the site of injection. Once teratomas are formed, these are extracted 
and analyzed through histological characterization and immunodetection to prove the 
presence of cell types and tissues derived from the three germ layers. This test has been 
considered a gold standard to characterize human iPSCs (Zhang et al., 2012), although 
some researchers claim that partially reprogrammed cells may also lead to positive 
results (Chan et al., 2009). In our case, we did not perform this test with our cell lines 
since it is not considered as an indispensable characterization test by the Spanish 
National Bank of Cell Lines, despite the prolonged duration of the experiment that raises 
the cost of the characterization considerably. Importantly, this test may be useful to 
detect anomalies in P3-derived iPSCs, as well as in other cell lines. 
X chromosome reactivation has additionally been studied as a feature of cells 
reprogrammed to pluripotency (reviewed by Pasque and Plath, 2015). During the 
development of mammalian female embryos, one of the X chromosomes is 
epigenetically repressed upon differentiation. Therefore, reactivation of the inactivated 
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X chromosome has been used as a characterization test in cell reprogramming 
experiments. However, this is not always the case in human iPSCs, since they tend to 
acquire a primed pluripotent state (similar to the pluripotency grade found in the inner 
cell mass of post-implantation embryos) and may still keep one X chromosome 
inactivated. This is contrary to mouse iPSCs that usually achieve a naïve pluripotency 
(ground state pluripotency, corresponding to the pluripotency grade found in the inner 
cell mass of pre-implantation embryos) (Hackett and Surani, 2014). Therefore, study of 
X chromosome reactivation in the characterization of human iPSCs has been deemed 
controversial and it was not considered as part of our characterization tests. Further, 
this test can only be used for female-derived samples and this was an additional reason 
to exclude it from our set of characterization tests. 
Some additional in vivo tests have been used to characterize mouse pluripotent cells, 
such as the study of chimera generation and germline transmission through tetraploid 
complementation assays (Zhao et al., 2009). However, these tests are not suitable to 
characterize human iPSCs due to technical and ethical issues. 
Despite each of these standard characterization tests being necessary to prove the 
pluripotency of reprogrammed cells, alternative high throughput tests with broader 
coverage are currently available. Among them, D’Antonio and colleagues have published 
a method to accelerate this process by characterizing iPSCs based on cytometry-
mediated detection of pluripotency markers, gene expression analysis through qPCR 
and digital karyotyping using SNP arrays (D’Antonio et al., 2017).  
Another test consists of analyzing the transcriptomic profile of the reprogrammed cell 
lines, comparing them with the profile of the original somatic cells and ES cell lines that 
are used as positive controls of pluripotency (Guenther et al., 2010; Bock et al., 2011; 
Araúzo-Bravo, 2016). Comparison of methylation profiles is also useful for 
characterization purposes (Bock et al., 2011; Ruiz et al., 2012).  
A more thorough characterization of our iPSC lines, for example through transcriptomic 
analysis, would likely detect differences on the degree of pluripotency achieved by our 
reprogrammed cell lines. Moreover, these expression results will potentially contribute 
to aid in determining whether P3-derived iPSCs have only been partially reprogrammed.  
In this regard, different research teams have aimed to investigate the degree of 
pluripotency achieved by reprogrammed cell lines. Although these studies have 
demonstrated a wide variety of experimental outcomes, it is generally agreed that 
mouse iPSCs tend to acquire a higher pluripotency degree, comparable to that of pre-
implantation epiblast cells, and are thus termed naïve pluripotent cells. On the contrary, 
human cell reprogramming leads to pluripotent cells corresponding to more advanced 
post-implantation embryonic stages, and are thus classified as primed pluripotent cells 
(De Los Angeles, et al., 2012; reviewed by Hackett & Surani, 2014). This may be 
attributed to divergences in signaling pathways controlling cell pluripotency in mice and 
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humans. As an example of these differences, mouse iPSCs depend on leukemia 
inhibitory factor (LIF) to maintain their pluripotency, whereas human iPSCs do not 
respond to LIF and depend on FGF2. In parallel, the use of 2i (a combination of the 
FGF/ERK pathway inhibitor PD03 and the GSK3β inhibitor CHIR99021) promotes the self-
renewal of mouse iPSCs, whereas it induces neural and mesodermal differentiation in 
human iPSCs (reviewed by Hackett and Surani, 2014). Importantly, epigenetic regulation 
appears to play a key role in the transition from the primed state to naïve pluripotency 
and vice versa (Leitch et al., 2013; Guo et al., 2017). This has led to the development of 
protocols that are able to reset primed human pluripotent stem cells back to a naïve 
state (Takashima et al., 2014; Theunissen et al., 2014, 2016; Guo et al., 2017).  
In parallel, partial or incomplete reprogramming is also concerning when the established 
cell lines are intended to be used for disease modeling or for future therapeutic 
purposes. Epigenetic memory is likely the main cause of this problem. Proper cell 
reprogramming implies robust genome wide demethylation (Shipony et al., 2014; Lee et 
al., 2014). Lack of complete reprogramming has been correlated with incomplete 
erasure of specific methylation sites (Lister et al., 2011; Ohi et al., 2011). This 
abnormality often causes a biased differentiation, leading to an increased ability of 
reprogrammed cells to differentiate into the cell type of origin (Bar-Nur et al., 2011; Kim 
et al., 2011; Hiler et al., 2015).  
Considering all of the characterization tests available and the hurdles of cell 
reprogramming, a wider characterization of our iPSC lines may had made it possible to 
determine the degree of pluripotency achieved, allowing us to classify them as partially 
reprogrammed, primed or naïve pluripotent stem cells. Moreover, this information 
would be useful to interpret the phenotype of the cell lines upon their subsequent 
myogenic differentiation.  
Optimizing the myogenic differentiation of iPSCs. Efficient and reproducible 
differentiation of iPSCs into specific cell types is crucial to generate in vitro disease 
models, as well as for future therapeutic applications. Despite innumerable 
differentiation protocols have been reported to induce differentiation of pluripotent 
cells into specific cell types, in vitro myogenic differentiation remains being a challenge, 
generally showing low efficiency and reproducibility (reviewed by Świerczek et al., 
2015). Therefore, to optimize the differentiation rate of the cultures, the majority of 
protocols include transient expression of specific transgenes and/or FACS-mediated 
selection of cells with myogenic potential (reviewed by Kodaka et al., 2017).  
Myogenic differentiation of pluripotent cells is generally achieved through a biphasic 
protocol, consisting of the initial mesodermal induction followed by myogenic 
differentiation (reviewed by Kodaka et al., 2017) A limited number of protocols have 
achieved myogenic differentiation by culturing the pluripotent cells in specific culture 
conditions, avoiding the overexpression of exogenous genes. Some of these protocols 
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induce an initial differentiation and perform a FACS-mediated selection of muscle 
progenitor cells, followed by their terminal differentiation (Borchin et al., 2013; Barberi 
et al., 2007). Recently, a few research teams have additionally established protocols to 
generate myogenic cultures from human iPSCs using neither transgene overexpression 
nor FACS-mediated purification of myogenic cells (Swartz et al., 2016; Chal et al., 2016). 
However, these protocols lead to heterogeneous cultures that contain myogenic cells, 
but also a large amount of undefined cell (Kim et al., 2017). Therefore, this 
heterogeneity, together with the limited expansion ability of these myogenic cells, casts 
doubts on their suitability for therapeutic purposes (Kim et al., 2017). 
Overexpression of myogenic transcription factors has achieved the greatest myogenic 
induction rates. Among them, MYOD1 (Goudenege et al., 2012; Tedesco et al., 2012; 
Tanaka et al., 2013; Yasuno et al., 2014; Abujarour et al., 2014; Li et al., 2015; Maffioletti 
et al., 2015) and PAX7 (Darabi et al., 2012) have been the most widely utilized 
transgenes for myogenic induction of human iPSCs. As previously mentioned, PAX7 is a 
crucial transcription factor in the generation and maintenance of satellite cells, which 
actively regenerate skeletal muscle tissue (reviewed by Dumont et al., 2015a). Darabi 
and colleagues demonstrated that transient overexpression of exogenous PAX7 in 
human ES and iPSCs, followed by their FACS-mediated selection, leads to a population 
of muscle progenitor cells that express surface markers described in mouse satellite 
cells, muscle progenitors cells and mesenchymal stem cells (Darabi et al., 2012). These 
myogenic progenitors can be terminally differentiated into myogenin- and MyHC-
expressing myotubes. Compared to PAX7-mediated myogenic induction, overexpression 
of MYOD1 leads to myogenic cells in more advanced stages of the differentiation process 
and thus, these cells can be quickly differentiated into myotubes. 
Considering this variety of approaches to induce myogenic differentiation of our iPSC 
lines, transgene expression was selected due to its high efficiency and shortened 
duration of the protocols. In particular, we decided to reproduce the protocol described 
by Darabi and colleagues (2012), which uses transient PAX7 overexpression to generate 
a pool of muscle progenitor cells, in order to study the role of calpain 3 in early as well 
as late myogenic differentiation stages. Overexpression of MYOD1 was not considered 
due to the potential interaction of this protein with calpain 3 (Stuelsatz et al., 2010), 
which could interfere with the phenotypes observed upon terminal differentiation.  
As an initial step, iPSC lines were infected with the doxycycline-inducible PAX7-
expression system. Various conditions were evaluated to optimize the infection 
efficiency, such as variable iPSC confluence, different cell dissociation reagents and 
increasing polybrene concentrations (data not shown). However, despite using 
optimized conditions, some cell lines were difficult to infect, whereas cell lines, such as 
C1, P1 and P4-derived iPSCs, were more prone to be infected. It has to be taken into 
consideration that iPSCs are one of the most difficult cell types to infect, likely due to 
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their compact shape and the fact that they grow in colonies, which hinders access of the 
viruses to the surface of the cells.  
The PAX7-inducible system consists of two vectors, and thus, a further difficulty derives 
from the fact that only the cells that are infected with both lentiviral vectors are capable 
of expressing exogenous PAX7 when cultured with doxycycline (Darabi and Perlingeiro, 
2014). Therefore, efficiencies of 20-25% were considered acceptable. Importantly, the 
percentage of GFP-positive cells increased throughout the induction process, and 
muscle progenitors purified at day 14 of the myogenic induction protocol were highly 
proliferative. Hence, 20-25% infection efficiencies allowed for the generation of a large 
pool of progenitor cells for subsequent experiments.  
It was not possible to achieve satisfactory infection rates for C2, P2 and P5-derived iPSC 
lines, as these cell lines were especially difficult to infect for unknown reasons. However, 
we proceeded with their myogenic induction since 12-17% infection rates were 
sufficient to generate a considerable pool of muscle progenitor cells following their 
myogenic induction.  
Once a stock of PAX7-infected iPSC lines was generated, we proceeded to induce 
differentiation into muscle progenitor cells, following the protocol described by Darabi 
and colleagues (Darabi et al., 2012, 2014). Throughout the induction protocol, cell 
morphology was comparable among the various cell lines. At the beginning of the 
process, each of the iPSC lines displayed a similar morphology. At day 2, EBs were 
already formed and looked visually similar regarding their smooth and transparent 
shape. However, considerable differences were detected regarding their size, likely due 
to differences in the amount of cells plated in each induction protocol, and/or the 
proliferative potential of these cells in suspension. These differences did not depend on 
the origin of the iPSC lines, as no differences were detected among healthy control and 
patient-derived cells. Notably, cell outgrowths had a similar morphology at day 10 and 
14 of the differentiation process, and also after selection and culture of GFP-positive 
cells. 
FACS-based analysis of the cell cultures at day 14 of the induction protocol allowed for 
the evaluation of cell distribution with regards to size and granularity. Of note, although 
slight variations were detected among the analyzed cell lines, distribution of the GFP-
positive cell population was very similar for each of the six cell lines, with relatively small 
size and granularity compared to the entire cell population. Sorted GFP-positive cells 
were also similar regarding their green fluorescence intensity, and only highly 
fluorescent cells were sorted and expanded through passage 3, generating a stock of 
frozen vials for subsequent experiments. 
Inhibition of GSK3β has been shown to activate the canonical Wnt signaling pathway, 
leading to enhanced myogenic differentiation (van der Velden et al., 2007; Xu et al., 
2013). Therefore, CHIR99021, one of the most selective GSK3β inhibitors described to 
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date, has been included in several myogenic differentiation protocols for human ES and 
iPSCs (Borchin et al., 2013; Shelton et al., 2014; Chal et al., 2016). Transient treatment 
of our cell lines with CHIR99021 during the induction process slightly altered the 
morphology of the EBs, which displayed a rougher surface. In addition, the percentage 
of GFP-positive cells was significantly increased following a 24 hour treatment with 
CHIR99021, although this increase was modest when the treatment was extended up to 
48 hours. It was interesting to notice that GSK3β inhibition at days 2-3 had a strong effect 
on the percentage of PAX7-expressing GFP-positive cells obtained at day 14 of the 
protocol. This is potentially due to the fact that an improved mesoderm induction at 
early stages of the induction protocol may positively act on the proliferative capacity of 
muscle progenitor cells, both before and after induction of PAX7 expression at day 10 of 
the protocol, thereby increasing the percentage of GFP-positive cells at day 14 of the 
induction protocol. However, contrary to our expectations, the use of CHIR99021 in the 
myogenic induction process did not improve the terminal differentiation efficiency, 
which was reduced in the cells treated for 48 hours. Previously published studies have 
clearly proven the beneficial effect of transient GSK3β inhibition in the myogenic 
induction process. Therefore, it may be necessary to further optimize GSK3β inhibition 
during the induction protocol described by Darabi and Perlingeiro (2014) to benefit from 
its positive effect on myogenesis. For example, GSK3β inhibition could be tested in later 
stages of the myogenic induction process, using various concentrations of the inhibitor 
and fluctuating the duration of the treatment. Since addition of CHIR99021 did not 
improve the terminal differentiation of our iPSC lines, we did not include it in our 
optimized differentiation protocol. 
iPSC-derived myotube cultures were generated by culturing GFP-positive cells to 
confluence, followed by their culture in terminal differentiation medium. Terminal 
differentiation media contained low serum levels or serum replacement, with neither 
FGF2 nor doxycycline. These conditions were expected to induce cell cycle withdrawal 
and cell fusion, leading to the expression of late myogenic markers such as MyHC, 
myogenin and dystrophin. Several differentiation protocols were evaluated to optimize 
myotube formation, which was assessed through immunofluorescence based on the 
detection of sarcomeric myosin-positive cells. 
The first differentiation medium evaluated contained only 2% of horse serum in DMEM 
medium. Horse serum is widely used to induce myogenic differentiation, due to its lower 
growth factor content and higher insulin levels. We additionally tested C2C12-
conditioned medium, as it has been shown to support and improve myogenic 
differentiation of several cell lineages (Dezawa et al., 2005; Patruno et al., 2017;). Lack 
of robust myogenic differentiation after 12 days of differentiation highlighted the need 
to examine alternative differentiation conditions that would lead to higher 
differentiation rates. Although conditioned medium appeared to improve cell 
maturation based on the presence of striations, overall myogenic differentiation was 
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inefficient. Moreover, conditioned medium is an undefined and highly variable medium 
and therefore, its use would be challenging to reproduce myogenic differentiations. 
Thus, alternative differentiation protocols were subsequently tested to achieve the 
desired terminally differentiated myogenic cultures.  
In the next optimization attempt, the protocol was shortened to 5 days based on the 
recommendations of the authors of the original differentiation protocol, since longer 
incubations may favor cell detachment. The use of a defined differentiation medium 
containing 20% knockout serum replacement was also compared with the previously 
tested 2% horse serum medium. Overall, these protocols did not improve considerably 
the myogenic differentiation rates, and differentiation outcomes were similar with both 
terminal differentiation media evaluated. Gene expression analysis of a set of myogenic 
differentiation markers did not contribute to determine the best differentiation 
medium. 20% KOSR medium was chosen for the following optimization experiments 
because myogenic gene expression rates were overall slightly higher compared to 
2% HS-differentiated samples. 
As previously mentioned, Chal and colleagues (2016) described a transgene-free and 
purification-free myogenic differentiation protocol. In the final optimization attempt we 
tested the terminal differentiation medium used in this protocol to differentiate PAX7-
expressing muscle progenitor cells. This medium, compared to the previously tested 
20% KOSR medium, led to a higher density of MyHC-positive cells in culture. Importantly, 
this differentiation medium contained IGF-I, which is known to promote proliferation 
and myogenic differentiation (Engert et al., 1996), and HGF, a crucial molecule for 
myogenic cell migration during development, as well as for epithelial to mesenchymal 
transition that occurs in early myogenesis during embryonic development (Brand-Saberi 
et al., 1996). Therefore, these two factors may play a crucial role in the myogenic 
differentiation of our PAX7-expressing muscle progenitor cells. In parallel, we evaluated 
the effect of providing a more complex extracellular matrix to the cells by covering them 
with a layer of extracellular matrix (matrigel), compared to the regular gelatin coating. 
This system was expected to improve cell differentiation and maturation (Toral-Ojeda 
et al., unpublished data). However, in our hands, the sandwich method did not improve 
the previous differentiation system, and it led to non-uniform cultures with similar, or 
even reduced, density of MyHC-positive myotubes in cultures. Henceforth, all 
differentiations were performed in 15% KOSR medium and in gelatin-coated wells. 
To date, it is not fully understood why iPSC lines display variable differentiation 
potentials, and to what extent these differentiation efficiencies can be improved by 
optimizing culture conditions. Our data demonstrate that myogenic differentiation of 
some cell lines can be considerably altered by using specific culture media. Serum types 
and concentrations, as well as growth factors included in these media may directly 
influence differentiation potential. However, although some cell lines are highly 
influenced by these culture conditions, other cell lines are highly resistant to 
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differentiate. In these cases, the pluripotency grade acquired during cell reprogramming 
may importantly impact the myogenic differentiation potential.  
Comparative myogenic differentiation of iPSCs. Simultaneous terminal differentiation 
of iPSC-derived muscle progenitor cells led to highly variable cultures. 
Immunofluorescence detection of terminal myogenic markers, such as sarcomeric 
myosin and myogenin, revealed inconsistent differentiation potential of the cell lines. 
These differences in the myogenic differentiation potential among the different cell 
lines, were not attributed to the mutations in CAPN3, since there were no expression 
patterns distinguishable between healthy control- and patient-derived cultures. 
Moreover, variability between the two healthy control-derived cells was as large as the 
variability observed among some patient-derived cells and among patient- and healthy 
control-derived cells.  
Gene expression results were consistent with immunofluorescence results. Cell lines 
with a greater differentiation potential displayed a higher expression of embryonic 
myosin (MYH3), adult myosin (MYH2), MYOD1 and myogenin (MYOG). As for myosin 
expression, embryonic myosin levels in differentiated cultures were much higher than 
adult myosin expression levels, which suggests that these cultures had room for further 
differentiation and/or maturation. MYOD1 was detected in progenitor cells, and its 
expression was augmented in differentiating cultures, whereas it was reduced in mildly 
or poorly differentiating cultures. Myogenin expression, together with myosin 
expression is considered a terminal myogenic differentiation marker. Results showed a 
similar expression trend in differentiated cultures, although expression rates were 
considerably higher compared to MYOD1 levels.  
Poorly differentiating cell lines appeared to have differentiated into non myogenic cell 
lineages based on their morphology. According to the previously discussed role of 
epigenetic memory, we suggest that our reprogrammed iPSC lines may have achieved a 
variable degree of pluripotency and thus, this would directly affect their differentiation 
potential into myogenic cells. It has been shown that pluripotent cells that retain strong 
epigenetic marks have a greater tendency to differentiate into the original cell type (Bar-
Nur et al., 2011; Hiler et al., 2015; Kim et al., 2011). In our case, poor epigenetic erasure 
in some of the reprogrammed cell lines may have led to limited myogenic differentiation 
potential, together with an intrinsic tendency to differentiate into the cell type of origin, 
fibroblasts. However, presence of fibroblasts in the differentiated cultures has not been 
assessed in our experiments.  
Despite the tremendous variability in the differentiation potential observed among the 
iPSC-derived myogenic cultures, two genes showed a differential expression among 
healthy control- and patient-derived cultures. On the one hand, embryonic myosin 
(MYH3) expression was upregulated in patient-derived muscle progenitor cells, which 
may be indicative of the increased differentiation tendency of patient-derived 
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progenitors. Conversely, dystrophin (DMD), traditionally considered as a terminal 
differentiation and maturation marker and recently described as a regulator of satellite 
cell activity (Dumont et al., 2015b), was downregulated in patient-derived cultures both 
in progenitors and differentiated cells. This may be indicative of a potential role of 
calpain 3 in the biology of muscle progenitor cells and differentiated cultures. In 
agreement with this, studies performed with C3KO mice demonstrated that calpain 3 
participates in the maturation of skeletal muscle (Kramerova et al., 2004). However, 
despite these differences being statistically significant, the low CAPN3 expression 
observed in muscle progenitor cells suggests that the phenotypes observed in 
progenitors may probably be calpain 3-independent. Moreover, the large variability 
observed among the cell lines highlights the need to perform gene rescue experiments 
to determine if these phenotypes are capain 3-specific. For example, correction of 
mutations in CAPN3 in patient-derived cell lines, or the generation of CAPN3-knockout 
cell lines from healthy control-derived cells through gene editing technologies would 
lead to isogenic cell lines that would clarify if these phenotypes are calpain 3-dependent 
or independent.  
Expression of PAX7 was also assessed in these differentiated cultures as well as in 
myogenic precursors. Both gene expression analysis through qPCR and protein 
detection through Western blot revealed that PAX7 was highly expressed in muscle 
progenitor cells. Both techniques detected total PAX7 levels, regardless of the 
exogenous or endogenous origin of the protein. However, at day 0 of differentiation 
(muscle progenitors), most of these gene expression and protein rates were potentially 
attributed to exogenous PAX7 since these cells were cultured with doxycycline, which 
activates the expression of transgenic PAX7. As expected, both gene expression and 
protein levels decreased dramatically following 5 days of terminal differentiation in the 
absence of doxycycline. Therefore, gene expression and protein levels at day 5 of 
differentiation were considered to derive primarily from endogenous PAX7. 
Importantly, a considerable proportion of cells stained positively for PAX7 in 
differentiated cultures, which suggests that these cultures still retain a strong myogenic 
identity, despite their variable myogenic terminal differentiation potential. However, 
this large proportion of PAX7-positive cells in differentiated cultures is inconsistent with 
the residual PAX7 expression reported by Darabi and colleagues (Darabi et al., 2012).  
PAX7-positive cells were nearly absent in P5-derived differentiated cultures. This fact, 
together with the null myogenic differentiation potential of this cell line, suggests that 
this specific cell line has not achieved the desired myogenic identity, despite the fact 
that it went through the previously described myogenic induction protocol, including 
transient exogenous PAX7 expression. Again, this may potentially be attributed to the 
epigenetic memory retained by the reprogrammed cells that may override its myogenic 
differentiation ability.  
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Since LGMD2A and other dystrophies cause a progressively increasing fibrosis, we 
questioned whether patient-derived muscle progenitor cells would have an increased 
tendency to express fibrosis-related genes upon differentiation. In this regard, 
fibronectin 1 and collagen type 1 α1 were both highly induced upon differentiation, 
although no statistically significant differences were detected between control- and 
patient-derived cultures, as it is the case for other dystrophies (Mehuron et al., 2014).  
Study of CAPN3 and calpain 3 expression in iPSC-derived cellular models. The study of 
calpain 3 encounters numerous challenges caused by its quick autocatalytic activity. 
Consequently, protein extraction from muscle biopsies require the use of specific 
protocols and buffers that prevent its degradation. Detection of calpain 3 in cell culture 
extracts is even more challenging than in skeletal muscle extracts, since the amount of 
calpain 3 protein is reduced when compared to muscle extracts. Moreover, calpain 3 
protein levels may be related to the myogenic maturity of the cultures, and thus, lack of 
proper maturation may lead to low calpain 3 protein levels. Finally, the presence of non-
specific bands and degradation bands hinders the study of calpain 3 via Western blot, 
and prevents its study through immunofluorescence. Considering each of these 
difficulties, the lack of calpain 3 in our differentiated cultures was one of our main 
concerns.  
Total CAPN3 expression was analyzed through qPCR using a Taqman probe against exon 
1 and 2. This probe was capable of detecting all the transcripts expressed by our cell 
lines, regardless of the mutations. Results demonstrated that CAPN3 expression was 
induced upon differentiation. Although overall gene expression levels were relatively 
low, the largest induction rates were observed in C1 and P1-derived cell lines. Notably, 
P1 had only one CAPN3 allele. Therefore, high myogenic differentiation capacity may 
promote CAPN3 expression. However, P5-derived cells also expressed CAPN3 upon 
induction of differentiation, despite this cell line not differentiating into myotubes. 
CAPN3 expression in the remainder of the cell lines did not strictly correlate with their 
differentiation potential either. This lack of correlation can be explained by two facts. 
First, CAPN3 is additionally expressed in non-myogenic cells (e.g. fibroblast and blood 
cells) at the mRNA level (Blázquez et al., 2008, 2013). Therefore, differentiated cultures 
at day 5 that do not display a strong myogenic differentiation may also activate CAPN3 
expression, which could vary according to the differentiated cell type. Alternatively, 
nonsense-mediated RNA decay has been described in LGMD2A-derived patients (Krahn 
et al., 2007). This phenomenon appears to be specific to certain mutations, which could 
likely alter the total amount of CAPN3 transcripts measured in the cultures. 
Due to the previously discussed difficulties when studying calpain 3 protein levels 
through Western blot, detection of calpain 3 was performed using two antibodies that 
recognize different epitopes of calpain 3. One of them, IS2, is a polyclonal antibody 
generated against the calpain 3-specific sequence IS2, whereas the second one, 12A2, is 
a monoclonal antibody generated against the protein region encoded by exon 8 of 
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CAPN3 and it recognizes ubiquitous calpains in addition to calpain 3 (Anderson et al., 
1998). Multiple bands were observed in Western blots, some of them potentially 
corresponding to calpain 3 proteolitic products and others to non-specific protein 
detection. Thus, we only focused on the full-size calpain 3 (94 kDa).  
Full-size calpain 3 was detected in each of the cell lines after 5 days of differentiation, 
with the exception of P5. This was consistent with the mutations found in the patients. 
P2 and P4 contained at least one missense mutation that potentially led to full size 
calpain 3, whereas P1 had only one CAPN3 allele that theoretically produces a 101 kDa 
band, which was hardly distinguishable from the 94 kDa band observed in the muscle 
extract used as a positive control. As expected, the 94 kDa calpain 3 was practically 
undetectable with both antibodies in patient 5-derived differentiated cultures, since the 
Basque mutation is expected to synthesize a truncated 91.5 kDa calpain 3 form that is 
quickly degraded. Moreover, previously, researchers in our lab reported a lack of 94 kDa 
band in Western blot analysis of a patient’s muscle extract with the Basque mutation in 
homozygosis (unpublished data). However, although unlikely, lack of myogenic 
differentiation could also cause the immediate degradation of the mutated calpain 3 in 
this cell line, due to the absence of myogenic structural proteins, such as titin, that 
protect calpain 3 from degradation. 
Densitometry-based quantification of full-size calpain 3 detected with these two 
antibodies did not strictly correlate, but showed somewhat similar patterns, where 
calpain 3 expression was residual or absent in P5-derived extracts. Calpain 3 levels in P2 
and P4-derived cultures were comparable to healthy controls. This may be attributed to 
the idea that some missense mutations may prevent calpain 3 autolysis, leading to 
partially functional, but structurally similar, calpain 3 variants. Overall, calpain 3 protein 
levels did not correlate with CAPN3 expression rates, not even in control-derived cell 
lines. This lack of correlation may be due to several factors that affect calpain 3 stability 
and autolysis, such as the presence of additional proteins that act over calpain 3.  
The results from this study indicate that patient- and control-specific iPSC-derived 
myogenic cultures express calpain 3 and therefore, could be used to study several 
aspects of the physiopathology of LGMD2A. However, improvements in the 
reprogramming process are required to achieve similar pluripotency levels that allow 
high myogenic differentiation rates, comparable among different iPSC lines. 
Alternatively, the development and comparison of isogenic cell lines through gene 
editing technologies would provide valuable information to elucidate the role of 
calpain 3 in myogenesis.  
Differential splicing of CAPN3 transcripts occurs during development, and this 
maturation is also recapitulated during in vitro myogenic differentiation (Herasse et al., 
1999; Spencer et al., 2002). Study of different CAPN3 transcripts revealed that CAPN3 
maturation occurred in C1 and H9 derived cultures, which showed a consistent 
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differentiation, whereas this switch from immature to mature CAPN3 transcripts was 
absent in mildly differentiating C2-derived cells. This correlates with total CAPN3 
transcript rates, which increase progressively along the myogenic differentiation 
process in C1- and H9-derived cells, whereas only a modest, although statistically 
significant, induction is detected in C2-derived cells. Therefore, these iPSC-derived in 
vitro models of myogenesis were able to recapitulate CAPN3 maturation as long as they 
possessed a robust myogenic differentiation potential, mimicking the maturation 
observed in muscle-derived in vitro models, as well as in vivo during development and 
muscle regeneration processes. 
In summary, we have generated iPSC-derived myogenic cultures from healthy donors 
and LGMD2A patients that can be used as tools to study the role of calpain 3 in 
myogenesis, as well as the physiopathology of LGMD2A. However, further 
improvements are necessary to achieve a higher and similar degree of pluripotency of 
iPSC lines. The transition of our set of iPSC lines to a naïve pluripotent state would likely 
allow comparative studies among our different cell lines, which could contribute to 
elucidate the role of calpain 3 in myogenesis.  
In discussion of differential expression of dystrophin in our differentiated cultures, it is 
notable that calpain 3 levels do not correlate with dystrophin levels. Therefore, if 
downregulation of dystrophin levels in patient-derived cultures are indeed related to 
calpain 3, functional calpain 3 would be required to induce proper dystrophin expression 
in the differentiated cultures.  
Finally, based on recent findings describing a direct correlation between calpain 3 and 
SERCA2 protein levels in skeletal muscle extracts, and their role in the control of calcium 
homeostasis, we studied SERCA2 in our cellular models. Contrary to our expectations, 
SERCA2 was detected in each of the cell lines in progenitor stage, where CAPN3 
expression rates were minimal. Upon induction of myogenic differentiation, SERCA2 was 
observed in each of the cell lines except for P5, where calpain 3 was also absent. Thus, 
in differentiated cultures, calpain 3 may interact with SERCA2 to promote its stability, 
whereas in muscle progenitors, SERCA2 is potentially stabilized through a calpain 3-
independent mechanism. 
Role of calpain 3 in the in vivo regenerative potential of iPSC-derived muscle progenitor 
cells. Intramuscular transplantation studies with control- and patient-derived muscle 
progenitor cells proved the muscle regenerative potential of these cells. Human lamin 
A/C detection labeled human cell nuclei and was used to study cell engraftment, 
whereas detection of human dystrophin represented the in vivo myogenic potential of 
the transplanted human cells, and was therefore indicative of their regenerative 
potential. Both healthy control-derived and patient-derived cells were clearly detected 
in transplanted mouse TAs, and these cells occasionally led to human dystrophin-
positive fibers. However, human cells were often incorporated to mouse fibers, but did 
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not express human dystrophin. Comparison of the regenerative capacity of P1- derived 
muscle progenitors and its age-matched C2-derived progenitors revealed large 
differences. Contrary to what was expected, patient-derived cells demonstrated a 
higher engraftment rate and a greater regenerative potential. Nevertheless, these 
differences are likely attributed to calpain 3-independent processes, since these two cell 
lines have previously shown a dissimilar myogenic differentiation potential in vitro. Of 
note, patient-derived cells did engraft and generate muscle fibers, which suggests that 
calpain 3 is not essential for in vivo regeneration of skeletal muscle. However, lack of 
functional calpain 3 may lead to regenerative defects that are not detectable with this 
experimental approach.  
Overall, considering the significant variability observed among the iPSC lines, which 
might probably be caused by variable pluripotency rates achieved by each cell line, it is 
not possible to perform comparative studies among the different cell lines to elucidate 
the role of calpain 3 in myogenesis. However, since iPSC-derived myogenic cultures do 
indeed express calpain 3, these cell lines could be used to study the role of calpain 3 by 
knocking out the CAPN3 gene in healthy donor-derived cell lines, or correcting the 
genetic mutations in patient-derived cell lines. Recently developed gene editing 
systems, such as the CRISPR/Cas9 technology, allow the generation of isogenic cell lines 
in a relatively quick and easy manner. Using this technology, we could generate isogenic 
cell lines that would only differ in their CAPN3 gene, and thus, any phenotype described 
in transplantation studies, as well as in in vitro differentiation experiments, would be 
attributable to calpain 3.  
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BACKGROUND AND HYPOTHESIS 
Since the discovery of mutations in CAPN3 as the origin of LGMD2A in 1995, numerous 
studies have aimed to elucidate the etiology of this disease. Calpain 3 is potentially 
implicated in numerous cellular processes, playing a structural as well as an enzymatic 
role (Baghdiguian et al., 1999; Kramerova et al., 2004, 2008; Ojima et al., 2010; Toral-
Ojeda et al., 2016). This is supported by the fact that calpain 3 has been described in 
several subcellular locations, interacting with a wide range of proteins. Moreover, in 
vitro studies have identified many substrates of calpain 3, although it is still unknown 
whether calpain 3 proteolyzes these molecules in vivo (Guyon et al., 2003; Taveau et al., 
2003; Ono et al., 2007). Despite the intense efforts to elucidate the role of calpain 3 in 
skeletal muscle, the mechanism still remains unknown. Current questions include why 
does a lack of functional calpain 3 lead to LGMD2A and, why does a calpain 3 deficiency 
affect a specific subset of muscles? Further, it is unknown why the muscle weakness is 
absent in newborns, but develops later in life. 
This late onset of muscle weakness leads us to consider that calpain 3 may be implicated 
in muscle regeneration processes, with minor activity during muscle generation. This 
fact would contribute to understand the late onset of the symptoms, which would 
become increasingly evident when muscle development or growth is diminished and 
muscle maintenance relies on regenerative mechanisms. Similar to the gradual age-
associated switch from muscle growth to regeneration, LGMD2A symptoms appear 
progressively. This implies that the development of biochemical and histological 
changes, such as hypeCKemia and eosinophilia in LGMD2A patients, usually occur 
silently before muscle weakness becomes evident.  
While investigating the potential role of calpain 3 in muscle regeneration, we questioned 
whether calpain 3 could directly participate in satellite cell biology, playing a role in their 
activation, proliferation, differentiation and/or return to quiescence. Each skeletal 
muscle has specific regenerative requirements and therefore, activity of satellite cells 
varies among different muscles (Ippolito et al., 2012). Thus, the implication of calpain 3 
in the regulation of satellite cells could partially explain why some specific muscles are 
predominantly affected in LGMD2A patients. Interestingly, a recent study has reported 
a novel type of autosomal recessive form of limb girdle muscular dystrophy mainly 
affecting proximal muscles with a late onset, caused by mutations in the POGLUT1 gene, 
which directly impairs satellite cell activity (Servián-Morilla et al., 2016). Therefore, the 
fact that satellite cell impairment leads to an LGMD phenotype supports the fact that 
calpain 3 may be implicated in satellite cell biology. However, mutations in POGLUT1 
cause loss of satellite cells, whereas the number of PAX7-positive cells increases in 
LGMD2A patients as the disease progresses (Rosales et al., 2013). 
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How could calpain 3 participate in satellite cell biology? Differential expression of 
calpain 3 observed in cancer cells supports the hypothesis that calpain 3 is potentially 
able to contribute to the control of cell cycle progression in some specific cell types 
(Moretti et al., 2009; Roperto et al., 2010). Moreover, the fact that calpain 3 has a 
nuclear localization sequence in its IS2 region (Sorimachi et al., 1989) suggests that it 
might localize in cell nuclei in one or more stages along the myogenic differentiation 
process. Since skeletal muscle is primarily constituted by post-mitotic multinucleated 
cells, this hypothetic role could be mainly conducted in muscle satellite cells, which tend 
to be quiescent in homeostasis, but proliferate upon injury. Satellite cell activation, 
proliferation, differentiation and return to quiescence need to be strictly controlled to 
maintain the regenerative potential of skeletal muscles throughout life. In this regard, 
Stuelsatz and colleagues (Stuelsatz et al., 2010) suggested a role for calpain 3 in the 
maintenance of reserve cells, which are quiescent muscle progenitors found in in vitro 
myogenic cultures. Overexpression of calpain 3 in C2C12 cells (a murine myoblast cell 
line) increased the population of reserve cells in culture, whereas its downregulation 
promoted their myogenic differentiation. These authors provided strong evidence that 
calpain 3 participates in the early stages of the myogenic differentiation process by 
reducing the transcriptional activity of MYOD1. These results suggest that calpain 3 
could potentially play a role in the maintenance of satellite cells in vivo and thus, lack of 
functional calpain 3 in LGMD2A patients would increase MYOD1 activity, leading to 
satellite cell depletion. However, similar to DMD biopsies, LGMD2A biopsies 
demonstrate that the number of PAX7-positive cells increases throughout the 
progression of the disease (Rosales et al., 2013). Therefore, it is unclear how calpain 3 
deficiency impacts on satellite cells of LGMD2A patients. 
In an attempt to evaluate whether calpain 3 is implicated in satellite cell biology, we 
aimed to study Capn3 expression in mouse satellite cells, as well as its potential role in 
the proliferative and differentiation potential of these cells. To do so, initially, we 
performed a Capn3 gene expression study in wild type satellite cells, both in quiescence 
and following in vivo activation, to prove its expression in these cells and its possible 
activation-dependent expression. Conversely, we analyzed if lack of calpain 3 had a 
functional effect in these cells by performing a colony assay with wild type and C3KO 
mouse-derived satellite cells. This test assesses the in vitro proliferative and 
differentiation potential of satellite cells. 
 
MATERIALS AND METHODS 
The following figures represent the experimental outline of both approaches, which are 
detailed below. Briefly, in order to investigate Capn3 expression in satellite cells in 
quiescence and following activation, mice were injured in one of their legs via 
intramuscular cardiotoxin injection. Muscle injury induced satellite cell activation, 
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whereas the other leg was not injected, and satellite cells were expected to remain 
quiescent. At days 3, 5 and 7 post injury, satellite cells were FACS-purified from injected 
and non injected TA (slightly affected in calpain 3-deficient mice) and soleus (notably 
affected in calpain 3-deficient mice), isolating activated and quiescent satellite cells, 
respectively. Finally, gene expression analysis was performed in these cells and Capn3 
expression was assessed in TA and soleus-derived satellite cells extracted from injured 
and non-injured muscles, at different timepoints (figure 49). Due to the low amount of 
satellite cells found in skeletal muscle, it was necessary to pool the samples extracted 
from 6 mice to achieve the minimum amount of RNA required for qPCR analysis.  
 
 
Figure 28. Experimental outline of the gene expression study. TA and soleus of the right leg of 18 mice 
were injured by intramuscular cardiotoxin injection at day 0. Satellite cells were isolated at days 3, 5 and 
7 after injury. Muscles of 6 mice were combined in 4 tubes at each experimental timepoint: TA non-injured 
(control), TA injured, soleus non-injured (control), and soleus injured. SC: satellite cells; Sol: soleus. Finally, 
gene expression was assessed in these samples.  
Alternatively, a colony assay was performed to determine if the lack of calpain 3 alters 
the proliferative and/or differentiation potential of satellite cells in vitro. To do so, 
satellite cells were extracted from TA and soleus muscles of WT and C3KO mice, and 
plated in 96 well-plates at a density of 1 satellite cell per well. After 8 days in culture in 
hypoxia, which is expected to favor satellite cell proliferation and differentiation, 
colonies were fixed and stained to detect cell nuclei and sarcomeric myosin expression. 
Using the G-tool software, the number of cell nuclei in each well were assessed as 
indicative of the proliferative potential of satellite cells. In parallel, myosin expression 
and cell fusion were assessed to estimate the differentiation potential of these satellite 
cells. Finally, WT and C3KO-derived colonies were compared to determine whether 
calpain 3 plays a role in satellite cell activity (figure 50). 
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Figure 50. Experimental outline of colony assay. Two WT and two C3KO mice were used to isolate satellite 
cells from their TA and soleus muscles. These cells were plated in 96 well-plates at a density of 1 cell per 
well, and cultured for 8 days to allow colony formation. Proliferation potential of WT and C3KO satellite 
cells, as well as their differentiation potential and fusion index were determined using the G-tool software 
and compared in order to find calpain 3-specific in vitro phenotypes.  
Experimental animals. For the gene expression experiment, eighteen adult wild type 
C57BL/6 mice were purchased from Charles River Laboratories and housed in the animal 
facility. Mice were 8-weeks-old at the time of satellite cell isolation. All procedures were 
performed following the guidelines and approval provided by Biodonostia Animal Care 
Committee and the Regional Government of Gipuzkoa (Donostia, Spain), in accordance 
with the Spanish Royal Decree (53/2013), the European Directive 2010/63/EU and the 
guidelines established by the National Council on Animal Care.  
The colony assay was performed at the Lillehei Heart Institute (University of Minnesota, 
USA). Two C3KO mice and two wild type controls were born and housed at the Lillehei 
Heart Institute’s animal facility until the experiment was performed at 6 weeks of age. 
All procedures were performed following the guidelines and approval of the Institutional 
Animal Care and Use Committee (IACUC).  
Cardiotoxin injury. Mice were anesthetized by inhaled isoflurane (Forane), administered 
at 5% concentration for induction and 3% concentration for maintenance during 
surgery. A lateral incision was made in the right leg of the mice to facilitate cardiotoxin 
administration. 3 µl of 50 µM cardiotoxin from Naja mossambica mossambica were 
injected in the TA, whereas the same volume of cardiotoxin at 16.7 µM was injected in 
the soleus of each animal, using a beveled 26G needle. Finally, the incision was sutured 
using a 6/0 suture thread, and mice were kept in a warm atmosphere until they 
recovered from anesthesia.  
Satellite cell isolation. For gene expression analysis, 6 wild type mice were sacrificed by 
inhalation of 5% isoflurane followed by inhalation of CO2 at 3, 5 and 7 days following 
cardiotoxin administration. For the colony assay, two 6-week-old C3KO mice and two 
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age-matched wild type controls were sacrificed by dislocation. Satellite cell isolation was 
performed following the same protocol in both experiments, as specified below. The 
skin of the hind limbs was removed and the TA and soleus muscles were harvested, 
chopped longitudinally using a razor blade and kept in 15 ml-tubes containing 5 ml of 
DS1 solution (DMEM High Glucose Media containing 0.2% collagenase II, 100 U/ml 
penicillin and 100  μg/ml streptomycin) on ice until all muscles were harvested. Muscles 
were collected in four tubes: TA from non-injured (control) legs, soleus from non-injured 
(control) legs, TA from injured legs and soleus from injured legs. Once all the muscles 
were harvested, chopped and placed in DS1-containing tubes, samples were incubated 
at 37°C, shaking at 220 rpm for 75 minutes. Next, tubes were inverted 5 times and 
centrifuged at 1500 rpm for 5 minutes at 4°C. The pellet was resuspended in 5 ml of 
F10+ solution (Ham’s/F-10 medium containing 10% horse serum, 0.01 M HEPES Buffer 
Solution, 100 U/ml penicillin and 100 μg/ml streptomycin), pipetted up and down with 
a P1000 micropipette and centrifuged again at 1500 rpm for 5 minutes at 4°C. This step 
was repeated 4 times, but in the third repetition, cells were pipetted using a pasteur 
pipette with the edge jagged, which favors the removal of adipose tissue and other 
contaminants. After the fourth repetition, each pellet was resuspended in 5 ml of freshly 
prepared DS2 solution (F10+ solution containing 0.06% dispase and 5.7% of DS1 
solution), vortexed for 30 seconds, incubated at 37°C shaking at 220 rpm for 30 minutes 
and vortexed again for 30 seconds. Hereafter, fibers were further disaggregated by 
drawing and releasing the mixtures into syringes with a 16-gauge needle 5 times and 
another 5 times into an 18-gauge needle. Then, samples were filtered using 40 µm cell 
strainers, and digestions were stopped by adding 5 ml of F10+ solution to each tube. 
Samples were centrifuged again at 1500 rpm for 5 minutes at 4°C and pellets were 
resuspended in 500 µl of staining media (Dulbecco’s Phosphate-buffered saline (DBPS) 
supplemented with 2% Fetal Bovine Serum (FBS)).  
Cells were stained by adding the corresponding amounts of each antibody (as indicated 
in table 15) and incubated on ice for 30 minutes, protected from light. 
Antibody  Complete 
staining 
FMO controls 
FM alexa-647 FM PE FM PE-Cy7 
Anti -integrin-α7-647 2.0 µg ----- 2.0 µg 2.0 µg 
Anti-CD106/VCAM-Biotin 0.5 µg 0.5 µg ----- 0.5 µg 
Anti-Streptavidin-PE 0.2 µg 0.2 µg ----- 0.2 µg 
Anti-CD45-PE-Cy7 0.2 µg 0.2 µg 0.2 µg ----- 
Anti-CD31-PE-Cy7 0.2 µg 0.2 µg 0.2 µg ----- 
 
Table 15. Antibodies for SC isolation. Antibody amounts indicated in the table refer to the amount of 
antibody added per muscle. Therefore, in order to calculate the amount of antibody added to each tube, 
these values were multiplied by the number of muscles processed in each tube.  
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Following the staining, cells were washed by adding 5 ml of staining medium to each 
tube followed by a centrifugation at 1500 rpm for 5 minutes at 4°C. Finally, cells were 
resuspended in 500 µl of staining medium containing 10 U/ml of DNAse II to prevent cell 
aggregation. Fifteen minutes prior to the sorting, SYTOX Green Nucleic Acid Stain was 
added to the cells at a final concentration of 30 nM. 
FACS gating approach. Cell sortings were performed on a BD FACsaria III (BD 
Biosciences) cell sorter equipped with 3 laser lines (488,635 and 561 nm). SYTOX-signal 
was collected from 488 nm blue laser line, PE and PE-Cy7 signals from the yellow-green 
561 nm laser line and alexa 647 fluorescence from 635 nm red laser line. FSC parameter 
was adquired in linear mode and SSC and fluorescence parameters were acquired in log 
amplification mode. Prior to each cell sorting, cell separation performance was verified 
using CS&T quality control beads. Cell sorting was performed using purity masks and a 
100 μm nozzle.  
Due to the large amount of blood cells found in the samples, a “dump channel” on 
PE- Cy7 was used to exclude blood and endothelial cells (CD31+ and CD45+). Next, 
PE- Cy7-negative cells were plotted for FSC- A (Forward scatter, representing cell size) 
versus green (BP530/30) SYTOX-derived fluorescence. SYTOX-negative cells were 
considered live cells and gated and plotted in a SSC- A versus FSC- A dot plot, where cells 
were distributed according to their granularity and size, respectively. The gate was set 
excluding the events corresponding to the smallest events, which were considered to be 
cell debris. Thereafter, gated cells were plotted according to FSC-H versus FSC-W, and 
only single events (singlets) were selected for the final gating, discarding the events that 
would potentially correspond to doublets or even larger cell aggregates. The final plot 
represented cells according to PE and Alexa fluor- 647 fluorescence corresponding to 
CD106/VCAM and integrin-α7 detection, respectively. This allowed the selection of 
CD106/VCAM and integrin-α7 double positive events, which corresponded to muscle 
satellite cells. Analysis of cell sorting was performed using the BD FACSDiva (BD 
Biosciences) software. 
Gating strategy based on FMO controls. Fluorescence Minus One (FMO) controls are 
commonly used to properly set the gates in a multicolor cytometry or FACS procedure. 
These controls use cells stained with the entire set of antibodies that will be used in the 
FACS procedure, except for the antibodies that are conjugated with one specific 
fluorochrome (minus one). One by one, all the minus one controls were tested, one for 
each fluorochrome: fluorescence minus PE, fluorescence minus PE-Cy7 and fluorescence 
minus Alexa fluor- 647. Each of them was used to set the gate for that specific 
fluorochrome, since the signal detected for that fluorochrome was considered to be 
unspecific or basal signal, and thus negative.  
Cell sorting and gene expression analysis. Sorted CD31-/CD45-/integrin-α7+/CD106+ 
cells from injured TA, injured soleus, uninjured TA and uninjured soleus of wild type mice 
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were collected in RNAprotect Cell Reagent, which promotes quick RNA stabilization 
following cell sorting. Samples were stored at -80°C until RNA was extracted using the 
NucleoSpin RNA XS extraction kit, as indicated by the manufacturer’s instructions. 18 ng 
of RNA were retrotranscribed using the High Capacity cDNA Reverse Transcription Kit, 
following manufacturer’s instructions. Due to the low amount of RNA extracted from 
the sorted cells, cDNA of target genes was preamplified using the TaqMan PreAmp 
Master Mix, following manufacturer’s instructions. Finally, gene expression was 
assessed through qPCR in a CFX384 Touch Real-Time PCR Detection System, using 
Taqman probes. TATA-Binding Protein (Tbp) was used as an internal control and gene 
expression rates were represented in relation to Tbp expression, which was considered 
as 100%. 
Cell sorting and colony assay. Sorted CD31-/CD45-/integrin-α7+/CD106+ cells from TA 
and soleus muscles of wild type and C3KO mice were individually plated in gelatinized 
96-well plates in DMEM/F12 medium containing 20% FBS, 10% horse serum, 50 ng/ml 
human FGF2, 100  U/ml penicillin, 100  μg/ml streptomycin and 0.5% chick embryo 
extract. Ninety-six wells were plated for each condition: C3KO TA-derived satellite cells, 
C3KO soleus-derived satellite cells, wild type TA-derived satellite cells and wild type 
soleus-derived satellite cells. In this experiment, previous muscle injury was not required 
since the in vitro culture of satellite cells itself induces their activation, proliferation and 
differentiation. Cells were incubated for 8 days in hypoxia (3% O2) to allow for colony 
formation. Following the incubation, cells were fixed in 4% paraformaldehyde for 20 
minutes at room temperature, permeabilized with 0.3% triton X-100 in PBS for 20 
minutes and blocked with 3% bovine serum albumin (BSA) in PBS for 1 hour at room 
temperature. Cells were stained overnight at 4°C with MF20 antibody diluted 1:25 in 3% 
BSA to detect sarcomeric myosin. The following day, plates were washed with PBS and 
incubated with goat-anti-mouse Alexa fluor- 555 (1:500) diluted in 3% BSA, as well as 
with 100 ng/ml 4',6-diamidino-2-phenylindole (DAPI) to stain cell nuclei. Finally, cells 
were washed once with PBS and colonies were imaged using an inverted fluorescence 
microscope. Cell proliferation and differentiation were assessed in at least 30 colonies 
per each condition, using the G-tool GUI algorithm developed by Ippolito and colleagues 
(Ippolito et al., 2012). This algorithm processed the images to increase the color contrast 
and was used to assess the following features of the colonies: proliferative potential, 
measured as the number of nuclei per colony, differentiation potential, measured as the 
proportion of nuclei within a myosin-positive cytoplasm, and fusion index, measured as 
the proportion of nuclei within myotubes containing three or more nuclei. Statistical 
significance of index values observed among wild type and C3KO mice-derived colony 
assays were analyzed though independent t-tests at a 95% confidence interval.  
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RESULTS 
FACS gating approach for SC isolation. The following gating approach was designed to 
optimize satellite cell isolation by FACS (figure 51). First, blood cells and endothelial cells 
were discarded by selecting PE-Cy7-negative cells (negative for CD45, a marker of 
leukocytes, and CD31, which labels endothelial cells, platelets, macrophages, and other 
blood cells)(not P1 region) (figure 51.a). Secondly, live cells were gated (P2) by negative 
selection of cells stained with the viability marker SYTOX Green (figure 51.b). Thirdly, 
cells were plotted according to their size and granularity and gated (P3) to exclude cell 
debris, corresponding to the smallest events represented in the FSC-A axis (figure 51.c). 
Next, cells were plotted according to FSC-H versus FSC-W, which makes it possible to 
exclude cell doublets and aggregates by gating the events with the size and shape 
corresponding to single cells (P4) (figure 51.d). Finally, cells were plotted according to 
Alexa fluor- 647 fluorescence versus PE fluorescence, corresponding to integrin-α7 and 
CD106/VCAM staining, respectively. Events positive for both markers were sorted and 
considered to be satellite cells (P5). Blue events in figure 51.a, figure 51.b and figure 51.e 
correspond to sorted CD31-/CD45-/integrin-α7+/CD106+ live cells.  
 
Figure 51. SC isolation strategy. a) Cells plotted according to their size (FSC-A) and PE-Cy7 fluorescence. 
b) PE-Cy7-negative cells plotted according to their size (FSC-A) and green fluorescence. c) Cells negative 
for SYTOX green (live cells) plotted according to their cell size (FSC-A) and cell granularity (SSC-A). Cells 
are gated in P3. Cell debris (green events) is excluded. d) Plot representing FSC-H versus FSC-W. Singlets 
(purple events) are selected. e) Plot representing Alexa fluor- 647 staining (integrin-α7) versus PE staining 
(CD106/VCAM). Events positive for both markers (blue events) are sorted and considered as satellite cells 
(P5).  
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Gating strategy based on FMO controls. To accurately set the gates for this isolation 
setup, FMO controls were used as negative control samples for each of the fluorophores. 
Figure 52 illustrates plots for each of the three FMO controls tested: Fluorescence Minus 
PE-Cy7 (figure 52.a, b and c), Fluorescence Minus PE (figure 52.d, e and f) and 
Fluorescence Minus Alexa fluor- 647 (figure 52.g, h and i).  
 
Figure 52. Plots corresponding to FMO controls. a, b and c correspond to Fluorescence Minus PE-Cy7 
staining. d, e and f correspond to Fluorescence Minus PE staining. g, h and i correspond to Fluorescence 
Minus Alexa fluor-647 staining. b, e and h represent events according to their size (FSC-A) and green 
fluorescence (SYTOX green). a, d and g represent events according to their size (FSC-A) and PE-Cy7 
fluorescence. Finally, c, f and i represent events according to their PE (CD106/VCAM) and Alexa fluor- 647 
(integrin- α7) fluorescence.  
Figure 52.a displays some events highly fluorescent for PE-Cy7 fluorescence, likely 
corresponding to dead cells. Therefore, these events were excluded when the gate for 
PE- Cy7 negative cells was set. Figure 52.f shows the staining for Alexa fluor- 647, and 
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this plot was used to set the gate for PE-positive staining since the PE signal detected in 
this plot was considered to be nonspecific. Figure 52.i shows cells positive for PE, and 
this plot was used to set the gate for Alexa fluor-647-positive cells since the events 
detected were considered to be a nonspecific signal. Therefore, information on figure 
52.f and.i was used to set the gate for CD106/integrin-α7 double positive cells. 
Cardiotoxin injury and satellite cell isolation. Once the strategy for satellite cell isolation 
was defined, satellite cell activation was induced by performing a muscle injury in the 
TA and soleus of one of the legs of wild type C57BL/6 mice via intramuscular injection of 
cardiotoxin, as specified in the materials and methods. Satellite cells were isolated at 3, 
5 and 7 days post-injury from the injured and non-injured muscles, to optimize the 
timing for the isolation of activated satellite cells from the injured muscles following 
cardiotoxin administration. Figure 53 displays FACS plots corresponding to the sorted 
cells from both injured and non-injured (control) TA and soleus at different timepoints 
after injury. Sorted events are represented in cyan in both plots corresponding to each 
sample. Distribution of the sorted events, gated in PE versus Alexa fluor-647 plots, can 
be visualized in the SSC-A versus FSC-A plots. These results showed that the distribution 
of quiescent satellite cell populations (isolated from non-injured, control muscles) 
according to their size and granularity was similar for both TA- and soleus-derived 
satellite cells, being considerably uniform. However, the population of satellite cells 
extracted from cardiotoxin-injured legs demonstrated a prominent dispersion in the 
FSC-A axis, which was highest at day 3 post-injury and decreased at day 5 and 7. 
Importantly, the distribution of cells in the PE versus Alexa fluor-647 plots was greatly 
affected by cardiotoxin injury, since a population of CD106+/integrin-α7- cells was 
clearly visible in these samples and absent in non-injured (control) muscle plots. The 
intensity of this staining progressively decreased as the days following injury increased.  
Therefore, these results suggest that cardiotoxin injury likely induced satellite cell 
activation, since the distribution of the satellite cell population was greatly influenced 
by muscle injury in both TA and soleus. The greatest change in distribution was observed 
at day 3 post-injury, and therefore, this seemed to be the timepoint at which the most 
prominent activation of satellite cells was achieved.  
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Figure 53. SC isolation. Dot plots corresponding to satellite cell isolation from injured and non-injured TA 
and soleus at days 3, 5 and 7 after intramuscular cardiotoxin administration. Plots in columns 1 and 3 
represent the entire cellular population according to their size and granularity. Plots in columns 2 and 4 
represent CD45- and CD31- live singlets, according to CD106 and integrin-α7 expression. Events 
corresponding to sorted cells are represented in cyan.  
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Gene expression analysis. Gene expression analysis demonstrated that Pax7 was highly 
expressed in satellite cells isolated from non-injured (control) muscles whereas its 
expression in satellite cells from injured legs was down-regulated to expression rates 
lower than 15% of that observed in control satellite cells at day 3 post-injury. Contrarily, 
expression of Myod1 was lower in satellite cells isolated from non-injured muscles, but 
was considerably induced (around 3-fold in TA-derived satellite cells and 4.5-fold in 
soleus-derived satellite cells) in satellite cells isolated at day 3 post injury (figure 54). 
Therefore, results confirmed that quiescent satellite cells were obtained from uninjured 
muscles whereas activated satellite cells were isolated from cardiotoxin-injured 
muscles. Moreover, the highest satellite cell activation rate was achieved at 3 days post- 
injury, as indicated by the most pronounced Pax7 down-regulation and Myod1 up-
regulation, compared to day 5 and 7 after injury. This is consistent with the highest 
dispersion of the satellite cell population observed at day 3-post injury in figure 53.  
Modulation of Pax7 and Myod1 expression in quiescent and activated satellite cells 
followed a similar tendency in both TA- and soleus-derived satellite cells. Of note, Pax7 
and Myod1 expression in quiescent satellite cells was increased in TA-derived satellite 
cells compared to soleus-derived satellite cells. 
 
Figure 54. Expression of Pax7 and Myod1 in satellite cells. Expression of Pax7 and Myod1 relative to the 
endogenous gene Tbp (100%), in %. a) Pax7 expression in TA-derived satellite cells and b) soleus-derived 
satellite cells. c) Myod1 expression in TA-derived satellite cells and d) soleus-derived satellite cells. Black 
bars correspond to gene expression rates found in satellite cells extracted from non-injured muscles at 
day 3, 5 and 7 post-injury. Blue and green bars represent gene expression rates in satellite cells extracted 
from cardiotoxin-injured TA (blue bars) and soleus (green bars) at days 3, 5 and 7 post-injury.  
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Myogenic markers embryonic myosin (Myh3), myogenin (Myog) and ryanodine receptor 
type 1 (Ryr1) were also upregulated in activated satellite cells (figure 55). Myh3 was 
greatly induced in satellite cells at 3 days post-injury and gradually reduced in satellite 
cells isolated from injured muscles at day 5 and 7 post-injury. Indeed, Myh3 expression 
levels in satellite cells isolated from injured muscles 7 days after injury resembled those 
of quiescent satellite cells, suggesting that satellite cells from injured muscles at day 7 
post-injury are gradually acquiring quiescence (figure 55.a and b). However, expression 
of Myog and Ryr1 was still considerably up-regulated in satellite cells isolated from 
injured muscles at day 5 and 7 after injury, compared to quiescent satellite cells (figure 
55.c-f). 
 
Figure 55. Expression of Myh3, Myog and Ryr1 in satellite cells. Expression of Myh3 (a, b) Myog (c, d) 
and Ryr1 (e, f) relative to the endogenous gene Tbp (100%), in TA-derived satellite cells (a, c, e) and soleus-
derived satellite cells (b, d, f). Black bars correspond to gene expression rates found in satellite cells 
isolated from non-injured muscles at day 3, 5 and 7 post injury. Color bars represent gene expression rates 
in satellite cells isolated from cardiotoxin-injured TA (blue bars) and soleus (green bars) at days 3, 5 and 7 
post-injury.  
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These gene expression data provided evidence that intramuscular cardiotoxin 
administration induced changes in the expression of a set of myogenic genes in satellite 
cells, which were consistent with their activation. Once isolation of quiescent and 
activated satellite cells was achieved from uninjured and injured muscles, respectively, 
expression of Capn3 was assessed in these cells. qPCR results demonstrated that 
expression of Capn3 was induced in activated satellite cells isolated at 3 days post-injury, 
and subsequently, it was progressively reduced (figure 56). Thus, these results 
confirmed that calpain 3 was expressed in satellite cells at mRNA level, being 
upregulated upon satellite cell activation. Notably, Capn3 expression rates were 
relatively low compared to expression rates of other genes typically expressed in 
satellite cells, such as Pax7 and MyoD.  
 
 
Figure 56. Capn3 expression in satellite cells. Expression of Capn3 relative to the endogenous gene Tbp 
(100%), in TA-derived satellite cells (a) and soleus-derived satellite cells (b). Black bars correspond to gene 
expression rates assessed in satellite cells isolated from non-injured muscles (control) at day 3, 5 and 7 
post-injury. Blue and green bars represent gene expression rates in satellite cells isolated from 
cardiotoxin-injured TA (blue bars) and soleus (green bars) at days 3, 5 and 7 post-injury.  
 
Expression of dystrophin (Dmd) and myosin heavy chain 2 (Myh2) in satellite cells were 
also evaluated. Both genes were found to be up-regulated in quiescent satellite cells, 
compared to activated satellite cells. Of note, the expression rate of Dmd in quiescent 
satellite cells was considerably high (similar to Tbp expression rates) whereas Myh2 
expression was markedly lower (figure 57). 
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Figure 57. Expression of Dmd and Myh2 in satellite cells. Expression of dystrophin (a,b) and Myh2 (c,d) 
relative to the endogenous gene Tbp (100%), in TA-derived satellite cells (a,c) and soleus-derived satellite 
cells (b,d). Grey bars correspond to gene expression rates found in satellite cells isolated from non-injured 
muscles at day 3, 5 and 7 post-injury. Color bars represent gene expression rates in satellite cells isolated 
from cardiotoxin-injured TA (blue bars) and soleus (green bars) at days 3, 5 and 7 post-injury.  
Colony assay. Satellite cells were isolated following the previously described protocol 
and gating approach from the TA and soleus of two 6 week-old C3KO mice and two age-
matched wild type controls. Cardiotoxin injury was not performed because in vitro 
culture of satellite cells itself leads to their activation and differentiation. The following 
figure shows FACS plots corresponding to CD106/VCAM and integrin-α7 double positive 
cells isolated and plated for the colony assay (figure 58). 
 
Figure 58. SC isolation for colony assay. Dot plots corresponding to CD106/VCAM and integrin-α7 double 
positive cells isolated (gated as P7) from the TA (a,b) and soleus (c, d) of wild type (a, c) and C3KO (b, d) 
mice. 
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Following 8 days of incubation, when colonies containing differentiated and 
undifferentiated cells were grown, these were processed to detect cell nuclei and 
sarcomeric myosin through immunofluorescence. Next, colonies were imaged and 
processed though the G-tool software, which sharpened and increased the contrast of 
the images (figure 59), and evaluated the number of cell nuclei detected in each colony, 
as well as the differentiation and fusion index. Overall, there was a high variability 
among the colonies generated from each muscle type (WT TA, WT soleus, C3KO TA and 
C3KO soleus), as represented in figure 60. 
 
 
Figure 59. Example of processing colony images with the G-tool software. Immunofluorescence images 
of colonies where sarcomeric myosin is stained in red and cell nuclei are visualized in blue. These images 
were processed with the G-tool software, generating colony images with very high contrast. Then, the 
same software measures the proliferation, differentiation and fusion index of each colony.  
No statistical differences (p<0.05) were observed between the proliferative capacity, 
differentiation potential and fusion index of WT and C3KO-derived satellite cells, 
regardless of their origin (TA or soleus).  
 
Figure 60. Colony assay results. Number of nuclei per colony (a, d), coefficient of differentiation (b, e) and 
fusion index (c,f) represented for TA-derived wild type and C3KO satellite cells (a, b, c) and soleus-derived 
wild type and C3KO satellite cells (d, e, f). Black bars represent mean and 95% confidence intervals.  
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DISCUSSION 
This project aimed at studying a potential role of calpain 3 in satellite cell biology. To do 
so, two experimental approaches were designed. The first approach consisted of gene 
expression analysis of Capn3 in quiescent and activated satellite cells, to test whether 
Capn3 is expressed in satellite cells, and if so, if it follows an activation-dependent 
expression pattern. The verification of its expression at the mRNA level in satellite cells 
would not directly prove that this protein plays a role in satellite cells, but it would 
establish a foundation for further experiments. Contrarily, lack of Capn3 expression in 
satellite cells would have ruled that possibility out.  
The designed experimental approach allowed us to successfully isolate both quiescent 
and in vivo activated satellite cells for gene expression analysis, as proven by the 
modulation Pax7 and Myod1 expression. Due to the small amount of satellite cells found 
in skeletal muscle (approximately only 2% of nuclei found in skeletal muscle correspond 
to satellite cells), samples of 6 mice were pooled to obtain the minimum amount of RNA 
required for gene expression analysis.  
Results indicated that the highest rate of activation was achieved in satellite cells 
isolated 3 days following injury, as this is the timepoint at which the most prominent 
down-regulation of Pax7 and the highest induction of Myod1 were observed in injured 
muscle-derived satellite cells. Later on, their expression rate tended to slowly moderate, 
resembling those of quiescent satellite cells. This is consistent with the distribution of 
sorted events in FACS plots, which showed the highest dispersion regarding cell size and 
granularity at day 3 after injury and receded at day 5 and 7 post injury. Muscle injury 
also led to the emergence of a CD106+/integrin-α7- population of cells, which was 
highest at 3 days after injury. The emergence of a population of CD106+/integrin- α7- 
cells could be a result of myogenic cells that induced CD106 expression following injury 
to recruit leukocytes to the site of injury (Jesse et al., 1998). 
Downregulation of Pax7 in activated cells attracted our attention since this transcription 
factor has also been described as a marker of activated satellite cells, despite of 
quiescent cells. This might be due to the fact that the panel of surface markers used for 
satellite cell isolation may also potentially select cells entering myogenesis in injured 
muscles, and these cells might have already downregulated Pax7 expression at mRNA 
level. However, further experiments are required to verify this fact.  
Besides Myod1, expression of other myogenic genes such as embryonic myosin, 
myogenin and ryanodine receptor type 1, was induced upon injury. Myh3 expression 
was rapidly and progressively down-regulated in satellite cells at day 5 and 7 post-injury, 
whereas Myog and Ryr1 kept being considerably expressed in satellite cells at day 5 and 
7 post-injury. Relevance of these different expression trends cannot be determined 
since we did not verify whether the expressed genes eventually led to protein synthesis 
in these cells. However, upregulation of myogenic genes in activated satellite cells is not 
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unexpected since the majority of these cells will activate their myogenic differentiation 
as to repair muscle damage. 
As for Capn3, its expression was highest in activated satellite cells at 3 days post injury, 
both in TA and soleus, and it was progressively down-regulated at day 5 and 7 post-
injury. Therefore, Capn3 displayed an expression pattern that resembled the expression 
of Myh3, although its Tbp-relative expression rate was much lower than that of Myh3. 
These results proved that calpain 3 is expressed in satellite cells at the mRNA level, 
showing an activation-dependent expression pattern. Contrary to expected, expression 
rates were similar in TA- and soleus-derived satellite cells, despite soleus is more 
affected in calpain 3-deficient mice compared to TA. This could be related to the age of 
the mice used in the experiment. Due to the progressive feature of LGMD2A, greater 
Capn3 expression rates and more evident differences between TA and soleus-derived 
satellite cells may potentially be observed as mice age. Despite Capn3 expression levels 
were modest, this might be significant since low expression rates may lead to calpain 3 
protein, as seen in the in vitro model of LGMD2A generated in chapter 1. 
Capn3 expression data have been contrasted with alternative gene expression studies 
performed in satellite cells by different research groups. When comparing these data to 
our results, it has to be kept in mind that each of the published studies were performed 
using a different mouse strain and a specific satellite cell isolation setup (i.e. 
combination of markers and FACS protocol, age of the mice and muscles), as well as 
various approaches to induce satellite cell activation. For example, Fukada and 
colleagues (Fukada et al., 2007) performed gene expression studies in quiescent and 
activated satellite cells isolated from hindlimb muscles based on the expression of the 
surface marker SM/C-2.6. Satellite cell activation was achieved by culturing the isolated 
cells ex vivo for 3-4 days. Expression of Capn3 in these cells was similar in quiescent and 
activated satellite cells. 
Additional transcriptome analysis performed by Pallafacchina and colleagues 
(Pallafacchina et al., 2010) compared satellite cells isolated from adult wild type, young 
wild type and adult mdx mice, as well as adult ex vivo-activated satellite cells, which 
were isolated based on Pax3 expression. This study reported that calpain 3 expression 
in adult quiescent satellite cells was 1.54 times higher compared to mdx satellite cells, 
and 2.23 times higher compared to ex vivo-activated satellite cells.  
However, despite these data showing Capn3 expression in satellite cells, it would be 
necessary to prove the presence of calpain 3 protein in satellite cells to elucidate 
whether satellite cells are directly implicated in the pathophysiology of LGMD2A. Due 
to the high instability of calpain 3, it is assumed that in the hypothetical case that 
calpain 3 was expressed in satellite cells, it would probably be autolyzed during the 
satellite cell isolation process, which can take up to 12 hours. Therefore, we considered 
that a functional test to look for phenotype differences between C3KO-derived and wild 
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type-derived satellite cells would be more informative to unravel a potential role of 
calpain 3 in satellite cells.  
Hence, a colony assay was performed with C3KO and wild type satellite cells isolated 
from the TA and soleus of 6 weeks-old mice. This assay measured the in vitro 
proliferative potential of satellite cells isolated from each mice and muscle, as well as 
their differentiation and fusion potential. Although no statistically significant differences 
were found among their phenotypes, this could be attributed to the fact that the animals 
used in the experiment were too young to display a phenotype. As previously indicated, 
animal models of calpainopathy show a very mild phenotype that is more evident as the 
mice age. Therefore, calpain 3-dependent phenotypes in satellite cells may be evident 
if the colony assay is performed with satellite cells isolated from older animals.  
Dmd was found to be highly expressed in quiescent satellite cells, whereas its expression 
decreased dramatically in activated satellite cells. This result confirms the findings 
reported by Dumont and colleagues (Dumont et al., 2015b), who also reported that 
dystrophin protein is synthetized in activated satellite cells and participates in the 
asymmetric division of these cells upon activation. Lack of dystrophin in the mdx mouse 
model of DMD leads to increased numbers of Pax7-positive cells at the beginning of the 
symptoms, as well as a reduced number of asymmetric divisions. Moreover, these 
Pax7- positive cells display reduced myogenin rates when myogenic differentiation is 
induced (Kottlors and Kirschner, 2010). Therefore, although dystrophin expression in 
satellite cells has only been reported once, such a strict regulation of Dmd in satellite 
cells might hide specific roles of this protein in satellite cells that are unknown to date.  
Myh2 is also up-regulated in quiescent satellite cells compared to activated satellite 
cells, although expression rates are considerably lower. To our knowledge, myosin 
protein expression in satellite cells has never been reported. Similar to Dmd expression, 
future studies may clarify the significance of these activation-dependent gene 
expression patterns in satellite cells.  
Overall, in an attempt to compare gene expression in TA- and soleus-derived satellite 
cells, only minor differences were found regarding gene expression rates. Importantly, 
none of the genes studied behaved contrarily in TA- and soleus-derived satellite cells 
upon activation.  
Variable gene expression rates in non-injured muscle-derived satellite cells at days 3, 5 
and 7 also attracted our attention. Satellite cells derived from these muscles were 
quiescent and expression of each specific gene was expected to be kept constant at the 
different experimental timepoints. However, these expression rates sometimes varied 
more than expected, as it is the case for Dmd in TA-derived satellite cells. This could be 
attributed to systemic factors released by immune cells concentrated at the site of the 
injury performed in the contralateral leg, which could activate an adaptive response in 
the quiescent satellite cells found in non-injured muscles, inducing minor modifications 
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in quiescent satellite cells that pushed them to a pre-activation state (Rodgers et al., 
2014). 
In summary, we were able to isolate quiescent and in vivo-activated satellite cells from 
TA and soleus to perform gene expression studies. The largest satellite cell activation 
rate was achieved at day 3 post-injury. Myogenic gene expression followed a 
comparable trend in TA and soleus-derived satellite cells in quiescence and following 
activation, although Tbp-relative gene expression rates varied in many of the genes 
studied. Capn3 was expressed in satellite cells and satellite cell activation seemed to 
increase its expression, which was progressively down-regulated as satellite cells 
returned to quiescence.  
Therefore, these experiments require repeating to statistically verify the results 
obtained in this study. However, gene expression results provide a basis to speculate 
that calpain 3 may potentially play a role in the regulation of satellite cells. Further gene 
expression, proteomics and functional studies on satellite cells will provide data to 
determine this potential role of calpain 3 in muscle regeneration.  
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Research on satellite cells has significantly increased in recent years as a result of studies 
that have elucidated their relevance in muscle regeneration. In line with this, satellite 
cells have been pointed as key players in muscle aging processes, and thus, as targets 
for therapeutic approaches to confront age-related muscle wasting. Lastly, the role of 
satellite cells in several muscular dystrophies is currently being evaluated. Satellite cells 
may potentially be implicated in many pathological conditions in two different ways: 
directly, due to the fact that the disease-causing gene and protein are expressed in these 
cells, playing a specific role in their biology, or indirectly, due to the continuous 
regenerative requirements of the affected muscles that exceed the regenerative 
potential of these cells, leading to their exhaustion.  
Studies of satellite cells in any of the previously mentioned conditions face numerous 
challenges. On the one hand, the proportion of satellite cells in skeletal muscle tissue is 
very low. Moreover, isolation protocols are tedious and time-consuming. On the other 
hand, satellite cells are defined based in their anatomic location; isolation and in vitro 
culture of these cells alters their properties and leads to their differentiation, which 
makers it unfeasible to expand the cells in vitro for future studies. 
In our attempt to explore the potential role of calpain 3 in satellite cells to contribute to 
the understanding of the physiopathology of LGMD2A, we developed two different 
approaches to address the issue. First, we established patient-specific iPSC-derived 
cellular models of the disease that allowed the generation of patient-specific muscle 
progenitor cells, as well as terminally differentiated cultures. Secondly, we studied 
Capn3 expression in mouse satellite cells and explored its potential role in the biology 
of these cells. This way, we hoped to address the hypothesis in two different set ups, 
minimizing the effect of the differences found among patients and murine mouse 
models of the disease.  
Overall, iPSCs allowed LGMD2A modeling in a dish, since these cultures were able to 
terminally differentiate, leading to calpain 3 expression. Moreover, these cell lines were 
also able to reproduce the maturation of CAPN3 isoforms in vitro. However, the 
generated set of muscle progenitor cells differed considerably from bona fide satellite 
cells, since these cells were constantly cycling in an in vitro set up and were expected to 
express markers of mesenchymal cells, despite satellite cell-specific markers. Moreover, 
the high variability observed among the different cells lines, which seems to be 
calpain 3-independent, prevented comparative studies among the different cell lines. 
This fact leaves room for the generation of improved cellular models.  
Recent publications suggest protocols to induce a greater pluripotency degree in 
reprogrammed cell lines. This could improve the pluripotency of our cell lines, allowing 
a better myogenic differentiation. An alternative approach to better study the role of 
calpain 3 in myogenesis would consist on generating isogenic cell lines that only 
differentiate in their CAPN3 gene. To do so, we could correct the mutations found in 
FINAL DISCUSSION 
188 
  
patient-derived cell lines, as well as generating CAPN3 knockout cell lines in healthy 
control-derived cell lines through gene editing technologies such as CRISPR/Cas9. 
Comparison of isogenic cell lines would probably decipher the role of calpain 3 in 
myogenesis, as well as offering a platform to screen the effect of a wide range of 
molecules with therapeutic potential.  
After considering the limitations of the iPSC-derived cellular model generated in the first 
chapter, we decided to address the study of satellite cells in mice, despite the 
differences observed among the patients and the murine models of LGMD2A. This 
experimental approach allowed confirmation of the expression of Capn3 in satellite 
cells, which showed an activation-dependent gene expression pattern. This suggests 
that calpain 3 may play a role in satellite cells and muscle regeneration, since as shown 
in chapter 1, modest CAPN3 levels were sufficient to synthetize calpain 3 protein.  
Due to the anticipated difficulties to directly detect calpain 3 in satellite cells as a result 
of its high autolytic activity, we aimed at analyzing calpain 3-dependent phenotypes in 
an in vitro set up. Isolation of satellite cells from the TA and soleus of WT and C3KO mice 
did not report any calpain 3-specific differences upon colony assay. The early age of the 
mice used in these studies might have prevented the detection of calpain 3-specific 
phenotypes in these cells. Thus, studies performed with older mice will confirm or refute 
this potential role of calpain 3 in satellite cells. 
In parallel, transcriptomic and proteomic analyses of murine quiescent and active 
satellite cells isolated from predominantly and mildly affected muscles will also provide 
data to clarify the potential implication of calpain 3 in satellite cells and muscle 
regeneration, as well as in the development of LGMD2A. This final goal will likely require 
further experiments in patient and healthy donor-derived cells.  
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CHAPTER 1. In vitro modeling of LGMD2A through patient-specific iPSC-derived cells.  
I. Mutations in CAPN3 do not alter the reprogramming potential of skin-
derived fibroblasts. Therefore, calpain 3 is not required for cell 
reprogramming.  
 
II. The set of characterization tests performed in this project do not provide 
enough information to thoroughly study the degree of pluripotency achieved 
by the reprogrammed cells.  
 
III. Human iPSC-derived myogenic cultures can achieve calpain 3 expression and 
thus, they can be used to model LGMD2A.  
 
IV. Variable myogenic differentiation potential observed among the established 
cell lines is calpain 3-independent. Consequently, this fact prevents the 
comparison of control- and patient-derived cellular phenotypes.  
 
V. Patient-derived muscle progenitor cells and terminally differentiated 
cultures express lower dystrophin levels compared to healthy control-
derived cultures. This might be indicative of the role of calpain 3 in myogenic 
differentiation and/or maturation, although it could also be an artifact of the 
variable differentiation potential of the cell lines.  
 
VI. Patient-derived muscle progenitor cells express higher embryonic myosin 
levels compared to healthy control-derived cultures. This might be indicative 
of the role of calpain 3 in the maintenance of the population of muscle 
progenitor cells, although it could also be an artifact of the variability  of the 
established cell lines. 
 
VII.  Both control- and patient-specific iPSC-derived muscle progenitor cells 
possess in vivo regenerative potential. Thus, calpain 3 may not be essential 
in iPSC-derived progenitor-mediated muscle regeneration.  
CHAPTER 2. Study of the potential role of calpain 3 in the regulation of muscle satellite 
cells. 
VIII. Intramuscular cartiotoxin administration leads to a robust activation of 
satellite cells in TA and soleus. This activation is highest at three days post-
injury (among the studied timepoints) and decreases progressively over time.  
 
IX. Satellite cell activation induces changes in gene expression rates of early, 
middle and late myogenic markers.  
 
X. Capn3 is expressed in satellite cells, and it is upregulated upon satellite cell 
activation, suggesting that calpain 3 may play a role in satellite cells. 
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However, its expression rate is moderate compared to the expression rates 
of classical satellite cell markers.  
 
XI. Lack of calpain 3 in young mice-derived satellite cells does not alter their in 
vitro proliferative potential or their differentiation and fusion capacity. 
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APPENDIX I: Product references chapter 1. 
Product Brand Reference 
Alkaline Phosphatase Blue Membrane Substrate Solution  Sigma-Aldrich AB0300 
Ampicillin (Gobemicin) 250mg Laboratorios Normon 624619.1 
AP-conjugated anti-DIG antibody Roche 000000011093274910 
Ascorbic acid (L) Sigma-Aldrich A4544 
Beta-mercaptoethanol Sigma-Aldrich M3148 
BigDye terminator v3.1 cycle sequencing kit Thermofisher 4337455 
Blocking Reagent  Roche Diagnostics 11096176001 
Bovine serum albumin Linus P6154 
B-27 supplement (50x) Gibco 17504044 
Cardiotoxin from Naja mossambica mossambica Sigma C9759 
CDP-Star Chemiluminiscent Substrate Sigma-Aldrich C0712 
Chick embryo extract Seralab CE-650-J 
CRL-2429 cell line, feeder cells ATCC CRL-2429 
DMEM/F-12 medium Gibco 11330057 
DMEM high glucose Gibco 11965-092 
DMEM low glucose Gibco 21885-025 
Donkey-anti-goat-IgG-Cy2 Jackson 705-225-147 
Donkey-anti-goat-IgG-Cy3 Jackson  705-165-147 
Donkey-anti-mouse-IgG-Cy2 Jackson 715-225-151 
Donkey-anti-mouse-IgG-488 Invitrogen A-21202 
Donkey-anti-mouse-IgG-555 Invitrogen A-31570 
Donkey-anti-mouse-IgM-Cy3 Jackson 715-165-140 
Donkey-anti-rabbit-IgG-Cy2 Jackson 711-225-152 
Donkey-anti-rabbit-IgG-Cy3  Jackson 711-165-152 
Donkey-anti-rabbit-IgG-488 Invitrogen A-21206 
Donkey Serum Jackson-Vitro JAC-017-000 
Doxycycline Sigma-Aldrich D9891 
DTT Sigma-Aldrich 000000010197777001 
Dulbecco’s Phosphate-Buffered Saline (DPBS) Gibco 14190144 
EDTA 0,5M Ambion AM9260G 
Embryomax 0,1% gelatin solution Merck-Millipore ES-006-B 
EDTA Titriplex III, powder Merck-Millipore 108418 
E-64 Sigma-Aldrich E3132 
Fetal Bovine Serum  Gibco 10099141/16000044 
Fluoro-Gel EMS 17985-10 
Formaldehyde solution about 37% Merck-Millipore 104002  
GlutaMAXTM Supplement  Gibco 35050061 
Goat-anti-calpain 3 (IS2)  Cosmobio  COP-080049 
Goat-anti-hHNF-3β/FoxA2 R&D Systems AF2400 
Goat-anti-mouse-HRP Dako P0447 
Goat-anti-mouse-IgG-Cy2 Jackson 115-225-071 
Goat-anti-mouse-IgG-Cy3 Jackson 115-165-071 
Goat-anti-mouse-IgM-Cy5 Jackson 115-175-075 
Goat-anti-Nanog R&D AF1997 
Goat-anti-rabbit-HRP Dako P0448 
Goat-anti-rat-IgM-Cy3 Jackson 112-165-020 
GSK3-inhibitor CHIR99021 StemCell Technologies 72052 
HEPES Buffer Solution, 1M Gibco 15630-106 
HGF, human recombinant Merck-Millipore GF116 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368814 
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HindIII restriction enzyme NEB R0104S 
Hoeschst (bisBenzimide H 33258) Sigma B2883 
Horse serum, heat inactivated Gibco 26050-088 
Hybond nylon membrane 0,45 μm Amersham 10600002 
Hydrochloric acid, fuming, 37% EMD Millipore 100317 
IGF1, human Sigma-Aldrich I3769 
IMDM medium Gibco 12440053 
Isopentane, 2-methylbutane Millipore 106065 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Sigma-Aldrich I6758  
KaryoMAX® Colcemid™ solution in PBS Gibco 15212012 
KaryoMAX® Potassium Chloride Solution Gibco 10575090 
KnockOutTM DMEM Gibco 10829018 
KnockOutTM Serum Replacement Gibco 10828028 
LB broth Lennox – Sigma L3022 
LB-Agar Lennox A41083 
L-glutamine 200mM Gibco 25030081 
Lipofectamine LTX with plus reagent Invitrogen  15338100 
Matrigel Basement Membrane Matrix BD-Corning 354234 
MEM medium Gibco 11090-081 
Methylamp DNA modification kit Epigentek P-1001 
Monothioglycerol Sigma-Aldrich M6145 
Mouse-anti-calpain 3 Novocastra NCL-CALP-12A2 
Mouse-anti-humanDystrophin Leica NCL-DYS3 
Mouse-anti-Myogenin DSHB F5D 
Mouse-anti-Oct4 Santa Cruz Sc-5279 
Mouse-anti-Pax7 DSHB Pax7, concentrated 
Mouse-anti-sarcomeric myosin DSHB MF20 
Mouse-anti-Serca2 Santa Cruz Biotech Sc-376235 
Mouse-anti-SSEA4 Hybridoma Bank MC-813-70 
Mouse-anti-Tra-1-60 Chemicon MAB4360 
Mouse-anti-Tra-1-81 Chemicon MAB4381 
Mouse-anti-α-smooth muscle actin Sigma-Aldrich A5228 
Mouse-anti-β-III-Tubulin Tuj1  Covance MMS-435P 
mTeSRTM1  StemCell Technologies 85850 
Neurobasal medium Gibco 21103049 
Newborn calf serum Gibco 16010159 
Non Essential Amino acids Solution (100X) Gibco 11140050 
N-2 supplement (100x) Gibco 17502001 
O.C.T. compound Tissue-Tek, Sakura 4583 
One shot TOP10 Chemically competent E. coli Invitrogen C404010 
Optimem  Gibco 31985-047 
Paraformaldehyde 4% Electron Micro. Sci.  175-4-100 
PCR DIG Probe Synthesis Kit  Roche Diagnostics 11636090910 
pCRII-TOPO vector Addgene pCRII-TOPO 
Penicillin/Streptomycin Gibco 15140-122 
Phoenix Amphotropic cells ATCC SD 3443 
Phosphate-buffered saline PBS Biosystems 44592 
pMSCV-Flag-hOct4  Addgene 20072 
pMSCV-Flag-hSox2 Addgene 20073 
pMSCV-Flag-hKlf4  Addgene 20074 
pMSCV-Flag-cMyc T58A Addgene 20075 
PMSF Sigma-Aldrich 78830 
Polybrene 10 mg ml−1 Merck-Millipore TR-1003-G 
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Polyvinyl alcohol mounting medium with DABCO® Sigma-Aldrich 10981 
Ponceau S solution Sigma-Aldrich P7170 
Precision Plus Kaleidoscope Prestained Protein Standards Biorad 1610375 
PstI restriction enzyme NEB R0140S 
Rabbit-anti-α -1-fetoprotein Dako A0008 
Rabbit-anti-GATA4 Santa Cruz sc-9053 
Rabbit-anti-GFAP  Dako Z0334 
Rabbit-anti-goat-HRP Dako P0449 
Rabbit-anti-humanLaminA/C Abcam ab108595 
Rabbit anti-Pax7 Novusbio NBP1-69130 
Rabbit-anti-Sox2 Thermofisher AI-16968 
Rat-anti-SSEA3 Hybridoma Bank MC-631 
Recombinant Human Basic Fibroblast Growth Factor Peprotech 100-18B 
ReLeSRTM StemCell Technologies 05872 
RNeasy mini kit Qiagen 74104 
ROCK inhibitor  StemCell Technologies Y-27632 
RPMI 1640 medium Gibco 31870-082 
Skimmed milk powder Sigma-Aldrich 70166 
Sodium chloride for analysis Panreac Applichem 131659 
Soybean trypsin inhibitor Sigma-Aldrich T6522 
StemPro Accutase Cell Dissociation Reagent Gibco A1110501 
Stripper micropipetter Origio MXL3-STR 
Stripper tips 100 μm Origio MXL3-100 
SuperScript® III First-Strand Synthesis SuperMix for qRT-PCR Invitrogen 11752050 
SuperSignal™ West Dura Extended Duration Substrate ThermoFisher scientific 34075 
SYBR green Real-Time Master Mix AB - Thermofisher 4309155 
Taqman gene expression master mix Applied biosystems 4369016 
Taqman probe for CAPN3 exon 1-2 Applied biosystems Hs00181057_m1 
Taqman probe for CAPN3 exon 5-6 Applied biosystems Hs01115988_m1 
Taqman probe for CAPN3 delta6 Applied biosystems Custom  
Taqman probe for COL1A1 Applied biosystems Hs00164004 
Taqman probe for DES Applied biosystems Hs00157258_m1 
Taqman probe for DMD Applied biosystems Hs00758098_m1 
Taqman probe for FN1 Applied biosystems Hs00365052_m1 
Taqman probe for GAPDH Applied biosystems Hs99999905_m1 
Taqman probe for MYH2 Applied biosystems Hs00430042_m1 
Taqman probe for MYH3 Applied biosystems Hs01074230_m1 
Taqman probe for MYOD1 Applied biosystems Hs00159528_m1 
Taqman probe for MYOG Applied biosystems Hs01072232_m1 
Taqman probe for PAX7 Applied biosystems Hs00242962_m1 
Taqman probe for TBP Applied biosystems Hs00427620_m1 
Tris pure, pharma grade Panreac Applichem 141940 
Triton X-100 Sigma-Aldrich T8787 
TRIzol Reagent Invitrogen 15596026 
Trypsin-EDTA 0,05%, phenol red Gibco 25300054 
Trypsin-EDTA 0,25%, phenol red Gibco 25200056 
QIAamp DNA mini kit  Qiagen 51304 
QIAprep Spin Miniprep Kit Qiagen 27104 
QIAquick Gel Extraction Kit Qiagen 28704 
QIAzol Lysis Regent Qiagen 79306 
X-tremeGene9 DNA Transfection reagent Roche XTG9-RO 
0,45 μm pore filter, PVDF, low protein binding, Durapore Merck-Millipore SLHV033RS 
2-mercaptoethanol Gibco 31350010 
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4',6-diamidino-2-phenylindole (DAPI) Sigma-aldrich D9542 
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APPENDIX II: Product references chapter 2. 
Product Manufacturer Reference 
Anti-CD106/VCAM-Biotin Clone 429 eBioscience 13-1061-85 
Anti-CD31-PE-Cy7 Clone 390 eBioscience 25-0311-82 
Anti-CD45-PE-Cy7 Clone 30-F11 eBioscience 25-0451-82 
Anti-integrin-α7-647 Clone R2F2 Ablab 67-0010-05 
Anti-sarcomeric-myosin DSHB MF20 
Bovine serum albumin Linus P6154 
Cardiotoxin from Naja mossambica mossambica Sigma C9759 
Cell strainers 40 μm BD 352340 
Chick embryo extract Seralab CE-650-J 
Collagenase II Gibco 17101-015 
CS&T quality control beads BD 656504 
Dispase Gibco 17105-041 
DMEM/F12 medium Gibco 31331-028 
DMEM/High Glucose Media Hyclone SH30243.01 
DNAse II from bovine Sigma D8764-30KU 
Dulbecco’s Phosphate-Buffered Saline (DPBS) Gibco 14190144 
Fetal Bovine Serum (FBS) Gibco 10270-106 
Forane (Isoflurane)  Abbott SPPL030 
Goat-anti-mouse alexa fluor 555 Invitrogen A28180 
Ham’s/F-10 media Hyclone SH30025.01 
HEPES Buffer Solution, 1M Gibco 15630-106 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368814 
Horse serum  Gibco 26050-088 
Human basic fibroblast growth factor Peprotech 100-18B 
NucleoSpin® RNA XS extraction kit Macherey-Nagel 740902 
Paraformaldehyde 4%  Electron Micros. Sci.  175-4-100 
Penicillin/Streptomycin Gibco 15140-122 
RNAprotect Cell Reagent Qiagen 76526 
Streptavidin-PE eBioscience 12-4317-87 
SYTOX Green Nucleic Acid Stain Molecular Probes S7020 
Taqman gene expression master mix Applied Biosystems 4369016 
TaqMan PreAmp Master Mix Applied Biosystems 4391128 
Taqman probe for Capn3 Applied Biosystems Mm00482985_m1 
Taqman probe for Dmd Applied Biosystems Mm01216951_m1 
Taqman probe for Gapdh Applied Biosystems Mm99999915_g1 
Taqman probe for a Myh2 Applied Biosystems Mm01332564_m1 
Taqman probe for Myh3 Applied Biosystems Mm01332463_m1 
Taqman probe for Myod1 Applied Biosystems Mm00440387_m1 
Taqman probe for Myog Applied Biosystems Mm00446194_m1 
Taqman probe for Pax7 Applied Biosystems Mm01354484_m1 
Taqman probe for Ryr1 Applied Biosystems Mm01175211_m1 
Taqman probe for Tbp Applied Biosystems Mm00446973_m1 
Triton X-100 Sigma-aldrich T8787 
4',6-diamidino-2-phenylindole (DAPI) Sigma-aldrich D9542 
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